A O O
cell O O
- O O
specific O O
enhancer O O
of O O
the O O
mouse O O
alpha O O
1 O O
- O O
antitrypsin O O
gene O O
has O O
multiple O O
functional O O
regions O O
and O O
corresponding O O
protein O O
- O O
binding O O
sites O O
. O O
A O O
cell O O
- O O
specific O O
enhancer O O
of O O
the O O
mouse O O
alpha O O
1 O O
- O O
antitrypsin O O
gene O O
has O O
multiple O O
functional O O
regions O O
and O O
corresponding O O
protein O O
- O O
binding O O
sites O O
. O O

We O O
have O O
previously O O
described O O
the O O
isolation O O
and O O
characterization O O
of O O
genomic O O
clones O O
corresponding O O
to O O
the O O
mouse O O
alpha O O
1 O O
- O O
antitrypsin O O
gene O O
( O O
Krauter O O
et O O
al O O
. O O
, O O
DNA O O
5 O O
: O O
29 O O
- O O
36 O O
, O O
1986 O O
) O O
. O O

In O O
this O O
report O O
, O O
we O O
have O O
analyzed O O
the O O
DNA O O
sequences O O
upstream O O
of O O
the O O
RNA O O
start O O
site O O
that O O
direct O O
hepatoma B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
expression O O
of O O
this O O
gene O O
when O O
incorporated O O
into O O
recombinant O O
plasmids O O
. O O

The O O
160 O O
nucleotides O O
5 O O
' O O
to O O
the O O
cap O O
site O O
direct O O
low O O
- O O
level O O
expression O O
in O O
hepatoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
and O O
sequences O O
between O O
- O O
520 O O
and O O
- O O
160 O O
bp O O
upstream O O
of O O
the O O
RNA O O
start O O
site O O
functioned O O
as O O
a O O
cell O O
- O O
specific O O
enhancer O O
of O O
expression O O
both O O
with O O
the O O
alpha O O
1 O O
- O O
antitrypsin O O
promoter O O
and O O
when O O
combined O O
with O O
a O O
functional O O
beta O O
- O O
globin O O
promoter O O
. O O
The O O
160 O O
nucleotides O O
5 O O
' O O
to O O
the O O
cap O O
site O O
direct O O
low O O
- O O
level O O
expression O O
in O O
hepatoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
and O O
sequences O O
between O O
- O O
520 O O
and O O
- O O
160 O O
bp O O
upstream O O
of O O
the O O
RNA O O
start O O
site O O
functioned O O
as O O
a O O
cell O O
- O O
specific O O
enhancer O O
of O O
expression O O
both O O
with O O
the O O
alpha O O
1 O O
- O O
antitrypsin O O
promoter O O
and O O
when O O
combined O O
with O O
a O O
functional O O
beta O O
- O O
globin O O
promoter O O
. O O

Within O O
the O O
enhancer O O
region O O
, O O
three O O
binding O O
sites O O
for O O
proteins O O
present O O
in O O
hepatoma B-CellLine O
nuclear O O
extracts O O
were O O
identified O O
. O O

The O O
location O O
of O O
each O O
site O O
was O O
positioned O O
, O O
using O O
both O O
methylation O O
protection O O
and O O
methylation O O
interference O O
experiments O O
. O O

Each O O
protein O O
- O O
binding O O
site O O
correlated O O
with O O
a O O
functionally O O
important O O
region O O
necessary O O
for O O
full O O
enhancer O O
activity O O
. O O

These O O
experiments O O
demonstrated O O
a O O
complex O O
arrangement O O
of O O
regulatory O O
elements O O
comprising O O
the O O
alpha O O
1 O O
- O O
antitrypsin O O
enhancer O O
. O O
These O O
experiments O O
demonstrated O O
a O O
complex O O
arrangement O O
of O O
regulatory O O
elements O O
comprising O O
the O O
alpha O O
1 O O
- O O
antitrypsin O O
enhancer O O
. O O

Significant O O
qualitative O O
differences O O
exist O O
between O O
the O O
findings O O
presented O O
here O O
and O O
the O O
cis O O
- O O
acting O O
elements O O
operative O O
in O O
regulating O O
expression O O
of O O
the O O
human O O
alpha O O
1 O O
- O O
antitrypsin O O
gene O O
( O O
Ciliberto O O
et O O
al O O
. O O
, O O
Cell O O
41 O O
: O O
531 O O
- O O
540 O O
, O O
1985 O O
; O O
De O O
Simone O O
et O O
al O O
. O O
, O O
EMBO O O
J O O
. O O
6 O O
: O O
2759 O O
- O O
2766 O O
, O O
1987 O O
) O O
. O O

Loading O O
of O O
DNA O O
- O O
binding O O
factors O O
to O O
an O O
erythroid B-CellLine B-CellLine
enhancer O O
. O O

The O O
HS O O
- O O
40 O O
enhancer O O
is O O
the O O
major O O
cis O O
- O O
acting O O
regulatory O O
element O O
responsible O O
for O O
the O O
developmental O O
stage O O
- O O
and O O
erythroid B-CellLine B-CellLine
lineage I-CellLine I-CellLine
- O O
specific O O
expression O O
of O O
the O O
human O O
alpha O O
- O O
like O O
globin O O
genes O O
, O O
the O O
embryonic O O
zeta O O
and O O
the O O
adult O O
alpha2 O O
/ O O
alpha O O
/ O O
1 O O
. O O

A O O
model O O
has O O
been O O
proposed O O
in O O
which O O
competitive O O
factor O O
binding O O
at O O
one O O
of O O
the O O
HS O O
- O O
40 O O
motifs O O
, O O
3 O O
' O O
- O O
NA O O
, O O
modulates O O
the O O
capability O O
of O O
HS O O
- O O
40 O O
to O O
activate O O
the O O
embryonic O O
zeta O O
- O O
globin O O
promoter O O
. O O
A O O
model O O
has O O
been O O
proposed O O
in O O
which O O
competitive O O
factor O O
binding O O
at O O
one O O
of O O
the O O
HS O O
- O O
40 O O
motifs O O
, O O
3 O O
' O O
- O O
NA O O
, O O
modulates O O
the O O
capability O O
of O O
HS O O
- O O
40 O O
to O O
activate O O
the O O
embryonic O O
zeta O O
- O O
globin O O
promoter O O
. O O

Furthermore O O
, O O
this O O
modulation O O
was O O
thought O O
to O O
be O O
mediated O O
through O O
configurational O O
changes O O
of O O
the O O
HS O O
- O O
40 O O
enhanceosome O O
during O O
development O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
further O O
investigated O O
the O O
molecular O O
basis O O
of O O
this O O
model O O
. O O

First O O
, O O
human O O
erythroid B-CellLine B-CellLine
K562 I-CellLine I-CellLine
cells I-CellLine I-CellLine
stably O O
integrated O O
with O O
various O O
HS O O
- O O
40 O O
mutants O O
cis O O
linked O O
to O O
a O O
human O O
alpha O O
- O O
globin O O
promoter O O
- O O
growth O O
hormone O O
hybrid O O
gene O O
were O O
analyzed O O
by O O
genomic O O
footprinting O O
and O O
expression O O
analysis O O
. O O

By O O
the O O
assay O O
, O O
we O O
demonstrate O O
that O O
factors O O
bound O O
at O O
different O O
motifs O O
of O O
HS O O
- O O
40 O O
indeed O O
act O O
in O O
concert O O
to O O
build O O
a O O
fully O O
functional O O
enhanceosome O O
. O O

Thus O O
, O O
modification O O
of O O
factor O O
binding O O
at O O
a O O
single O O
motif O O
could O O
drastically O O
change O O
the O O
configuration O O
and O O
function O O
of O O
the O O
HS O O
- O O
40 O O
enhanceosome O O
. O O

Second O O
, O O
a O O
specific O O
1 O O
- O O
bp O O
, O O
GC O O
- O O
- O O
> O O
TA O O
mutation O O
in O O
the O O
3 O O
' O O
- O O
NA O O
motif O O
of O O
HS O O
- O O
40 O O
, O O
3 O O
' O O
- O O
NA O O
( O O
II O O
) O O
, O O
has O O
been O O
shown O O
previously O O
to O O
cause O O
significant O O
derepression O O
of O O
the O O
embryonic O O
zeta O O
- O O
globin O O
promoter O O
activity O O
in O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
Second O O
, O O
a O O
specific O O
1 O O
- O O
bp O O
, O O
GC O O
- O O
- O O
> O O
TA O O
mutation O O
in O O
the O O
3 O O
' O O
- O O
NA O O
motif O O
of O O
HS O O
- O O
40 O O
, O O
3 O O
' O O
- O O
NA O O
( O O
II O O
) O O
, O O
has O O
been O O
shown O O
previously O O
to O O
cause O O
significant O O
derepression O O
of O O
the O O
embryonic O O
zeta O O
- O O
globin O O
promoter O O
activity O O
in O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

This O O
derepression O O
was O O
hypothesized O O
to O O
be O O
regulated O O
through O O
competitive O O
binding O O
of O O
different O O
nuclear O O
factors O O
, O O
in O O
particular O O
AP1 O O
and O O
NF O O
- O O
E2 O O
, O O
to O O
the O O
3 O O
' O O
- O O
NA O O
motif O O
. O O

By O O
gel O O
mobility O O
shift O O
and O O
transient O O
cotransfection O O
assays O O
, O O
we O O
now O O
show O O
that O O
3 O O
' O O
- O O
NA O O
( O O
II O O
) O O
mutation O O
completely O O
abolishes O O
the O O
binding O O
of O O
small O O
MafK O O
homodimer O O
. O O

Surprisingly O O
, O O
NF O O
- O O
E2 O O
as O O
well O O
as O O
AP1 O O
can O O
still O O
bind O O
to O O
the O O
3 O O
' O O
- O O
NA O O
( O O
II O O
) O O
sequence O O
. O O

The O O
association O O
constants O O
of O O
both O O
NF O O
- O O
E2 O O
and O O
AP1 O O
are O O
similar O O
to O O
their O O
interactions O O
with O O
the O O
wild O O
- O O
type O O
3 O O
' O O
- O O
NA O O
motif O O
. O O

However O O
, O O
the O O
3 O O
' O O
- O O
NA O O
( O O
II O O
) O O
mutation O O
causes O O
an O O
approximately O O
twofold O O
reduction O O
of O O
the O O
binding O O
affinity O O
of O O
NF O O
- O O
E2 O O
factor O O
to O O
the O O
3 O O
' O O
- O O
NA O O
motif O O
. O O

This O O
reduction O O
of O O
affinity O O
could O O
be O O
accounted O O
for O O
by O O
a O O
twofold O O
- O O
higher O O
rate O O
of O O
dissociation O O
of O O
the O O
NF O O
- O O
E2 O O
- O O
3 O O
' O O
- O O
NA O O
( O O
II O O
) O O
complex O O
. O O

Finally O O
, O O
we O O
show O O
by O O
chromatin O O
immunoprecipitation O O
experiments O O
that O O
only O O
binding O O
of O O
NF O O
- O O
E2 O O
, O O
not O O
AP1 O O
, O O
could O O
be O O
detected O O
in O O
vivo O O
in O O
K562 B-CellLine B-CellLine
cells I-CellLine I-CellLine
around O O
the O O
HS O O
- O O
40 O O
region O O
. O O

These O O
data O O
exclude O O
a O O
role O O
for O O
AP1 O O
in O O
the O O
developmental O O
regulation O O
of O O
the O O
human O O
alpha O O
- O O
globin O O
locus O O
via O O
the O O
3 O O
' O O
- O O
NA O O
motif O O
of O O
HS O O
- O O
40 O O
in O O
embryonic O O
/ O O
fetal O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
These O O
data O O
exclude O O
a O O
role O O
for O O
AP1 O O
in O O
the O O
developmental O O
regulation O O
of O O
the O O
human O O
alpha O O
- O O
globin O O
locus O O
via O O
the O O
3 O O
' O O
- O O
NA O O
motif O O
of O O
HS O O
- O O
40 O O
in O O
embryonic O O
/ O O
fetal O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Furthermore O O
, O O
extrapolation O O
of O O
the O O
in O O
vitro O O
binding O O
studies O O
suggests O O
that O O
factors O O
other O O
than O O
NF O O
- O O
E2 O O
, O O
such O O
as O O
the O O
small O O
Maf O O
homodimers O O
, O O
are O O
likely O O
involved O O
in O O
the O O
regulation O O
of O O
the O O
HS O O
- O O
40 O O
function O O
in O O
vivo O O
. O O

Direct O O
interaction O O
of O O
NF O O
- O O
E2 O O
with O O
hypersensitive O O
site O O
2 O O
of O O
the O O
beta O O
- O O
globin O O
locus O O
control O O
region O O
in O O
living O O
cells O O
. O O

The O O
human O O
beta O O
- O O
globin O O
locus O O
control O O
region O O
( O O
LCR O O
) O O
confers O O
high O O
- O O
level O O
, O O
tissue O O
- O O
specific O O
expression O O
to O O
the O O
beta O O
- O O
globin O O
genes O O
. O O

Tandem O O
Maf O O
recognition O O
elements O O
( O O
MAREs O O
) O O
within O O
the O O
hypersensitive O O
site O O
2 O O
( O O
HS2 O O
) O O
subregion O O
of O O
the O O
LCR O O
are O O
important O O
for O O
the O O
strong O O
enhancer O O
activity O O
of O O
the O O
LCR O O
. O O

Multiple O O
proteins O O
are O O
capable O O
of O O
interacting O O
with O O
these O O
sites O O
in O O
vitro O O
, O O
including O O
the O O
erythroid B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
and O O
megakaryocyte B-CellLine B-CellLine
- O O
specific O O
transcription O O
factor O O
, O O
NF O O
- O O
E2 O O
. O O

The O O
importance O O
of O O
NF O O
- O O
E2 O O
for O O
beta O O
- O O
globin O O
gene O O
expression O O
is O O
evident O O
in O O
murine O O
erythroleukemia B-CellLine B-CellLine
cells I-CellLine I-CellLine
lacking O O
the O O
p45 O O
subunit O O
of O O
NF O O
- O O
E2 O O
. O O

These O O
CB3 B-CellLine B-CellLine
cells I-CellLine I-CellLine
have O O
a O O
severe O O
defect O O
in O O
alpha O O
- O O
and O O
beta O O
- O O
globin O O
gene O O
transcription O O
, O O
which O O
can O O
be O O
restored O O
by O O
expression O O
of O O
NF O O
- O O
E2 O O
. O O

However O O
, O O
mice O O
nullizygous O O
for O O
p45 O O
express O O
nearly O O
normal O O
levels O O
of O O
beta O O
- O O
globin O O
. O O

Thus O O
, O O
either O O
a O O
redundant O O
factor O O
( O O
s O O
) O O
exists O O
in O O
mice O O
that O O
can O O
functionally O O
replace O O
NF O O
- O O
E2 O O
, O O
or O O
NF O O
- O O
E2 O O
does O O
not O O
function O O
through O O
the O O
LCR O O
to O O
regulate O O
beta O O
- O O
globin O O
gene O O
expression O O
. O O

To O O
address O O
this O O
issue O O
, O O
we O O
asked O O
whether O O
NF O O
- O O
E2 O O
binds O O
directly O O
to O O
the O O
tandem O O
MAREs O O
of O O
HS2 O O
in O O
intact O O
cells O O
. O O

Using O O
a O O
chromatin O O
immunoprecipitation O O
assay O O
, O O
we O O
provide O O
evidence O O
for O O
NF O O
- O O
E2 O O
binding O O
directly O O
and O O
specifically O O
to O O
HS2 O O
in O O
living O O
erythroleukemia B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
in O O
mouse O O
fetal O O
liver B-CellLine B-CellLine
. O O

The O O
specific O O
immunoisolation O O
of O O
HS2 O O
sequences O O
was O O
dependent O O
on O O
the O O
presence O O
of O O
p45 O O
and O O
on O O
intact O O
MAREs O O
within O O
HS2 O O
. O O

These O O
results O O
support O O
a O O
direct O O
role O O
for O O
NF O O
- O O
E2 O O
in O O
the O O
regulation O O
of O O
beta O O
- O O
globin O O
gene O O
expression O O
through O O
activation O O
of O O
the O O
LCR O O
. O O

Stem B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
epigenetic O O
priming O O
and O O
B B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
transcriptional O O
activation O O
at O O
the O O
mouse O O
Cd19 O O
locus O O
. O O

Low O O
- O O
level O O
expression O O
of O O
multiple O O
lineage O O
- O O
specific O O
genes O O
is O O
a O O
hallmark O O
of O O
hematopoietic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
HSCs B-CellLine B-CellLine
) O O
. O O
HSCs B-CellLine B-CellLine
predominantly O O
express O O
genes O O
specific O O
for O O
the O O
myeloid B-CellLine B-CellLine
or O O
megakaryocytic B-CellLine B-CellLine
- I-CellLine O
erythroid I-CellLine B-CellLine
lineages I-CellLine I-CellLine
, O O
whereas O O
the O O
transcription O O
of O O
lymphoid B-CellLine B-CellLine
specific O O
genes O O
appears O O
to O O
begin O O
after O O
lymphoid B-CellLine B-CellLine
specification O O
. O O

It O O
has O O
been O O
demonstrated O O
for O O
a O O
number O O
of O O
genes O O
that O O
epigenetic O O
priming O O
occurs O O
before O O
gene O O
expression O O
and O O
lineage O O
specification O O
; O O
however O O
, O O
little O O
is O O
known O O
about O O
how O O
epigenetic O O
priming O O
of O O
lymphoid B-CellLine B-CellLine
genes O O
is O O
regulated O O
. O O

To O O
address O O
the O O
question O O
of O O
how O O
B B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
restricted O O
expression O O
is O O
established O O
, O O
we O O
studied O O
activation O O
of O O
the O O
Cd19 O O
gene O O
during O O
hematopoietic B-CellLine O
development O O
. O O

We O O
identified O O
a O O
B B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
upstream O O
enhancer O O
and O O
showed O O
that O O
the O O
developmental O O
regulation O O
of O O
Cd19 O O
expression O O
involves O O
precisely O O
coordinated O O
alterations O O
in O O
transcription O O
factor O O
binding O O
and O O
chromatin O O
remodeling O O
at O O
Cd19 O O
cis O O
- O O
regulatory O O
elements O O
. O O
We O O
identified O O
a O O
B B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
upstream O O
enhancer O O
and O O
showed O O
that O O
the O O
developmental O O
regulation O O
of O O
Cd19 O O
expression O O
involves O O
precisely O O
coordinated O O
alterations O O
in O O
transcription O O
factor O O
binding O O
and O O
chromatin O O
remodeling O O
at O O
Cd19 O O
cis O O
- O O
regulatory O O
elements O O
. O O

In O O
multipotent O O
progenitor O O
cells O O
, O O
Cd19 O O
chromatin O O
is O O
first O O
remodeled O O
at O O
the O O
upstream O O
enhancer O O
, O O
and O O
this O O
remodeling O O
is O O
associated O O
with O O
binding O O
of O O
E2A O O
. O O

This O O
is O O
followed O O
by O O
the O O
binding O O
of O O
EBF O O
and O O
PAX5 O O
during O O
B B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
differentiation O O
. O O

The O O
Cd19 O O
promoter O O
is O O
transcriptionally O O
activated O O
only O O
after O O
PAX5 O O
binding O O
. O O
The O O
Cd19 O O
promoter O O
is O O
transcriptionally O O
activated O O
only O O
after O O
PAX5 O O
binding O O
. O O

Our O O
experiments O O
give O O
important O O
mechanistic O O
insights O O
into O O
how O O
widely O O
expressed O O
and O O
B O B-CellLine
lineage O I-CellLine
- O O
specific O O
transcription O O
factors O O
cooperate O O
to O O
mediate O O
the O O
developmental O O
regulation O O
of O O
lymphoid B-CellLine B-CellLine
genes O O
during O O
hematopoiesis O O
. O O

Methyltransferase O O
Set7 O O
/ O O
9 O O
maintains O O
transcription O O
and O O
euchromatin O O
structure O O
at O O
islet B-CellLine B-CellLine
- O O
enriched O O
genes O O
. O O

OBJECTIVE O O
: O O
The O O
activation O O
of O O
beta B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
genes O O
, O O
particularly O O
of O O
those O O
encoding O O
preproinsulin O O
, O O
requires O O
an O O
appropriate O O
euchromatin O O
( O O
or O O
" O O
open O O
" O O
) O O
DNA O O
template O O
characterized O O
by O O
hypermethylation O O
of O O
Lys4 O O
of O O
histone O O
H3 O O
. O O

We O O
hypothesized O O
that O O
this O O
modification O O
is O O
maintained O O
in O O
islet B-CellLine B-CellLine
beta I-CellLine B-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
the O O
action O O
of O O
the O O
histone O O
methyltransferase O O
Set7 O O
/ O O
9 O O
. O O

RESEARCH O O
DESIGN O O
AND O O
METHODS O O
: O O
To O O
identify O O
the O O
role O O
of O O
Set7 O O
/ O O
9 O O
, O O
we O O
characterized O O
its O O
expression O O
pattern O O
and O O
gene O O
regulation O O
and O O
studied O O
its O O
function O O
using O O
RNA O O
interference O O
in O O
both O O
cell O O
lines O O
and O O
primary O O
mouse O O
islets B-CellLine B-CellLine
. O O

RESULTS O O
: O O
Within O O
the O O
pancreas B-CellLine B-CellLine
, O O
Set7 O O
/ O O
9 O O
protein O O
shows O O
striking O O
specificity O O
for O O
islet B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
including O O
alpha B-CellLine O
- I-CellLine O
and O O
beta B-CellLine B-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
as O O
well O O
as O O
occasional O O
cells O O
within O O
ducts O O
. O O

Consistent O O
with O O
these O O
findings O O
, O O
the O O
Set7 O O
/ O O
9 O O
gene O O
promoter O O
contained O O
an O O
islet B-CellLine B-CellLine
- O O
specific O O
enhancer O O
located O O
between O O
- O O
5 O O
, O O
768 O O
and O O
- O O
6 O O
, O O
030 O O
base O O
pairs O O
( O O
relative O O
to O O
the O O
transcriptional O O
start O O
site O O
) O O
that O O
exhibited O O
Pdx1 O O
- O O
responsive O O
activation O O
in O O
beta B-CellLine B-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O
Consistent O O
with O O
these O O
findings O O
, O O
the O O
Set7 O O
/ O O
9 O O
gene O O
promoter O O
contained O O
an O O
islet B-CellLine B-CellLine
- O O
specific O O
enhancer O O
located O O
between O O
- O O
5 O O
, O O
768 O O
and O O
- O O
6 O O
, O O
030 O O
base O O
pairs O O
( O O
relative O O
to O O
the O O
transcriptional O O
start O O
site O O
) O O
that O O
exhibited O O
Pdx1 O O
- O O
responsive O O
activation O O
in O O
beta B-CellLine B-CellLine
- I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

To O O
study O O
Set7 O O
/ O O
9 O O
function O O
, O O
we O O
depleted O O
insulinoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
primary O O
mouse O O
islets B-CellLine B-CellLine
of O O
Set7 O O
/ O O
9 O O
protein O O
using O O
siRNA O O
. O O

Following O O
siRNA O O
treatment O O
, O O
we O O
observed O O
striking O O
repression O O
of O O
genes O O
involved O O
in O O
glucose O O
- O O
stimulated O O
insulin O O
secretion O O
, O O
including O O
Ins1 O O
/ O O
2 O O
, O O
Glut2 O O
, O O
and O O
MafA O O
. O O

These O O
changes O O
in O O
transcription O O
were O O
accompanied O O
by O O
loss O O
of O O
dimethylated O O
H3 O O
Lys4 O O
and O O
RNA O O
polymerase O O
II O O
recruitment O O
, O O
particularly O O
at O O
the O O
Ins1 O O
/ O O
2 O O
and O O
Glut2 O O
genes O O
. O O

Consistent O O
with O O
these O O
data O O
, O O
depletion O O
of O O
Set7 O O
/ O O
9 O O
in O O
islets B-CellLine B-CellLine
led O O
to O O
defects O O
in O O
glucose O O
- O O
stimulated O O
Ca O O
( O O
2 O O
+ O O
) O O
mobilization O O
and O O
insulin O O
secretion O O
. O O

CONCLUSIONS O O
: O O
We O O
conclude O O
that O O
Set7 O O
/ O O
9 O O
is O O
required O O
for O O
normal O O
beta B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
function O O
, O O
likely O O
through O O
the O O
maintenance O O
of O O
euchromatin O O
structure O O
at O O
genes O O
necessary O O
for O O
glucose O O
- O O
stimulated O O
insulin O O
secretion O O
. O O

A O O
far O O
- O O
upstream O O
Oct O O
- O O
1 O O
motif O O
regulates O O
cytokine O O
- O O
induced O O
transcription O O
of O O
the O O
human O O
inducible O O
nitric O O
oxide O O
synthase O O
gene O O
. O O
A O O
far O O
- O O
upstream O O
Oct O O
- O O
1 O O
motif O O
regulates O O
cytokine O O
- O O
induced O O
transcription O O
of O O
the O O
human O O
inducible O O
nitric O O
oxide O O
synthase O O
gene O O
. O O

Transcriptional O O
regulation O O
of O O
the O O
human O O
inducible O O
nitric O O
oxide O O
synthase O O
( O O
hiNOS O O
) O O
gene O O
is O O
highly O O
complex O O
and O O
requires O O
an O O
orchestrated O O
flow O O
of O O
positive O O
and O O
negative O O
transcription O O
factors O O
that O O
bind O O
to O O
specific O O
cis O O
- O O
acting O O
upstream O O
response O O
elements O O
. O O

Very O O
little O O
specific O O
information O O
exists O O
about O O
the O O
far O O
- O O
upstream O O
region O O
of O O
the O O
hiNOS O O
gene O O
. O O
Oct O O
- O O
1 O O
protein O O
belongs O O
to O O
the O O
Pit O O
- O O
Oct O O
- O O
Unc O O
domain O O
transcription O O
factor O O
family O O
and O O
is O O
constitutively O O
expressed O O
in O O
all O O
dividing O O
cells O O
. O O

It O O
is O O
essential O O
for O O
proliferation O O
, O O
differentiation O O
, O O
and O O
other O O
key O O
cell O O
processes O O
. O O

However O O
, O O
the O O
role O O
of O O
Oct O O
- O O
1 O O
in O O
regulating O O
hiNOS O O
gene O O
expression O O
has O O
not O O
been O O
reported O O
. O O

In O O
this O O
work O O
, O O
the O O
octamer O O
sequence O O
5 O O
' O O
- O O
ATGCAAAT O O
- O O
3 O O
' O O
at O O
- O O
10 O O
. O O
2 O O
kb O O
in O O
the O O
hiNOS O O
promoter O O
was O O
identified O O
as O O
high O O
- O O
affinity O O
Oct O O
- O O
1 O O
binding O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
in O O
vitro O O
and O O
chromatin O O
immunoprecipitation O O
assay O O
in O O
vivo O O
. O O
In O O
this O O
work O O
, O O
the O O
octamer O O
sequence O O
5 O O
' O O
- O O
ATGCAAAT O O
- O O
3 O O
' O O
at O O
- O O
10 O O
. O O
2 O O
kb O O
in O O
the O O
hiNOS O O
promoter O O
was O O
identified O O
as O O
high O O
- O O
affinity O O
Oct O O
- O O
1 O O
binding O O
by O O
electrophoretic O O
mobility O O
shift O O
assay O O
in O O
vitro O O
and O O
chromatin O O
immunoprecipitation O O
assay O O
in O O
vivo O O
. O O

Mutation O O
of O O
Oct O O
- O O
1 O O
motif O O
at O O
- O O
10 O O
. O O
2 O O
kb O O
in O O
the O O
hiNOS O O
promoter O O
decreased O O
cytokine O O
- O O
induced O O
hiNOS O O
promoter O O
activity O O
by O O
40 O O
% O O
. O O
Mutation O O
of O O
Oct O O
- O O
1 O O
motif O O
at O O
- O O
10 O O
. O O
2 O O
kb O O
in O O
the O O
hiNOS O O
promoter O O
decreased O O
cytokine O O
- O O
induced O O
hiNOS O O
promoter O O
activity O O
by O O
40 O O
% O O
. O O

Cytokine O O
- O O
induced O O
hiNOS O O
promoter O O
activity O O
was O O
also O O
significantly O O
reduced O O
by O O
Oct O O
- O O
1 O O
small O O
interfering O O
RNA O O
targeting O O
. O O
Cytokine O O
- O O
induced O O
hiNOS O O
promoter O O
activity O O
was O O
also O O
significantly O O
reduced O O
by O O
Oct O O
- O O
1 O O
small O O
interfering O O
RNA O O
targeting O O
. O O

Overexpression O O
of O O
Oct O O
- O O
1 O O
increased O O
cytokine O O
- O O
induced O O
hiNOS O O
protein O O
expression O O
in O O
primary O O
human O O
hepatocytes B-CellLine B-CellLine
. O O

Furthermore O O
, O O
the O O
Oct O O
- O O
1 O O
motif O O
at O O
- O O
10 O O
. O O
2 O O
kb O O
of O O
the O O
hiNOS O O
promoter O O
conferred O O
increased O O
transcriptional O O
activity O O
to O O
the O O
heterologous O O
thymidine O O
kinase O O
promoter O O
irrespective O O
of O O
cytokine O O
induction O O
. O O
Furthermore O O
, O O
the O O
Oct O O
- O O
1 O O
motif O O
at O O
- O O
10 O O
. O O
2 O O
kb O O
of O O
the O O
hiNOS O O
promoter O O
conferred O O
increased O O
transcriptional O O
activity O O
to O O
the O O
heterologous O O
thymidine O O
kinase O O
promoter O O
irrespective O O
of O O
cytokine O O
induction O O
. O O

Taken O O
together O O
, O O
this O O
work O O
identifies O O
a O O
far O O
- O O
upstream O O
functional O O
Oct O O
- O O
1 O O
enhancer O O
motif O O
at O O
- O O
10 O O
. O O
2 O O
kb O O
in O O
the O O
hiNOS O O
promoter O O
that O O
regulates O O
cytokine O O
- O O
induced O O
hiNOS O O
gene O O
transcription O O
and O O
further O O
underscores O O
tight O O
control O O
mechanisms O O
regulating O O
the O O
expression O O
of O O
the O O
hiNOS O O
gene O O
. O O
Taken O O
together O O
, O O
this O O
work O O
identifies O O
a O O
far O O
- O O
upstream O O
functional O O
Oct O O
- O O
1 O O
enhancer O O
motif O O
at O O
- O O
10 O O
. O O
2 O O
kb O O
in O O
the O O
hiNOS O O
promoter O O
that O O
regulates O O
cytokine O O
- O O
induced O O
hiNOS O O
gene O O
transcription O O
and O O
further O O
underscores O O
tight O O
control O O
mechanisms O O
regulating O O
the O O
expression O O
of O O
the O O
hiNOS O O
gene O O
. O O

Chromatin O O
and O O
DNA O O
methylation O O
dynamics O O
during O O
retinoic O O
acid O O
- O O
induced O O
RET O O
gene O O
transcriptional O O
activation O O
in O O
neuroblastoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Although O O
it O O
is O O
well O O
known O O
that O O
RET O O
gene O O
is O O
strongly O O
activated O O
by O O
retinoic O O
acid O O
( O O
RA O O
) O O
in O O
neuroblastoma B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
the O O
mechanisms O O
underlying O O
such O O
activation O O
are O O
still O O
poorly O O
understood O O
. O O

Here O O
we O O
show O O
that O O
a O O
complex O O
series O O
of O O
molecular O O
events O O
, O O
that O O
include O O
modifications O O
of O O
both O O
chromatin O O
and O O
DNA O O
methylation O O
state O O
, O O
accompany O O
RA O O
- O O
mediated O O
RET O O
activation O O
. O O

Our O O
results O O
indicate O O
that O O
the O O
primary O O
epigenetic O O
determinants O O
of O O
RA O O
- O O
induced O O
RET O O
activation O O
differ O O
between O O
enhancer O O
and O O
promoter O O
regions O O
. O O

At O O
promoter O O
region O O
, O O
the O O
main O O
mark O O
of O O
RET O O
activation O O
was O O
the O O
increase O O
of O O
H3K4me3 O O
levels O O
while O O
no O O
significant O O
changes O O
of O O
the O O
methylation O O
state O O
of O O
H3K27 O O
and O O
H3K9 O O
were O O
observed O O
. O O

At O O
RET O O
enhancer O O
region O O
a O O
bipartite O O
chromatin O O
domain O O
was O O
detected O O
in O O
unstimulated O O
cells O O
and O O
a O O
prompt O O
demethylation O O
of O O
H3K27me3 O O
marked O O
RET O O
gene O O
activation O O
upon O O
RA O O
exposure O O
. O O
At O O
RET O O
enhancer O O
region O O
a O O
bipartite O O
chromatin O O
domain O O
was O O
detected O O
in O O
unstimulated O O
cells O O
and O O
a O O
prompt O O
demethylation O O
of O O
H3K27me3 O O
marked O O
RET O O
gene O O
activation O O
upon O O
RA O O
exposure O O
. O O

Moreover O O
, O O
ChIP O O
experiments O O
demonstrated O O
that O O
EZH2 O O
and O O
MeCP2 O O
repressor O O
complexes O O
were O O
associated O O
to O O
the O O
heavily O O
methylated O O
enhancer O O
region O O
in O O
the O O
absence O O
of O O
RA O O
while O O
both O O
complexes O O
were O O
displaced O O
during O O
RA O O
stimulation O O
. O O

Finally O O
, O O
our O O
data O O
show O O
that O O
a O O
demethylation O O
of O O
a O O
specific O O
CpG O O
site O O
at O O
the O O
enhancer O O
region O O
could O O
favor O O
the O O
displacement O O
of O O
MeCP2 O O
from O O
the O O
heavily O O
methylated O O
RET O O
enhancer O O
region O O
providing O O
a O O
novel O O
potential O O
mechanism O O
for O O
transcriptional O O
regulation O O
of O O
methylated O O
RA O O
- O O
regulated O O
loci O O
. O O
Finally O O
, O O
our O O
data O O
show O O
that O O
a O O
demethylation O O
of O O
a O O
specific O O
CpG O O
site O O
at O O
the O O
enhancer O O
region O O
could O O
favor O O
the O O
displacement O O
of O O
MeCP2 O O
from O O
the O O
heavily O O
methylated O O
RET O O
enhancer O O
region O O
providing O O
a O O
novel O O
potential O O
mechanism O O
for O O
transcriptional O O
regulation O O
of O O
methylated O O
RA O O
- O O
regulated O O
loci O O
. O O

A O O
3 O O
- O O
bp O O
deletion O O
in O O
the O O
HBS1L O O
- O O
MYB O O
intergenic O O
region O O
on O O
chromosome O O
6q23 O O
is O O
associated O O
with O O
HbF O O
expression O O
. O O

Fetal O O
hemoglobin O O
( O O
HbF O O
) O O
is O O
regulated O O
as O O
a O O
multigenic O O
trait O O
. O O

By O O
genome O O
- O O
wide O O
association O O
study O O
, O O
we O O
confirmed O O
that O O
HBS1L O O
- O O
MYB O O
intergenic O O
polymorphisms O O
( O O
HMIP O O
) O O
and O O
BCL11A O O
polymorphisms O O
are O O
highly O O
associated O O
with O O
HbF O O
in O O
Chinese O O
beta O O
- O O
thalassemia O O
heterozygotes O O
. O O

In O O
this O O
population O O
, O O
the O O
variance O O
in O O
HbF O O
resulting O O
from O O
the O O
HMIP O O
is O O
13 O O
. O O
5 O O
% O O
; O O
that O O
resulting O O
from O O
the O O
BCL11A O O
polymorphism O O
is O O
6 O O
. O O
4 O O
% O O
. O O

To O O
identify O O
the O O
functional O O
variant O O
in O O
HMIP O O
, O O
we O O
used O O
1000 O O
Genomes O O
Project O O
data O O
, O O
single O O
nucleotide O O
polymorphism O O
imputation O O
, O O
comparisons O O
of O O
association O O
results O O
across O O
populations O O
, O O
potential O O
transcription O O
factor O O
binding O O
sites O O
, O O
and O O
analysis O O
of O O
phylogenetic O O
conservation O O
. O O

Based O O
on O O
these O O
studies O O
, O O
a O O
hitherto O O
unreported O O
association O O
between O O
HbF O O
expression O O
and O O
a O O
3 O O
- O O
bp O O
deletion O O
, O O
between O O
135 O O
460 O O
326 O O
and O O
135 O O
460 O O
328 O O
bp O O
on O O
chromosome O O
6q23 O O
was O O
found O O
. O O

This O O
3 O O
- O O
bp O O
deletion O O
is O O
in O O
complete O O
linkage O O
disequilibrium O O
with O O
rs9399137 O O
, O O
which O O
is O O
the O O
single O O
nucleotide O O
polymorphism O O
in O O
HMIP O O
most O O
significantly O O
associated O O
with O O
HbF O O
among O O
Chinese O O
, O O
Europeans O O
, O O
and O O
Africans O O
. O O

Chromatin O O
immunoprecipitation O O
assays O O
confirmed O O
erythropoiesis O O
- O O
related O O
transcription O O
factors O O
binding O O
to O O
this O O
region O O
in O O
K562 B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Based O O
on O O
transient O O
expression O O
of O O
a O O
luciferase O O
reporter O O
plasmid O O
, O O
the O O
DNA O O
fragment O O
encompassing O O
the O O
3 O O
- O O
bp O O
deletion O O
polymorphism O O
has O O
enhancer O O
- O O
like O O
activity O O
that O O
is O O
further O O
augmented O O
by O O
the O O
introduction O O
of O O
the O O
3 O O
- O O
bp O O
deletion O O
. O O

This O O
3 O O
- O O
bp O O
deletion O O
polymorphism O O
is O O
probably O O
the O O
most O O
significant O O
functional O O
motif O O
accounting O O
for O O
HMIP O O
modulation O O
of O O
HbF O O
in O O
all O O
3 O O
populations O O
. O O

Genetic O O
and O O
metabolic O O
characterization O O
of O O
insomnia O O
. O O
Insomnia O O
is O O
reported O O
to O O
chronically O O
affect O O
10 O O
~ O O
15 O O
% O O
of O O
the O O
adult O O
population O O
. O O

However O O
, O O
very O O
little O O
is O O
known O O
about O O
the O O
genetics O O
and O O
metabolism O O
of O O
insomnia O O
. O O

Here O O
we O O
surveyed O O
10 O O
, O O
038 O O
Korean O O
subjects O O
whose O O
genotypes O O
have O O
been O O
previously O O
profiled O O
on O O
a O O
genome O O
- O O
wide O O
scale O O
. O O

About O O
16 O O
. O O
5 O O
% O O
reported O O
insomnia O O
and O O
displayed O O
distinct O O
metabolic O O
changes O O
reflecting O O
an O O
increase O O
in O O
insulin O O
secretion O O
, O O
a O O
higher O O
risk O O
of O O
diabetes O O
, O O
and O O
disrupted O O
calcium O O
signaling O O
. O O
Insomnia O O
- O O
associated O O
genotypic O O
differences O O
were O O
highly O O
concentrated O O
within O O
genes O O
involved O O
in O O
neural O O
function O O
. O O

The O O
most O O
significant O O
SNPs O O
resided O O
in O O
ROR1 O O
and O O
PLCB1 O O
, O O
genes O O
known O O
to O O
be O O
involved O O
in O O
bipolar O O
disorder O O
and O O
schizophrenia O O
, O O
respectively O O
. O O

Putative O O
enhancers O O
, O O
as O O
indicated O O
by O O
the O O
histone O O
mark O O
H3K4me1 O O
, O O
were O O
discovered O O
within O O
both O O
genes O O
near O O
the O O
significant O O
SNPs O O
. O O

In O O
neuronal B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
the O O
enhancers O O
were O O
bound O O
by O O
PAX6 O O
, O O
a O O
neural O O
transcription O O
factor O O
that O O
is O O
essential O O
for O O
central B-CellLine B-CellLine
nervous I-CellLine I-CellLine
system I-CellLine I-CellLine
development O O
. O O

Open O O
chromatin O O
signatures O O
were O O
found O O
on O O
the O O
enhancers O O
in O O
human O O
pancreas B-CellLine B-CellLine
, O O
a O O
tissue O O
where O O
PAX6 O O
is O O
known O O
to O O
play O O
a O O
role O O
in O O
insulin O O
secretion O O
. O O

In O O
PLCB1 O O
, O O
CTCF O O
was O O
found O O
to O O
bind O O
downstream O O
of O O
the O O
enhancer O O
and O O
interact O O
with O O
PAX6 O O
, O O
suggesting O O
that O O
it O O
can O O
probably O O
inhibit O O
gene O O
activation O O
by O O
PAX6 O O
. O O
PLCB4 O O
, O O
a O O
circadian O O
gene O O
that O O
is O O
closely O O
located O O
downstream O O
of O O
PLCB1 O O
, O O
was O O
identified O O
as O O
a O O
candidate O O
target O O
gene O O
. O O

Hence O O
, O O
dysregulation O O
of O O
ROR1 O O
, O O
PLCB1 O O
, O O
or O O
PLCB4 O O
by O O
PAX6 O O
and O O
CTCF O O
may O O
be O O
one O O
mechanism O O
that O O
links O O
neural O O
and O O
pancreatic O O
dysfunction O O
not O O
only O O
in O O
insomnia O O
but O O
also O O
in O O
the O O
relevant O O
psychiatric O O
disorders O O
that O O
are O O
accompanied O O
with O O
circadian O O
rhythm O O
disruption O O
and O O
metabolic O O
syndrome O O
. O O

Differential O O
regulation O O
of O O
sense O O
and O O
antisense O O
promoter O O
activity O O
at O O
the O O
Csf1R O O
locus O O
in O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
by O O
the O O
transcription O O
factor O O
PAX5 O O
. O O
Differential O O
regulation O O
of O O
sense O O
and O O
antisense O O
promoter O O
activity O O
at O O
the O O
Csf1R O O
locus O O
in O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
by O O
the O O
transcription O O
factor O O
PAX5 O O
. O O

OBJECTIVE O O
: O O
The O O
transcription O O
factor O O
PAX5 O O
is O O
essential O O
for O O
the O O
activation O O
of O O
B B-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
genes O O
and O O
for O O
the O O
silencing O O
of O O
myeloid B-CellLine B-CellLine
- O O
specific O O
genes O O
. O O

We O O
previously O O
determined O O
the O O
molecular O O
mechanism O O
by O O
which O O
PAX5 O O
silences O O
the O O
myeloid B-CellLine B-CellLine
- O O
specific O O
colony O O
- O O
stimulating O O
- O O
factor O O
- O O
receptor O O
( O O
Csf1R O O
) O O
gene O O
and O O
showed O O
that O O
PAX5 O O
directly O O
binds O O
to O O
the O O
Csf1r O O
promoter O O
as O O
well O O
as O O
to O O
an O O
intronic O O
enhancer O O
that O O
generates O O
an O O
antisense O O
transcript O O
in O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Here O O
we O O
examine O O
the O O
role O O
of O O
PAX5 O O
in O O
the O O
regulation O O
of O O
sense O O
and O O
antisense O O
transcription O O
in O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
performed O O
PAX5 O O
- O O
specific O O
chromatin O O
immunoprecipitation O O
analyses O O
across O O
the O O
Csfr1 O O
locus O O
. O O
MATERIALS O O
AND O O
METHODS O O
: O O
We O O
performed O O
PAX5 O O
- O O
specific O O
chromatin O O
immunoprecipitation O O
analyses O O
across O O
the O O
Csfr1 O O
locus O O
. O O

We O O
investigated O O
the O O
role O O
of O O
PAX5 O O
in O O
regulating O O
Csf1r O O
sense O O
and O O
antisense O O
promoter O O
activity O O
by O O
transient O O
transfections O O
and O O
by O O
employing O O
a O O
Pax5 O O
( O O
- O O
/ O O
- O O
) O O
pro B-CellLine O
- I-CellLine O
B I-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
expressing O O
an O O
inducible O O
PAX5 O O
protein O O
. O O
PAX5 O O
interacting O O
factors O O
were O O
identified O O
by O O
pull O O
- O O
down O O
experiments O O
. O O
We O O
investigated O O
the O O
role O O
of O O
PAX5 O O
in O O
regulating O O
Csf1r O O
sense O O
and O O
antisense O O
promoter O O
activity O O
by O O
transient O O
transfections O O
and O O
by O O
employing O O
a O O
Pax5 O O
( O O
- O O
/ O O
- O O
) O O
pro B-CellLine O
- I-CellLine O
B I-CellLine B-CellLine
- I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
expressing O O
an O O
inducible O O
PAX5 O O
protein O O
. O O
PAX5 O O
interacting O O
factors O O
were O O
identified O O
by O O
pull O O
- O O
down O O
experiments O O
. O O

The O O
role O O
of O O
the O O
transcription O O
factor O O
Sp3 O O
in O O
driving O O
antisense O O
promoter O O
expression O O
was O O
examined O O
in O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
from O O
Sp3 O O
knockout O O
mice O O
. O O

RESULTS O O
: O O
PAX5 O O
differentially O O
regulates O O
the O O
Csf1r O O
promoter O O
and O O
the O O
promoter O O
of O O
the O O
antisense O O
transcript O O
. O O
PAX5 O O
interferes O O
with O O
PU O O
. O O
1 O O
transactivation O O
at O O
the O O
sense O O
promoter O O
by O O
binding O O
to O O
a O O
PAX5 O O
consensus O O
sequence O O
. O O
RESULTS O O
: O O
PAX5 O O
differentially O O
regulates O O
the O O
Csf1r O O
promoter O O
and O O
the O O
promoter O O
of O O
the O O
antisense O O
transcript O O
. O O
PAX5 O O
interferes O O
with O O
PU O O
. O O
1 O O
transactivation O O
at O O
the O O
sense O O
promoter O O
by O O
binding O O
to O O
a O O
PAX5 O O
consensus O O
sequence O O
. O O

At O O
the O O
antisense O O
promoter O O
, O O
PAX5 O O
does O O
not O O
specifically O O
recognize O O
DNA O O
, O O
but O O
interacts O O
with O O
Sp3 O O
to O O
upregulate O O
antisense O O
promoter O O
activity O O
. O O
Antisense O O
promoter O O
activation O O
by O O
PAX5 O O
is O O
dependent O O
on O O
the O O
presence O O
of O O
its O O
partial O O
homeo O O
- O O
domain O O
. O O

CONCLUSIONS O O
: O O
We O O
demonstrate O O
that O O
PAX5 O O
regulates O O
Csf1r O O
in O O
B B-CellLine B-CellLine
cells I-CellLine I-CellLine
by O O
reducing O O
the O O
frequency O O
of O O
binding O O
of O O
the O O
basal O O
transcription O O
machinery O O
to O O
the O O
promoter O O
and O O
by O O
activating O O
antisense O O
RNA O O
expression O O
. O O

N O O
- O O
carbamylglutamate O O
enhancement O O
of O O
ureagenesis O O
leads O O
to O O
discovery O O
of O O
a O O
novel O O
deleterious O O
mutation O O
in O O
a O O
newly O O
defined O O
enhancer O O
of O O
the O O
NAGS O O
gene O O
and O O
to O O
effective O O
therapy O O
. O O
N O O
- O O
acetylglutamate O O
synthase O O
( O O
NAGS O O
) O O
catalyzes O O
the O O
conversion O O
of O O
glutamate O O
and O O
acetyl O O
- O O
CoA O O
to O O
NAG O O
, O O
the O O
essential O O
allosteric O O
activator O O
of O O
carbamyl O O
phosphate O O
synthetase O O
I O O
, O O
the O O
first O O
urea O O
cycle O O
enzyme O O
in O O
mammals O O
. O O
N O O
- O O
carbamylglutamate O O
enhancement O O
of O O
ureagenesis O O
leads O O
to O O
discovery O O
of O O
a O O
novel O O
deleterious O O
mutation O O
in O O
a O O
newly O O
defined O O
enhancer O O
of O O
the O O
NAGS O O
gene O O
and O O
to O O
effective O O
therapy O O
. O O
N O O
- O O
acetylglutamate O O
synthase O O
( O O
NAGS O O
) O O
catalyzes O O
the O O
conversion O O
of O O
glutamate O O
and O O
acetyl O O
- O O
CoA O O
to O O
NAG O O
, O O
the O O
essential O O
allosteric O O
activator O O
of O O
carbamyl O O
phosphate O O
synthetase O O
I O O
, O O
the O O
first O O
urea O O
cycle O O
enzyme O O
in O O
mammals O O
. O O

A O O
17 O O
- O O
year O O
- O O
old O O
female O O
with O O
recurrent O O
hyperammonemia O O
attacks O O
, O O
the O O
cause O O
of O O
which O O
remained O O
undiagnosed O O
for O O
8 O O
years O O
in O O
spite O O
of O O
multiple O O
molecular O O
and O O
biochemical O O
investigations O O
, O O
showed O O
markedly O O
enhanced O O
ureagenesis O O
( O O
measured O O
by O O
isotope O O
incorporation O O
) O O
in O O
response O O
to O O
N O O
- O O
carbamylglutamate O O
( O O
NCG O O
) O O
. O O

This O O
led O O
to O O
sequencing O O
of O O
the O O
regulatory O O
regions O O
of O O
the O O
NAGS O O
gene O O
and O O
identification O O
of O O
a O O
deleterious O O
single O O
- O O
base O O
substitution O O
in O O
the O O
upstream O O
enhancer O O
. O O

The O O
homozygous O O
mutation O O
( O O
c O O
. O O
- O O
3064C O O
> O O
A O O
) O O
, O O
affecting O O
a O O
highly O O
conserved O O
nucleotide O O
within O O
the O O
hepatic O O
nuclear O O
factor O O
1 O O
( O O
HNF O O
- O O
1 O O
) O O
binding O O
site O O
, O O
was O O
not O O
found O O
in O O
single O O
nucleotide O O
polymorphism O O
databases O O
and O O
in O O
a O O
screen O O
of O O
1 O O
, O O
086 O O
alleles O O
from O O
a O O
diverse O O
population O O
. O O
The O O
homozygous O O
mutation O O
( O O
c O O
. O O
- O O
3064C O O
> O O
A O O
) O O
, O O
affecting O O
a O O
highly O O
conserved O O
nucleotide O O
within O O
the O O
hepatic O O
nuclear O O
factor O O
1 O O
( O O
HNF O O
- O O
1 O O
) O O
binding O O
site O O
, O O
was O O
not O O
found O O
in O O
single O O
nucleotide O O
polymorphism O O
databases O O
and O O
in O O
a O O
screen O O
of O O
1 O O
, O O
086 O O
alleles O O
from O O
a O O
diverse O O
population O O
. O O

Functional O O
assays O O
demonstrated O O
that O O
this O O
mutation O O
decreases O O
transcription O O
and O O
binding O O
of O O
HNF O O
- O O
1 O O
to O O
the O O
NAGS O O
gene O O
, O O
while O O
a O O
consensus O O
HNF O O
- O O
1 O O
binding O O
sequence O O
enhances O O
binding O O
to O O
HNF O O
- O O
1 O O
and O O
increases O O
transcription O O
. O O
Functional O O
assays O O
demonstrated O O
that O O
this O O
mutation O O
decreases O O
transcription O O
and O O
binding O O
of O O
HNF O O
- O O
1 O O
to O O
the O O
NAGS O O
gene O O
, O O
while O O
a O O
consensus O O
HNF O O
- O O
1 O O
binding O O
sequence O O
enhances O O
binding O O
to O O
HNF O O
- O O
1 O O
and O O
increases O O
transcription O O
. O O

Oral O O
daily O O
NCG O O
therapy O O
restored O O
ureagenesis O O
in O O
this O O
patient O O
, O O
normalizing O O
her O O
biochemical O O
markers O O
, O O
and O O
allowing O O
discontinuation O O
of O O
alternate O O
pathway O O
therapy O O
and O O
normalization O O
of O O
her O O
diet O O
with O O
no O O
recurrence O O
of O O
hyperammonemia O O
. O O

Inc O O
. O O

The O O
estrogen O O
- O O
regulated O O
transcription O O
factor O O
PITX1 O O
coordinates O O
gene O O
- O O
specific O O
regulation O O
by O O
estrogen O O
receptor O O
- O O
alpha O O
in O O
breast B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

The O O
estrogen O O
receptor O O
alpha O O
( O O
ERalpha O O
) O O
is O O
a O O
master O O
regulator O O
of O O
gene O O
expression O O
and O O
works O O
along O O
with O O
cooperating O O
transcription O O
factors O O
in O O
mediating O O
the O O
actions O O
of O O
the O O
hormone O O
estradiol O O
( O O
E2 O O
) O O
in O O
ER O O
- O O
positive O O
tissues O O
and O O
breast O O
tumors O O
. O O

Here O O
, O O
we O O
report O O
that O O
expression O O
of O O
paired O O
- O O
like O O
homeodomain O O
transcription O O
factor O O
( O O
PITX1 O O
) O O
, O O
a O O
tumor O O
suppressor O O
and O O
member O O
of O O
the O O
homeobox O O
family O O
of O O
transcription O O
factors O O
, O O
is O O
robustly O O
up O O
- O O
regulated O O
by O O
E2 O O
in O O
several O O
ERalpha B-CellLine O
- I-CellLine O
positive I-CellLine O
breast I-CellLine B-CellLine
cancer I-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
via O O
ERalpha O O
- O O
dependent O O
interaction O O
between O O
the O O
proximal O O
promoter O O
and O O
an O O
enhancer O O
region O O
5 O O
' O O
upstream O O
of O O
the O O
PITX1 O O
gene O O
. O O
Here O O
, O O
we O O
report O O
that O O
expression O O
of O O
paired O O
- O O
like O O
homeodomain O O
transcription O O
factor O O
( O O
PITX1 O O
) O O
, O O
a O O
tumor O O
suppressor O O
and O O
member O O
of O O
the O O
homeobox O O
family O O
of O O
transcription O O
factors O O
, O O
is O O
robustly O O
up O O
- O O
regulated O O
by O O
E2 O O
in O O
several O O
ERalpha B-CellLine O
- I-CellLine O
positive I-CellLine O
breast I-CellLine B-CellLine
cancer I-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
via O O
ERalpha O O
- O O
dependent O O
interaction O O
between O O
the O O
proximal O O
promoter O O
and O O
an O O
enhancer O O
region O O
5 O O
' O O
upstream O O
of O O
the O O
PITX1 O O
gene O O
. O O

Overexpression O O
of O O
PITX1 O O
selectively O O
inhibited O O
the O O
transcriptional O O
activity O O
of O O
ERalpha O O
and O O
ERbeta O O
, O O
while O O
enhancing O O
the O O
activities O O
of O O
the O O
glucocorticoid O O
receptor O O
and O O
progesterone O O
receptor O O
. O O

Reduction O O
of O O
PITX1 O O
by O O
small O O
interfering O O
RNA O O
enhanced O O
ERalpha O O
- O O
dependent O O
transcriptional O O
regulation O O
of O O
a O O
subset O O
of O O
ERalpha O O
target O O
genes O O
. O O

The O O
consensus O O
PITX1 O O
binding O O
motif O O
was O O
found O O
to O O
be O O
present O O
in O O
28 O O
% O O
of O O
genome O O
- O O
wide O O
ERalpha O O
binding O O
sites O O
and O O
was O O
in O O
close O O
proximity O O
to O O
estrogen O O
response O O
elements O O
in O O
a O O
subset O O
of O O
ERalpha O O
binding O O
sites O O
, O O
and O O
E2 O O
treatment O O
enhanced O O
PITX1 O O
as O O
well O O
as O O
ERalpha O O
recruitment O O
to O O
these O O
binding O O
sites O O
. O O
The O O
consensus O O
PITX1 O O
binding O O
motif O O
was O O
found O O
to O O
be O O
present O O
in O O
28 O O
% O O
of O O
genome O O
- O O
wide O O
ERalpha O O
binding O O
sites O O
and O O
was O O
in O O
close O O
proximity O O
to O O
estrogen O O
response O O
elements O O
in O O
a O O
subset O O
of O O
ERalpha O O
binding O O
sites O O
, O O
and O O
E2 O O
treatment O O
enhanced O O
PITX1 O O
as O O
well O O
as O O
ERalpha O O
recruitment O O
to O O
these O O
binding O O
sites O O
. O O

These O O
studies O O
identify O O
PITX1 O O
as O O
a O O
new O O
ERalpha O O
transcriptional O O
target O O
that O O
acts O O
as O O
a O O
repressor O O
to O O
coordinate O O
and O O
fine O O
tune O O
target O O
- O O
specific O O
, O O
ERalpha O O
- O O
mediated O O
transcriptional O O
activity O O
in O O
human O O
breast B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Androgen O O
receptor O O
overexpression O O
alters O O
binding O O
dynamics O O
of O O
the O O
receptor O O
to O O
chromatin O O
and O O
chromatin O O
structure O O
. O O

BACKGROUND O O
: O O
Castration O O
- O O
resistant O O
prostate O O
cancers O O
( O O
CRPCs O O
) O O
overexpress O O
often O O
androgen O O
receptor O O
( O O
AR O O
) O O
. O O

Here O O
, O O
we O O
investigated O O
the O O
effect O O
of O O
AR O O
overexpression O O
on O O
the O O
dynamics O O
of O O
AR O O
loading O O
and O O
RNA O O
polymerase O O
II O O
( O O
RNA O O
Pol O O
II O O
) O O
recruitment O O
to O O
chromatin O O
. O O

Acetylation O O
of O O
histone O O
3 O O
( O O
AcH3 O O
) O O
on O O
lysines O O
9 O O
and O O
14 O O
( O O
K9 O O
and O O
K14 O O
) O O
was O O
also O O
studied O O
. O O

METHODS O O
: O O
We O O
used O O
an O O
LNCaP B-CellLine B-CellLine
- I-CellLine O
based I-CellLine O
AR I-CellLine O
overexpression I-CellLine O
cell I-CellLine O
line I-CellLine O
model O O
that O O
includes O O
a O O
control O O
line O O
and O O
two O O
sublines O O
, O O
LNCaP B-CellLine B-CellLine
- I-CellLine I-CellLine
ARmo I-CellLine I-CellLine
and O O
LNCaP B-CellLine B-CellLine
- I-CellLine I-CellLine
ARhi I-CellLine I-CellLine
, O O
which O O
overexpress O O
AR O O
twofold O O
to O O
threefold O O
and O O
fourfold O O
to O O
fivefold O O
, O O
respectively O O
. O O

Cells O O
were O O
exposed O O
to O O
1 O O
or O O
100 O O
nM O O
of O O
dihydrotestosterone O O
( O O
DHT O O
) O O
. O O

Chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
on O O
the O O
promoters O O
and O O
enhancers O O
of O O
prostate O O
specific O O
antigen O O
( O O
PSA O O
) O O
and O O
transmembrane O O
protease O O
, O O
serine O O
2 O O
( O O
TMPRSS2 O O
) O O
genes O O
was O O
performed O O
. O O
qRT O O
- O O
PCR O O
was O O
used O O
to O O
measure O O
the O O
levels O O
of O O
PSA O O
and O O
TMPRSS2 O O
transcripts O O
. O O
Chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
on O O
the O O
promoters O O
and O O
enhancers O O
of O O
prostate O O
specific O O
antigen O O
( O O
PSA O O
) O O
and O O
transmembrane O O
protease O O
, O O
serine O O
2 O O
( O O
TMPRSS2 O O
) O O
genes O O
was O O
performed O O
. O O
qRT O O
- O O
PCR O O
was O O
used O O
to O O
measure O O
the O O
levels O O
of O O
PSA O O
and O O
TMPRSS2 O O
transcripts O O
. O O

RESULTS O O
: O O
Upon O O
stimulation O O
with O O
1 O O
nM O O
DHT O O
, O O
AR O O
and O O
RNA O O
Pol O O
II O O
were O O
recruited O O
onto O O
PSA O O
and O O
TMPRSS2 O O
enhancer O O
regions O O
to O O
a O O
greater O O
extent O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
in O O
AR O O
- O O
overexpressing O O
cells O O
compared O O
to O O
control O O
cells O O
. O O
RESULTS O O
: O O
Upon O O
stimulation O O
with O O
1 O O
nM O O
DHT O O
, O O
AR O O
and O O
RNA O O
Pol O O
II O O
were O O
recruited O O
onto O O
PSA O O
and O O
TMPRSS2 O O
enhancer O O
regions O O
to O O
a O O
greater O O
extent O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
in O O
AR O O
- O O
overexpressing O O
cells O O
compared O O
to O O
control O O
cells O O
. O O

The O O
difference O O
in O O
AR O O
loading O O
between O O
the O O
control O O
and O O
AR O O
- O O
overexpressing O O
cells O O
was O O
abolished O O
by O O
a O O
higher O O
DHT O O
concentration O O
. O O

The O O
ratio O O
of O O
AcH3 O O
/ O O
H3 O O
was O O
increased O O
in O O
AR O O
- O O
overexpressing O O
cells O O
. O O

The O O
induction O O
of O O
transcription O O
of O O
PSA O O
and O O
TMPRSS2 O O
occurred O O
earlier O O
in O O
the O O
AR O O
- O O
overexpressing O O
cells O O
. O O

CONCLUSIONS O O
: O O
Our O O
findings O O
suggest O O
that O O
the O O
levels O O
of O O
AR O O
potentiate O O
the O O
recruitment O O
of O O
the O O
AR O O
, O O
as O O
well O O
as O O
components O O
of O O
the O O
basic O O
transcription O O
machinery O O
, O O
to O O
chromatin O O
and O O
affect O O
the O O
acetylation O O
of O O
histones O O
in O O
the O O
presence O O
of O O
low O O
levels O O
of O O
androgens O O
. O O

These O O
changes O O
result O O
in O O
enhanced O O
gene O O
transcription O O
of O O
AR O O
target O O
genes O O
. O O

Role O O
of O O
runt O O
- O O
related O O
transcription O O
factor O O
3 O O
( O O
RUNX3 O O
) O O
in O O
transcription O O
regulation O O
of O O
natural O O
cytotoxicity O O
receptor O O
1 O O
( O O
NCR1 O O
/ O O
NKp46 O O
) O O
, O O
an O O
activating O O
natural O B-CellLine
killer O I-CellLine
( O I-CellLine
NK O I-CellLine
) O I-CellLine
cell O I-CellLine
receptor O O
. O O
Natural O O
cytotoxicity O O
receptor O O
1 O O
( O O
NCR1 O O
) O O
, O O
also O O
known O O
as O O
NKp46 O O
, O O
is O O
a O O
natural O O
killer O O
( O O
NK O O
) O O
lymphocyte O O
- O O
activating O O
receptor O O
. O O

It O O
is O O
involved O O
in O O
major O O
aspects O O
of O O
NK O O
immune O O
function O O
and O O
shows O O
a O O
high O O
degree O O
of O O
lineage O O
specificity O O
in O O
blood B-CellLine B-CellLine
and O O
bone B-CellLine B-CellLine
marrow I-CellLine I-CellLine
. O O

The O O
nature O O
of O O
its O O
NK O O
- O O
restricted O O
expression O O
is O O
not O O
well O O
understood O O
. O O

In O O
this O O
study O O
, O O
we O O
confirm O O
that O O
human O O
NCR1 O O
NK O O
- O O
specific O O
expression O O
is O O
achieved O O
at O O
the O O
mRNA O O
level O O
. O O

We O O
found O O
two O O
key O O
cis O O
- O O
regulatory O O
elements O O
in O O
the O O
immediate O O
vicinity O O
upstream O O
of O O
the O O
gene O O
. O O

One O O
element O O
acts O O
as O O
an O O
essential O O
promoter O O
, O O
whereas O O
the O O
other O O
acts O O
as O O
a O O
tissue O O
- O O
dependent O O
enhancer O O
/ O O
repressor O O
. O O

This O O
latter O O
regulatory O O
element O O
contains O O
a O O
runt O O
related O O
- O O
transcription O O
factor O O
( O O
RUNX O O
) O O
recognition O O
motif O O
that O O
preferentially O O
binds O O
RUNX3 O O
. O O

Interfering O O
with O O
RUNX O O
proteins O O
using O O
a O O
dominant O O
negative O O
form O O
results O O
in O O
decreased O O
Ncr1 O O
expression O O
. O O
RUNX3 O O
overexpression O O
had O O
the O O
opposite O O
effect O O
. O O

These O O
findings O O
shed O O
light O O
on O O
the O O
role O O
of O O
RUNX3 O O
in O O
the O O
control O O
of O O
an O O
important O O
NK O O
- O O
activating O O
receptor O O
. O O

Regulation O O
of O O
human O O
microsomal O O
prostaglandin O O
E O O
synthase O O
- O O
1 O O
by O O
IL O O
- O O
1beta O O
requires O O
a O O
distal O O
enhancer O O
element O O
with O O
a O O
unique O O
role O O
for O O
C O O
/ O O
EBPbeta O O
. O O

The O O
studies O O
of O O
PGE2 O O
( O O
prostaglandin O O
E2 O O
) O O
biosynthesis O O
have O O
focused O O
primarily O O
on O O
the O O
role O O
of O O
cyclo O O
- O O
oxygenases O O
. O O

Efforts O O
have O O
shifted O O
towards O O
the O O
specific O O
PGE2 O O
terminal O O
synthases O O
, O O
particularly O O
mPGES O O
- O O
1 O O
( O O
microsomal O O
PGE O O
synthase O O
1 O O
) O O
, O O
which O O
has O O
emerged O O
as O O
the O O
crucial O O
inducible O O
synthase O O
with O O
roles O O
in O O
pain O O
, O O
cancer O O
and O O
inflammation O O
. O O
mPGES O O
- O O
1 O O
is O O
induced O O
by O O
pro O O
- O O
inflammatory O O
cytokines O O
with O O
studies O O
focusing O O
on O O
the O O
proximal O O
promoter O O
, O O
mediated O O
specifically O O
through O O
Egr O O
- O O
1 O O
( O O
early O O
growth O O
- O O
response O O
factor O O
1 O O
) O O
. O O

Numerous O O
studies O O
demonstrate O O
that O O
the O O
mPGES O O
- O O
1 O O
promoter O O
( O O
PTGES O O
) O O
alone O O
cannot O O
account O O
for O O
the O O
level O O
of O O
IL O O
- O O
1beta O O
( O O
interleukin O O
1beta O O
) O O
induction O O
. O O
Numerous O O
studies O O
demonstrate O O
that O O
the O O
mPGES O O
- O O
1 O O
promoter O O
( O O
PTGES O O
) O O
alone O O
cannot O O
account O O
for O O
the O O
level O O
of O O
IL O O
- O O
1beta O O
( O O
interleukin O O
1beta O O
) O O
induction O O
. O O

We O O
identified O O
two O O
DNase O O
I O O
- O O
hypersensitive O O
sites O O
within O O
the O O
proximal O O
promoter O O
near O O
the O O
Egr O O
- O O
1 O O
element O O
and O O
a O O
novel O O
distal O O
site O O
near O O
- O O
8 O O
. O O
6 O O
kb O O
. O O

Functional O O
analysis O O
of O O
the O O
distal O O
site O O
revealed O O
two O O
elements O O
that O O
co O O
- O O
operate O O
with O O
basal O O
promoter O O
expression O O
and O O
a O O
stimulus O O
- O O
dependent O O
enhancer O O
. O O

A O O
specific O O
binding O O
site O O
for O O
C O O
/ O O
EBPbeta O O
( O O
CCAAT O O
/ O O
enhancer O O
- O O
binding O O
protein O O
beta O O
) O O
in O O
the O O
enhancer O O
was O O
directly O O
responsible O O
for O O
inducible O O
enhancer O O
activity O O
. O O
A O O
specific O O
binding O O
site O O
for O O
C O O
/ O O
EBPbeta O O
( O O
CCAAT O O
/ O O
enhancer O O
- O O
binding O O
protein O O
beta O O
) O O
in O O
the O O
enhancer O O
was O O
directly O O
responsible O O
for O O
inducible O O
enhancer O O
activity O O
. O O

ChIP O O
( O O
chromatin O O
immunoprecipitation O O
) O O
analysis O O
demonstrated O O
constitutive O O
Egr O O
- O O
1 O O
binding O O
to O O
the O O
promoter O O
and O O
induced O O
RNA O O
polymerase O O
II O O
and O O
C O O
/ O O
EBPbeta O O
binding O O
to O O
the O O
promoter O O
and O O
enhancer O O
respectively O O
. O O

Knockout O O
/ O O
knockdown O O
studies O O
established O O
a O O
functional O O
role O O
for O O
C O O
/ O O
EBPbeta O O
in O O
mPGES O O
- O O
1 O O
gene O O
regulation O O
and O O
the O O
documented O O
interaction O O
between O O
Egr O O
- O O
1 O O
and O O
C O O
/ O O
EBPbeta O O
highlights O O
the O O
proximal O O
promoter O O
co O O
- O O
operation O O
with O O
a O O
novel O O
distal O O
enhancer O O
element O O
in O O
regulating O O
inducible O O
mPGES O O
- O O
1 O O
expression O O
. O O

ISL1 O O
directly O O
regulates O O
FGF10 O O
transcription O O
during O O
human O O
cardiac O O
outflow O O
formation O O
. O O

The O O
LIM O O
homeodomain O O
gene O O
Islet O O
- O O
1 O O
( O O
ISL1 O O
) O O
encodes O O
a O O
transcription O O
factor O O
that O O
has O O
been O O
associated O O
with O O
the O O
multipotency O O
of O O
human O O
cardiac B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
, O O
and O O
in O O
mice O O
enables O O
the O O
correct O O
deployment O O
of O O
second B-CellLine O
heart I-CellLine B-CellLine
field I-CellLine I-CellLine
( O O
SHF B-CellLine B-CellLine
) O O
cells O O
to O O
become O O
the O O
myocardium B-CellLine B-CellLine
of O O
atria B-CellLine B-CellLine
, O O
right B-CellLine B-CellLine
ventricle I-CellLine I-CellLine
and O O
outflow B-CellLine B-CellLine
tract I-CellLine I-CellLine
. O O

Other O O
markers O O
have O O
been O O
identified O O
that O O
characterize O O
subdomains O O
of O O
the O O
SHF B-CellLine O
, O O
such O O
as O O
the O O
fibroblast B-CellLine O
growth O O
factor O O
Fgf10 O O
in O O
its O O
anterior O O
region O O
. O O

While O O
functional O O
evidence O O
of O O
its O O
essential O O
contribution O O
has O O
been O O
demonstrated O O
in O O
many O O
vertebrate O O
species O O
, O O
SHF B-CellLine O
expression O O
of O O
Isl1 O O
has O O
been O O
shown O O
in O O
only O O
some O O
models O O
. O O

We O O
examined O O
the O O
relationship O O
between O O
human O O
ISL1 O O
and O O
FGF10 O O
within O O
the O O
embryonic O O
time O O
window O O
during O O
which O O
the O O
linear B-CellLine O
heart I-CellLine B-CellLine
tube I-CellLine I-CellLine
remodels O O
into O O
four O O
chambers O O
. O O
ISL1 O O
transcription O O
demarcated O O
an O O
anatomical O O
region O O
supporting O O
the O O
conserved O O
existence O O
of O O
a O O
SHF B-CellLine O
in O O
humans O O
, O O
and O O
transcription O O
factors O O
of O O
the O O
GATA O O
family O O
were O O
co O O
- O O
expressed O O
therein O O
. O O

In O O
conjunction O O
, O O
we O O
identified O O
a O O
novel O O
enhancer O O
containing O O
a O O
highly O O
conserved O O
ISL1 O O
consensus O O
binding O O
site O O
within O O
the O O
FGF10 O O
first O O
intron O O
. O O
In O O
conjunction O O
, O O
we O O
identified O O
a O O
novel O O
enhancer O O
containing O O
a O O
highly O O
conserved O O
ISL1 O O
consensus O O
binding O O
site O O
within O O
the O O
FGF10 O O
first O O
intron O O
. O O

ChIP O O
and O O
EMSA O O
demonstrated O O
its O O
direct O O
occupation O O
by O O
ISL1 O O
. O O

Transcription O O
mediated O O
by O O
ISL1 O O
from O O
this O O
FGF10 O O
intronic O O
element O O
was O O
enhanced O O
by O O
the O O
presence O O
of O O
GATA4 O O
and O O
TBX20 O O
cardiac O O
transcription O O
factors O O
. O O
Transcription O O
mediated O O
by O O
ISL1 O O
from O O
this O O
FGF10 O O
intronic O O
element O O
was O O
enhanced O O
by O O
the O O
presence O O
of O O
GATA4 O O
and O O
TBX20 O O
cardiac O O
transcription O O
factors O O
. O O

Finally O O
, O O
transgenic O O
mice O O
confirmed O O
that O O
endogenous O O
factors O O
bound O O
the O O
human O O
FGF10 O O
intronic O O
enhancer O O
to O O
drive O O
reporter O O
expression O O
in O O
the O O
developing O O
cardiac B-CellLine B-CellLine
outflow I-CellLine I-CellLine
tract I-CellLine I-CellLine
. O O
Finally O O
, O O
transgenic O O
mice O O
confirmed O O
that O O
endogenous O O
factors O O
bound O O
the O O
human O O
FGF10 O O
intronic O O
enhancer O O
to O O
drive O O
reporter O O
expression O O
in O O
the O O
developing O O
cardiac B-CellLine B-CellLine
outflow I-CellLine I-CellLine
tract I-CellLine I-CellLine
. O O

These O O
findings O O
highlight O O
the O O
interest O O
of O O
examining O O
developmental O O
regulatory O O
networks O O
directly O O
in O O
human O O
tissues O O
, O O
when O O
possible O O
, O O
to O O
assess O O
candidate O O
non O O
- O O
coding O O
regions O O
that O O
may O O
be O O
responsible O O
for O O
congenital O O
malformations O O
. O O

Regulation O O
of O O
cooperative O O
function O O
of O O
the O O
Il12b O O
enhancer O O
and O O
promoter O O
by O O
the O O
interferon O O
regulatory O O
factors O O
3 O O
and O O
5 O O
. O O
Regulation O O
of O O
cooperative O O
function O O
of O O
the O O
Il12b O O
enhancer O O
and O O
promoter O O
by O O
the O O
interferon O O
regulatory O O
factors O O
3 O O
and O O
5 O O
. O O

The O O
regulation O O
of O O
the O O
Il12b O O
gene O O
, O O
encoding O O
the O O
shared O O
p40 O O
subcomponent O O
for O O
IL O O
- O O
12 O O
and O O
IL O O
- O O
23 O O
, O O
is O O
critical O O
for O O
innate O O
immune O O
responses O O
and O O
subsequent O O
T B-CellLine B-CellLine
cell I-CellLine I-CellLine
polarization O O
. O O

This O O
gene O O
is O O
robustly O O
induced O O
upon O O
Toll O O
- O O
like O O
receptor O O
( O O
TLR O O
) O O
stimulation O O
, O O
wherein O O
an O O
enhancer O O
located O O
10kb O O
upstream O O
of O O
the O O
transcription O O
start O O
site O O
is O O
required O O
for O O
promoter O O
activity O O
; O O
however O O
, O O
the O O
underlying O O
mechanisms O O
that O O
regulate O O
this O O
enhancer O O
in O O
cooperation O O
with O O
the O O
promoter O O
has O O
remained O O
elusive O O
. O O

We O O
show O O
here O O
that O O
the O O
Il12b O O
enhancer O O
contains O O
functional O O
ISREs O O
for O O
recognition O O
by O O
interferon O O
regulatory O O
factors O O
( O O
IRFs O O
) O O
, O O
and O O
provide O O
evidence O O
that O O
TLR O O
- O O
activated O O
IRF5 O O
mediates O O
cooperativity O O
of O O
the O O
enhancer O O
with O O
the O O
promoter O O
which O O
also O O
contains O O
ISREs O O
. O O
We O O
show O O
here O O
that O O
the O O
Il12b O O
enhancer O O
contains O O
functional O O
ISREs O O
for O O
recognition O O
by O O
interferon O O
regulatory O O
factors O O
( O O
IRFs O O
) O O
, O O
and O O
provide O O
evidence O O
that O O
TLR O O
- O O
activated O O
IRF5 O O
mediates O O
cooperativity O O
of O O
the O O
enhancer O O
with O O
the O O
promoter O O
which O O
also O O
contains O O
ISREs O O
. O O

By O O
contrast O O
, O O
IRF3 O O
activated O O
by O O
cytosolic O O
RIG O O
- O O
I O O
- O O
like O O
receptor O O
( O O
RLR O O
) O O
signaling O O
binds O O
to O O
these O O
ISREs O O
and O O
causes O O
gene O O
suppression O O
. O O

Consistently O O
, O O
IRF5 O O
binding O O
is O O
accompanied O O
with O O
chromatin O O
remodeling O O
of O O
both O O
regulatory O O
regions O O
and O O
the O O
formation O O
of O O
a O O
productive O O
transcriptional O O
complex O O
containing O O
other O O
transcription O O
factors O O
, O O
whereas O O
these O O
events O O
are O O
inhibited O O
by O O
IRF3 O O
binding O O
. O O

We O O
show O O
that O O
the O O
ISREs O O
embedded O O
in O O
the O O
enhancer O O
are O O
indeed O O
critical O O
for O O
its O O
activation O O
by O O
IRF5 O O
. O O

We O O
also O O
adduce O O
evidence O O
that O O
the O O
5 O O
' O O
sequences O O
of O O
the O O
enhancer O O
and O O
promoter O O
ISREs O O
, O O
all O O
of O O
which O O
deviate O O
from O O
consensus O O
ISREs O O
, O O
critically O O
affect O O
the O O
function O O
of O O
IRF3 O O
. O O

The O O
dual O O
commitment O O
of O O
these O O
IRFs O O
in O O
the O O
regulation O O
of O O
the O O
Il12b O O
enhancer O O
and O O
promoter O O
is O O
unique O O
and O O
may O O
have O O
implications O O
for O O
understanding O O
the O O
evolution O O
of O O
this O O
gene O O
. O O
The O O
dual O O
commitment O O
of O O
these O O
IRFs O O
in O O
the O O
regulation O O
of O O
the O O
Il12b O O
enhancer O O
and O O
promoter O O
is O O
unique O O
and O O
may O O
have O O
implications O O
for O O
understanding O O
the O O
evolution O O
of O O
this O O
gene O O
. O O

eRNAs O O
are O O
required O O
for O O
p53 O O
- O O
dependent O O
enhancer O O
activity O O
and O O
gene O O
transcription O O
. O O

Binding O O
within O O
or O O
nearby O O
target O O
genes O O
involved O O
in O O
cell O O
proliferation O O
and O O
survival O O
enables O O
the O O
p53 O O
tumor O O
suppressor O O
gene O O
to O O
regulate O O
their O O
transcription O O
and O O
cell O O
- O O
cycle O O
progression O O
. O O

Using O O
genome O O
- O O
wide O O
chromatin O O
- O O
binding O O
profiles O O
, O O
we O O
describe O O
binding O O
of O O
p53 O O
also O O
to O O
regions O O
located O O
distantly O O
from O O
any O O
known O O
p53 O O
target O O
gene O O
. O O

Interestingly O O
, O O
many O O
of O O
these O O
regions O O
possess O O
conserved O O
p53 O O
- O O
binding O O
sites O O
and O O
all O O
known O O
hallmarks O O
of O O
enhancer O O
regions O O
. O O
Interestingly O O
, O O
many O O
of O O
these O O
regions O O
possess O O
conserved O O
p53 O O
- O O
binding O O
sites O O
and O O
all O O
known O O
hallmarks O O
of O O
enhancer O O
regions O O
. O O

We O O
demonstrate O O
that O O
these O O
p53 O O
- O O
bound O O
enhancer O O
regions O O
( O O
p53BERs O O
) O O
indeed O O
contain O O
enhancer O O
activity O O
and O O
interact O O
intrachromosomally O O
with O O
multiple O O
neighboring O O
genes O O
to O O
convey O O
long O O
- O O
distance O O
p53 O O
- O O
dependent O O
transcription O O
regulation O O
. O O
We O O
demonstrate O O
that O O
these O O
p53 O O
- O O
bound O O
enhancer O O
regions O O
( O O
p53BERs O O
) O O
indeed O O
contain O O
enhancer O O
activity O O
and O O
interact O O
intrachromosomally O O
with O O
multiple O O
neighboring O O
genes O O
to O O
convey O O
long O O
- O O
distance O O
p53 O O
- O O
dependent O O
transcription O O
regulation O O
. O O

Furthermore O O
, O O
p53BERs O O
produce O O
, O O
in O O
a O O
p53 O O
- O O
dependent O O
manner O O
, O O
enhancer O O
RNAs O O
( O O
eRNAs O O
) O O
that O O
are O O
required O O
for O O
efficient O O
transcriptional O O
enhancement O O
of O O
interacting O O
target O O
genes O O
and O O
induction O O
of O O
a O O
p53 O O
- O O
dependent O O
cell O O
- O O
cycle O O
arrest O O
. O O

Thus O O
, O O
our O O
results O O
ascribe O O
transcription O O
enhancement O O
activity O O
to O O
p53 O O
with O O
the O O
capacity O O
to O O
regulate O O
multiple O O
genes O O
from O O
a O O
single O O
genomic O O
binding O O
site O O
. O O

Moreover O O
, O O
eRNA O O
production O O
from O O
p53BERs O O
is O O
required O O
for O O
efficient O O
p53 O O
transcription O O
enhancement O O
. O O

Two O O
novel O O
and O O
functional O O
DNA O O
sequence O O
variants O O
within O O
an O O
upstream O O
enhancer O O
of O O
the O O
human O O
NKX2 O O
- O O
5 O O
gene O O
in O O
ventricular O O
septal O O
defects O O
. O O
Two O O
novel O O
and O O
functional O O
DNA O O
sequence O O
variants O O
within O O
an O O
upstream O O
enhancer O O
of O O
the O O
human O O
NKX2 O O
- O O
5 O O
gene O O
in O O
ventricular O O
septal O O
defects O O
. O O

Mortality O O
in O O
patients O O
with O O
congenital O O
heart O O
disease O O
( O O
CHD O O
) O O
is O O
significantly O O
increased O O
even O O
with O O
successful O O
surgeries O O
. O O

The O O
main O O
causes O O
are O O
late O O
cardiac O O
complications O O
, O O
such O O
as O O
heart O O
failure O O
and O O
arrhythmia O O
, O O
probably O O
due O O
to O O
genetic O O
defects O O
. O O

To O O
date O O
, O O
genetic O O
causes O O
for O O
CHD O O
remain O O
largely O O
unknown O O
. O O
NKX2 O O
- O O
5 O O
gene O O
encodes O O
a O O
highly O O
conserved O O
homeobox O O
transcription O O
factor O O
, O O
which O O
is O O
essential O O
to O O
the O O
heart B-CellLine O
development O O
in O O
embryos B-CellLine B-CellLine
and O O
cardiac O O
function O O
in O O
adults O O
. O O

Mutations O O
in O O
NKX2 O O
- O O
5 O O
gene O O
have O O
been O O
implicated O O
in O O
diverse O O
types O O
of O O
CHD O O
, O O
including O O
ventricular O O
septal O O
defect O O
( O O
VSD O O
) O O
. O O

As O O
NKX2 O O
- O O
5 O O
is O O
a O O
dosage O O
- O O
sensitive O O
regulator O O
, O O
we O O
have O O
speculated O O
that O O
changed O O
NKX2 O O
- O O
5 O O
levels O O
may O O
mediate O O
CHD O O
development O O
by O O
influencing O O
cardiac O O
gene O O
regulatory O O
network O O
. O O

In O O
previous O O
studies O O
, O O
we O O
have O O
analyzed O O
the O O
NKX2 O O
- O O
5 O O
gene O O
promoter O O
and O O
a O O
proximal O O
enhancer O O
in O O
VSD O O
patients O O
. O O
In O O
previous O O
studies O O
, O O
we O O
have O O
analyzed O O
the O O
NKX2 O O
- O O
5 O O
gene O O
promoter O O
and O O
a O O
proximal O O
enhancer O O
in O O
VSD O O
patients O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
further O O
genetically O O
and O O
functionally O O
analyzed O O
an O O
upstream O O
enhancer O O
of O O
the O O
NKX2 O O
- O O
5 O O
gene O O
in O O
large O O
cohorts O O
of O O
VSD O O
patients O O
( O O
n O O
= O O
340 O O
) O O
and O O
controls O O
( O O
n O O
= O O
347 O O
) O O
. O O
In O O
the O O
present O O
study O O
, O O
we O O
further O O
genetically O O
and O O
functionally O O
analyzed O O
an O O
upstream O O
enhancer O O
of O O
the O O
NKX2 O O
- O O
5 O O
gene O O
in O O
large O O
cohorts O O
of O O
VSD O O
patients O O
( O O
n O O
= O O
340 O O
) O O
and O O
controls O O
( O O
n O O
= O O
347 O O
) O O
. O O

Two O O
novel O O
heterozygous O O
DNA O O
sequence O O
variants O O
( O O
DSVs O O
) O O
, O O
g O O
. O O
17483576C O O
> O O
G O O
and O O
g O O
. O O
17483564C O O
> O O
T O O
, O O
were O O
identified O O
in O O
three O O
VSD O O
patients O O
, O O
but O O
none O O
in O O
controls O O
. O O

Functionally O O
, O O
these O O
two O O
DSVs O O
significantly O O
decreased O O
the O O
activity O O
of O O
the O O
enhancer O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Another O O
novel O O
heterozygous O O
DSV O O
, O O
g O O
. O O
17483557Ins O O
, O O
was O O
found O O
in O O
both O O
VSD O O
patients O O
and O O
controls O O
with O O
similar O O
frequencies O O
( O O
P O O
> O O
0 O O
. O O
05 O O
) O O
. O O

Taken O O
together O O
, O O
our O O
data O O
suggested O O
that O O
the O O
DSVs O O
within O O
the O O
upstream O O
enhancer O O
of O O
the O O
NKX2 O O
- O O
5 O O
gene O O
may O O
contribute O O
to O O
a O O
small O O
number O O
of O O
VSD O O
. O O
Taken O O
together O O
, O O
our O O
data O O
suggested O O
that O O
the O O
DSVs O O
within O O
the O O
upstream O O
enhancer O O
of O O
the O O
NKX2 O O
- O O
5 O O
gene O O
may O O
contribute O O
to O O
a O O
small O O
number O O
of O O
VSD O O
. O O

Therefore O O
, O O
genetic O O
studies O O
of O O
CHD O O
may O O
provide O O
insight O O
into O O
designing O O
novel O O
therapies O O
for O O
adult O O
CHD O O
patients O O
. O O

Finding O O
of O O
IFNgamma O O
gene O O
enhancers O O
and O O
their O O
core O O
sequences O O
. O O
Finding O O
of O O
IFNgamma O O
gene O O
enhancers O O
and O O
their O O
core O O
sequences O O
. O O

DNA O O
segmentation O O
methods O O
were O O
used O O
to O O
study O O
which O O
fragments O O
of O O
the O O
human O O
IFNgamma O O
gene O O
possess O O
enhancer O O
activity O O
. O O

The O O
human O O
IFNgamma O O
gene O O
was O O
divided O O
into O O
240 O O
- O O
bp O O
fragments O O
, O O
which O O
were O O
inserted O O
between O O
the O O
GFP O O
gene O O
and O O
the O O
Alu O O
tandem O O
sequence O O
to O O
determine O O
whether O O
the O O
inserted O O
sequences O O
eliminate O O
the O O
inhibition O O
induced O O
by O O
the O O
Alu O O
tandem O O
sequence O O
. O O

We O O
found O O
that O O
five O O
different O O
240 O O
- O O
bp O O
fragments O O
( O O
FUIFN3F3R O O
, O O
IFN4F4R O O
, O O
IFN6F6R O O
, O O
IFN21F21R O O
, O O
and O O
IFN22F22R O O
) O O
and O O
two O O
60 O O
- O O
bp O O
core O O
sequences O O
( O O
IFN6 O O
- O O
2F2R O O
and O O
IFN21 O O
- O O
3 O O
- O O
4F3 O O
- O O
4R O O
) O O
derived O O
from O O
the O O
IFNgamma O O
gene O O
contain O O
enhancers O O
that O O
can O O
activate O O
the O O
GFP O O
reporter O O
gene O O
. O O

These O O
enhancers O O
may O O
be O O
targets O O
of O O
IFNgamma O O
gene O O
expression O O
regulation O O
. O O

Hypoxia O O
enhances O O
the O O
expression O O
of O O
prostate O O
- O O
specific O O
antigen O O
by O O
modifying O O
the O O
quantity O O
and O O
catalytic O O
activity O O
of O O
Jumonji O O
C O O
domain O O
- O O
containing O O
histone O O
demethylases O O
. O O

Oxygen O O
concentration O O
in O O
prostate O O
cancer O O
tissue O O
is O O
significantly O O
low O O
, O O
i O O
. O O
e O O
. O O
~ O O
0 O O
. O O
3 O O
% O O
O2 O O
. O O

This O O
study O O
showed O O
that O O
pathological O O
hypoxia O O
( O O
< O O
0 O O
. O O
5 O O
% O O
O2 O O
) O O
increased O O
the O O
expression O O
of O O
androgen O O
receptor O O
( O O
AR O O
) O O
target O O
genes O O
such O O
as O O
prostate O O
- O O
specific O O
antigen O O
( O O
PSA O O
) O O
and O O
kallikrein O O
- O O
related O O
peptidase O O
2 O O
in O O
LNCaP B-CellLine B-CellLine
human I-CellLine I-CellLine
prostate I-CellLine I-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
by O O
modifying O O
the O O
quantity O O
and O O
activity O O
of O O
related O O
Jumonji O O
C O O
domain O O
- O O
containing O O
histone O O
demethylases O O
( O O
JMJDs O O
) O O
. O O

Under O O
pathological O O
hypoxia O O
, O O
the O O
catalytic O O
activities O O
of O O
JMJD2A O O
, O O
JMJD2C O O
and O O
Jumonji O O
/ O O
ARID O O
domain O O
- O O
containing O O
protein O O
1B O O
( O O
JARID1B O O
) O O
were O O
blocked O O
due O O
to O O
the O O
lack O O
of O O
their O O
substrate O O
, O O
i O O
. O O
e O O
. O O
oxygen O O
. O O

Chromatin O O
immunoprecipitation O O
analyses O O
showed O O
that O O
hypoxia O O
increased O O
the O O
appearance O O
of O O
H3K9me3 O O
and O O
H3K4me3 O O
, O O
substrates O O
of O O
JMJD2s O O
and O O
JARID1B O O
, O O
respectively O O
, O O
in O O
the O O
PSA O O
enhancer O O
. O O
Chromatin O O
immunoprecipitation O O
analyses O O
showed O O
that O O
hypoxia O O
increased O O
the O O
appearance O O
of O O
H3K9me3 O O
and O O
H3K4me3 O O
, O O
substrates O O
of O O
JMJD2s O O
and O O
JARID1B O O
, O O
respectively O O
, O O
in O O
the O O
PSA O O
enhancer O O
. O O

In O O
contrast O O
, O O
JMJD1A O O
, O O
which O O
demethylates O O
both O O
H3K9me2 O O
and O O
H3K9me1 O O
, O O
maintained O O
its O O
catalytic O O
activity O O
even O O
under O O
severe O O
hypoxia O O
. O O

Furthermore O O
, O O
hypoxia O O
increased O O
the O O
expression O O
of O O
JMJD1A O O
. O O
Hypoxia O O
and O O
androgen O O
additively O O
increased O O
the O O
recruitment O O
of O O
JMJD1A O O
and O O
p300 O O
on O O
the O O
enhancer O O
region O O
of O O
PSA O O
through O O
interaction O O
with O O
the O O
hypoxia O O
- O O
inducible O O
factor O O
- O O
1alpha O O
and O O
AR O O
, O O
both O O
of O O
which O O
bind O O
the O O
PSA O O
enhancer O O
. O O
Furthermore O O
, O O
hypoxia O O
increased O O
the O O
expression O O
of O O
JMJD1A O O
. O O
Hypoxia O O
and O O
androgen O O
additively O O
increased O O
the O O
recruitment O O
of O O
JMJD1A O O
and O O
p300 O O
on O O
the O O
enhancer O O
region O O
of O O
PSA O O
through O O
interaction O O
with O O
the O O
hypoxia O O
- O O
inducible O O
factor O O
- O O
1alpha O O
and O O
AR O O
, O O
both O O
of O O
which O O
bind O O
the O O
PSA O O
enhancer O O
. O O

Thus O O
, O O
hypoxia O O
enhanced O O
the O O
demethylation O O
of O O
H3K9me2 O O
and O O
H3K9me1 O O
, O O
leading O O
to O O
provide O O
unmethylated O O
H3K9 O O
residues O O
that O O
are O O
substrates O O
for O O
histone O O
acetyltransferase O O
, O O
p300 O O
. O O

Consequently O O
, O O
hypoxia O O
increased O O
the O O
acetylation O O
of O O
histones O O
of O O
the O O
PSA O O
enhancer O O
, O O
which O O
facilitates O O
its O O
transcription O O
. O O
Consequently O O
, O O
hypoxia O O
increased O O
the O O
acetylation O O
of O O
histones O O
of O O
the O O
PSA O O
enhancer O O
, O O
which O O
facilitates O O
its O O
transcription O O
. O O

Asymmetric O O
activation O O
of O O
Dll4 O O
- O O
Notch O O
signaling O O
by O O
Foxn4 O O
and O O
proneural O O
factors O O
activates O O
BMP O O
/ O O
TGFbeta O O
signaling O O
to O O
specify O O
V2b B-CellLine O
interneurons I-CellLine B-CellLine
in O O
the O O
spinal B-CellLine B-CellLine
cord I-CellLine I-CellLine
. O O

During O O
development O O
of O O
the O O
ventral O B-CellLine
spinal B-CellLine I-CellLine
cord I-CellLine I-CellLine
, O O
the O O
V2 B-CellLine B-CellLine
interneurons I-CellLine I-CellLine
emerge O O
from O O
p2 B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
and O O
diversify O O
into O O
two O O
major O O
subtypes O O
, O O
V2a B-CellLine O
and O O
V2b B-CellLine O
, O O
that O O
play O O
key O O
roles O O
in O O
locomotor O O
coordination O O
. O O
Dll4 O O
- O O
mediated O O
Notch O O
activation O O
in O O
a O O
subset O O
of O O
p2 B-CellLine O
precursors I-CellLine O
constitutes O O
the O O
crucial O O
first O O
step O O
towards O O
generating O O
neuronal O O
diversity O O
in O O
this O O
domain O O
. O O

The O O
mechanism O O
behind O O
the O O
asymmetric O O
Notch O O
activation O O
and O O
downstream O O
signaling O O
events O O
are O O
, O O
however O O
, O O
unknown O O
at O O
present O O
. O O

We O O
show O O
here O O
that O O
the O O
Ascl1 O O
and O O
Neurog O O
basic O O
helix O O
- O O
loop O O
- O O
helix O O
( O O
bHLH O O
) O O
proneural O O
factors O O
are O O
expressed O O
in O O
a O O
mosaic O O
pattern O O
in O O
p2 B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
and O O
that O O
Foxn4 O O
is O O
required O O
for O O
setting O O
and O O
maintaining O O
this O O
expression O O
mosaic O O
. O O

By O O
binding O O
directly O O
to O O
a O O
conserved O O
Dll4 O O
enhancer O O
, O O
Foxn4 O O
and O O
Ascl1 O O
activate O O
Dll4 O O
expression O O
, O O
whereas O O
Neurog O O
proteins O O
prevent O O
this O O
effect O O
, O O
thereby O O
resulting O O
in O O
asymmetric O O
activation O O
of O O
Dll4 O O
expression O O
in O O
V2 B-CellLine O
precursors I-CellLine O
expressing O O
different O O
combinations O O
of O O
proneural O O
and O O
Foxn4 O O
transcription O O
factors O O
. O O
By O O
binding O O
directly O O
to O O
a O O
conserved O O
Dll4 O O
enhancer O O
, O O
Foxn4 O O
and O O
Ascl1 O O
activate O O
Dll4 O O
expression O O
, O O
whereas O O
Neurog O O
proteins O O
prevent O O
this O O
effect O O
, O O
thereby O O
resulting O O
in O O
asymmetric O O
activation O O
of O O
Dll4 O O
expression O O
in O O
V2 B-CellLine O
precursors I-CellLine O
expressing O O
different O O
combinations O O
of O O
proneural O O
and O O
Foxn4 O O
transcription O O
factors O O
. O O

Lineage O O
tracing O O
using O O
the O O
Cre O O
- O O
LoxP O O
system O O
reveals O O
selective O O
expression O O
of O O
Dll4 O O
in O O
V2a B-CellLine O
precursors I-CellLine O
, O O
whereas O O
Dll4 O O
expression O O
is O O
initially O O
excluded O O
from O O
V2b B-CellLine O
precursors I-CellLine O
. O O

We O O
provide O O
evidence O O
that O O
BMP O O
/ O O
TGFbeta O O
signaling O O
is O O
activated O O
in O O
V2b B-CellLine O
precursors I-CellLine O
and O O
that O O
Dll4 O O
- O O
mediated O O
Notch O O
signaling O O
is O O
responsible O O
for O O
this O O
activation O O
. O O

Using O O
a O O
gain O O
- O O
of O O
- O O
function O O
approach O O
and O O
by O O
inhibiting O O
BMP O O
/ O O
TGFbeta O O
signal O O
transduction O O
with O O
pathway O O
antagonists O O
and O O
RNAi O O
knockdown O O
, O O
we O O
further O O
demonstrate O O
that O O
BMP O O
/ O O
TGFbeta O O
signaling O O
is O O
both O O
necessary O O
and O O
sufficient O O
for O O
V2b B-CellLine O
fate O O
specification O O
. O O

Our O O
data O O
together O O
thus O O
suggest O O
that O O
the O O
mosaic O O
expression O O
of O O
Foxn4 O O
and O O
proneural O O
factors O O
may O O
serve O O
as O O
the O O
trigger O O
to O O
initiate O O
asymmetric O O
Dll4 O O
- O O
Notch O O
and O O
subsequent O O
BMP O O
/ O O
TGFbeta O O
signaling O O
events O O
required O O
for O O
neuronal O O
diversity O O
in O O
the O O
V2 B-CellLine O
domain O O
. O O

ABCC4 O O
copy O O
number O O
variation O O
is O O
associated O O
with O O
susceptibility O O
to O O
esophageal O O
squamous O O
cell O O
carcinoma O O
. O O
Esophageal O O
squamous O O
cell O O
carcinoma O O
( O O
ESCC O O
) O O
is O O
the O O
eighth O O
most O O
common O O
cause O O
of O O
cancer O O
- O O
related O O
death O O
worldwide O O
. O O

However O O
, O O
previous O O
genome O O
- O O
wide O O
single O O
nucleotide O O
polymorphism O O
association O O
analyses O O
have O O
not O O
explained O O
the O O
high O O
heritability O O
associated O O
with O O
ESCC O O
. O O

In O O
this O O
study O O
, O O
we O O
performed O O
genome O O
- O O
wide O O
copy O O
number O O
variation O O
( O O
CNV O O
) O O
analysis O O
on O O
128 O O
discordant O O
sibling O O
pairs O O
to O O
identify O O
novel O O
genes O O
that O O
contribute O O
to O O
ESCC O O
susceptibility O O
. O O

A O O
total O O
of O O
57 O O
774 O O
individual O O
CNVs O O
were O O
identified O O
, O O
and O O
an O O
interactive O O
network O O
of O O
common O O
CNV O O
- O O
associated O O
genes O O
was O O
constructed O O
, O O
which O O
showed O O
that O O
several O O
ABC O O
transporter O O
genes O O
contain O O
CNVs O O
in O O
ESCC O O
patients O O
. O O

Independent O O
validation O O
of O O
a O O
CNV O O
at O O
13q32 O O
. O O
1 O O
in O O
1048 O O
northern O O
Chinese O O
Han O O
subjects O O
demonstrated O O
that O O
the O O
amplification O O
of O O
ABCC4 O O
significantly O O
correlated O O
with O O
ESCC O O
risk O O
[ O O
odds O O
ratio O O
: O O
3 O O
. O O
36 O O
( O O
1 O O
. O O
65 O O
- O O
7 O O
. O O
93 O O
) O O
, O O
P O O
= O O
0 O O
. O O
0013 O O
] O O
. O O

Immunohistochemistry O O
staining O O
suggested O O
that O O
high O O
copy O O
numbers O O
correlated O O
with O O
increased O O
protein O O
levels O O
. O O

High O O
expression O O
of O O
ABCC4 O O
was O O
an O O
independent O O
poor O O
prognostic O O
factor O O
for O O
ESCC O O
[ O O
relative O O
risk O O
: O O
1 O O
. O O
73 O O
( O O
1 O O
. O O
10 O O
- O O
2 O O
. O O
73 O O
) O O
, O O
P O O
= O O
0 O O
. O O
0181 O O
] O O
. O O

The O O
CNV O O
region O O
showed O O
strong O O
enhancer O O
activity O O
. O O

Furthermore O O
, O O
inhibition O O
of O O
ABCC4 O O
protein O O
in O O
ESCC B-CellLine B-CellLine
cells I-CellLine I-CellLine
decreased O O
cell O O
proliferation O O
and O O
motility O O
via O O
the O O
inhibition O O
of O O
COX O O
- O O
2 O O
, O O
PGE2 O O
receptors O O
and O O
c O O
- O O
Myc O O
expression O O
; O O
AKT O O
, O O
extracellular O O
signal O O
- O O
regulated O O
kinase O O
and O O
cAMP O O
response O O
element O O
- O O
binding O O
protein O O
phosphorylation O O
; O O
and O O
beta O O
- O O
catenin O O
nuclear O O
translocation O O
in O O
ESCC B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

In O O
conclusion O O
, O O
the O O
CNV O O
at O O
13q32 O O
. O O
1 O O
is O O
associated O O
with O O
ESCC O O
susceptibility O O
, O O
and O O
a O O
gene O O
within O O
this O O
locus O O
, O O
ABCC4 O O
, O O
activates O O
the O O
oncogenic O O
pathways O O
in O O
ESCC O O
and O O
thus O O
facilitates O O
cancer B-CellLine B-CellLine
cell I-CellLine I-CellLine
development O O
and O O
progression O O
. O O

A O O
direct O O
genetic O O
contribution O O
of O O
ESCC O O
risk O O
through O O
CNV O O
common O O
variants O O
was O O
determined O O
in O O
this O O
study O O
, O O
and O O
ABCC4 O O
might O O
therefore O O
have O O
predictive O O
and O O
therapeutic O O
potential O O
for O O
ESCC O O
. O O

Enhancer O O
RNAs O O
participate O O
in O O
androgen O O
receptor O O
- O O
driven O O
looping O O
that O O
selectively O O
enhances O O
gene O O
activation O O
. O O

The O O
androgen O O
receptor O O
( O O
AR O O
) O O
is O O
a O O
key O O
factor O O
that O O
regulates O O
the O O
behavior O O
and O O
fate O O
of O O
prostate B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

The O O
AR O O
- O O
regulated O O
network O O
is O O
activated O O
when O O
AR O O
binds O O
enhancer O O
elements O O
and O O
modulates O O
specific O O
enhancer O O
- O O
promoter O O
looping O O
. O O
Kallikrein O O
- O O
related O O
peptidase O O
3 O O
( O O
KLK3 O O
) O O
, O O
which O O
codes O O
for O O
prostate O O
- O O
specific O O
antigen O O
( O O
PSA O O
) O O
, O O
is O O
a O O
well O O
- O O
known O O
AR O O
- O O
regulated O O
gene O O
and O O
its O O
upstream O O
enhancers O O
produce O O
bidirectional O O
enhancer O O
RNAs O O
( O O
eRNAs O O
) O O
, O O
termed O O
KLK3e O O
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
KLK3e O O
facilitates O O
the O O
spatial O O
interaction O O
of O O
the O O
KLK3 O O
enhancer O O
and O O
the O O
KLK2 O O
promoter O O
and O O
enhances O O
long O O
- O O
distance O O
KLK2 O O
transcriptional O O
activation O O
. O O
KLK3e O O
carries O O
the O O
core O O
enhancer O O
element O O
derived O O
from O O
the O O
androgen O O
response O O
element O O
III O O
( O O
ARE O O
III O O
) O O
, O O
which O O
is O O
required O O
for O O
the O O
interaction O O
of O O
AR O O
and O O
Mediator O O
1 O O
( O O
Med1 O O
) O O
. O O
Here O O
, O O
we O O
demonstrate O O
that O O
KLK3e O O
facilitates O O
the O O
spatial O O
interaction O O
of O O
the O O
KLK3 O O
enhancer O O
and O O
the O O
KLK2 O O
promoter O O
and O O
enhances O O
long O O
- O O
distance O O
KLK2 O O
transcriptional O O
activation O O
. O O
KLK3e O O
carries O O
the O O
core O O
enhancer O O
element O O
derived O O
from O O
the O O
androgen O O
response O O
element O O
III O O
( O O
ARE O O
III O O
) O O
, O O
which O O
is O O
required O O
for O O
the O O
interaction O O
of O O
AR O O
and O O
Mediator O O
1 O O
( O O
Med1 O O
) O O
. O O

Furthermore O O
, O O
we O O
show O O
that O O
KLK3e O O
processes O O
RNA O O
- O O
dependent O O
enhancer O O
activity O O
depending O O
on O O
the O O
integrity O O
of O O
core O O
enhancer O O
elements O O
. O O

The O O
transcription O O
of O O
KLK3e O O
was O O
detectable O O
and O O
its O O
expression O O
is O O
significantly O O
correlated O O
with O O
KLK3 O O
( O O
R O O
( O O
2 O O
) O O
= O O
0 O O
. O O
6213 O O
, O O
P O O
< O O
5 O O
x O O
10 O O
( O O
- O O
11 O O
) O O
) O O
and O O
KLK2 O O
( O O
R O O
( O O
2 O O
) O O
= O O
0 O O
. O O
5893 O O
, O O
P O O
< O O
5 O O
x O O
10 O O
( O O
- O O
10 O O
) O O
) O O
in O O
human O O
prostate B-CellLine O
tissues O O
. O O

Interestingly O O
, O O
RNAi O O
silencing O O
of O O
KLK3e O O
resulted O O
in O O
a O O
modest O O
negative O O
effect O O
on O O
prostate B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cell I-CellLine I-CellLine
proliferation O O
. O O

Accordingly O O
, O O
we O O
report O O
that O O
an O O
androgen O O
- O O
induced O O
eRNA O O
scaffolds O O
the O O
AR O O
- O O
associated O O
protein O O
complex O O
that O O
modulates O O
chromosomal O O
architecture O O
and O O
selectively O O
enhances O O
AR O O
- O O
dependent O O
gene O O
expression O O
. O O

Reorganization O O
of O O
enhancer O O
patterns O O
in O O
transition O O
from O O
naive O O
to O O
primed O O
pluripotency O O
. O O

Naive O O
and O O
primed O O
pluripotency O O
is O O
characterized O O
by O O
distinct O O
signaling O O
requirements O O
, O O
transcriptomes O O
, O O
and O O
developmental O O
properties O O
, O O
but O O
both O O
cellular O O
states O O
share O O
key O O
transcriptional O O
regulators O O
: O O
Oct4 O O
, O O
Sox2 O O
, O O
and O O
Nanog O O
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
transition O O
between O O
these O O
two O O
pluripotent O O
states O O
is O O
associated O O
with O O
widespread O O
Oct4 O O
relocalization O O
, O O
mirrored O O
by O O
global O O
rearrangement O O
of O O
enhancer O O
chromatin O O
landscapes O O
. O O

Our O O
genomic O O
and O O
biochemical O O
analyses O O
identified O O
candidate O O
mediators O O
of O O
primed O O
state O O
- O O
specific O O
Oct4 O O
binding O O
, O O
including O O
Otx2 O O
and O O
Zic2 O O
/ O O
3 O O
. O O

Even O O
when O O
differentiation O O
cues O O
are O O
blocked O O
, O O
premature O O
Otx2 O O
overexpression O O
is O O
sufficient O O
to O O
exit O O
the O O
naive O O
state O O
, O O
induce O O
transcription O O
of O O
a O O
substantial O O
subset O O
of O O
primed O O
pluripotency O O
- O O
associated O O
genes O O
, O O
and O O
redirect O O
Oct4 O O
to O O
previously O O
inaccessible O O
enhancer O O
sites O O
. O O

However O O
, O O
the O O
ability O O
of O O
Otx2 O O
to O O
engage O O
new O O
enhancer O O
regions O O
is O O
determined O O
by O O
its O O
levels O O
, O O
cis O O
- O O
encoded O O
properties O O
of O O
the O O
sites O O
, O O
and O O
the O O
signaling O O
environment O O
. O O

Our O O
results O O
illuminate O O
regulatory O O
mechanisms O O
underlying O O
pluripotency O O
and O O
suggest O O
that O O
the O O
capacity O O
of O O
transcription O O
factors O O
such O O
as O O
Otx2 O O
and O O
Oct4 O O
to O O
pioneer O O
new O O
enhancer O O
sites O O
is O O
highly O O
context O O
dependent O O
. O O

Human O O
skin B-CellLine B-CellLine
color O O
is O O
influenced O O
by O O
an O O
intergenic O O
DNA O O
polymorphism O O
regulating O O
transcription O O
of O O
the O O
nearby O O
BNC2 O O
pigmentation O O
gene O O
. O O

Single O O
nucleotide O O
polymorphisms O O
( O O
SNPs O O
) O O
found O O
to O O
be O O
statistically O O
significant O O
when O O
associated O O
with O O
human O O
diseases O O
, O O
and O O
other O O
phenotypes O O
are O O
most O O
often O O
located O O
in O O
non O O
- O O
coding O O
regions O O
of O O
the O O
genome O O
. O O

One O O
example O O
is O O
rs10765819 O O
located O O
in O O
the O O
first O O
intron O O
of O O
the O O
BNC2 O O
gene O O
previously O O
associated O O
with O O
( O O
saturation O O
of O O
) O O
human O O
skin B-CellLine B-CellLine
color O O
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
a O O
nearby O O
intergenic O O
SNP O O
( O O
rs12350739 O O
) O O
in O O
high O O
linkage O O
disequilibrium O O
with O O
rs10756819 O O
is O O
likely O O
the O O
causal O O
DNA O O
variant O O
for O O
the O O
observed O O
BNC2 O O
skin B-CellLine B-CellLine
color O O
association O O
. O O

The O O
highly O O
conserved O O
region O O
surrounding O O
rs12350739 O O
functions O O
as O O
an O O
enhancer O O
element O O
regulating O O
BNC2 O O
transcription O O
in O O
human O O
melanocytes B-CellLine B-CellLine
, O O
while O O
the O O
activity O O
of O O
this O O
enhancer O O
element O O
depends O O
on O O
the O O
allelic O O
status O O
of O O
rs12350739 O O
. O O

When O O
the O O
rs12350739 O O
- O O
AA O O
allele O O
is O O
present O O
, O O
the O O
chromatin O O
at O O
the O O
region O O
surrounding O O
rs12350739 O O
is O O
inaccessible O O
and O O
the O O
enhancer O O
element O O
is O O
only O O
slightly O O
active O O
, O O
resulting O O
in O O
low O O
expression O O
of O O
BNC2 O O
, O O
corresponding O O
with O O
light O O
skin B-CellLine B-CellLine
pigmentation O O
. O O

When O O
the O O
rs12350739 O O
- O O
GG O O
allele O O
is O O
present O O
however O O
, O O
the O O
chromatin O O
at O O
the O O
region O O
surrounding O O
rs12350739 O O
is O O
more O O
accessible O O
and O O
the O O
enhancer O O
is O O
active O O
, O O
resulting O O
in O O
a O O
higher O O
expression O O
of O O
BNC2 O O
, O O
corresponding O O
with O O
dark O O
skin B-CellLine O
pigmentation O O
. O O

Overall O O
, O O
we O O
demonstrate O O
the O O
identification O O
of O O
the O O
functional O O
DNA O O
variant O O
that O O
explains O O
the O O
BNC2 O O
skin B-CellLine O
color O O
association O O
signal O O
, O O
providing O O
another O O
important O O
step O O
towards O O
further O O
understanding O O
human O O
pigmentation O O
genetics O O
beyond O O
statistical O O
association O O
. O O

We O O
thus O O
deliver O O
a O O
clear O O
example O O
of O O
how O O
an O O
intergenic O O
non O O
- O O
coding O O
DNA O O
variant O O
modulates O O
the O O
regulatory O O
potential O O
of O O
the O O
enhancer O O
element O O
it O O
is O O
located O O
within O O
, O O
which O O
in O O
turn O O
results O O
in O O
allele O O
- O O
dependent O O
differential O O
gene O O
expression O O
affecting O O
variation O O
in O O
common O O
human O O
traits O O
. O O

Intersection O O
of O O
population O O
variation O O
and O O
autoimmunity O O
genetics O O
in O O
human O O
T B-CellLine B-CellLine
cell I-CellLine I-CellLine
activation O O
. O O
T B-CellLine B-CellLine
lymphocyte I-CellLine I-CellLine
activation O O
by O O
antigen O O
conditions O O
adaptive O O
immune O O
responses O O
and O O
immunopathologies O O
, O O
but O O
we O O
know O O
little O O
about O O
its O O
variation O O
in O O
humans O O
and O O
its O O
genetic O O
or O O
environmental O O
roots O O
. O O

We O O
analyzed O O
gene O O
expression O O
in O O
CD4 B-CellLine B-CellLine
( I-CellLine I-CellLine
+ I-CellLine I-CellLine
) I-CellLine I-CellLine
T I-CellLine I-CellLine
cells I-CellLine I-CellLine
during O O
unbiased O O
activation O O
or O O
in O O
T B-CellLine B-CellLine
helper I-CellLine I-CellLine
17 I-CellLine I-CellLine
( B-CellLine I-CellLine
T I-CellLine I-CellLine
( I-CellLine I-CellLine
H I-CellLine I-CellLine
) I-CellLine I-CellLine
17 I-CellLine I-CellLine
) I-CellLine O
conditions O O
from O O
348 O O
healthy O O
participants O O
representing O O
European O O
, O O
Asian O O
, O O
and O O
African O O
ancestries O O
. O O

We O O
observed O O
interindividual O O
variability O O
, O O
most O O
marked O O
for O O
cytokine O O
transcripts O O
, O O
with O O
clear O O
biases O O
on O O
the O O
basis O O
of O O
ancestry O O
, O O
and O O
following O O
patterns O O
more O O
complex O O
than O O
simple O O
T B-CellLine O
( I-CellLine O
H I-CellLine O
) I-CellLine O
1 I-CellLine O
/ O O
2 B-CellLine O
/ O O
17 B-CellLine O
partitions O O
. O O

We O O
identified O O
39 O O
genetic O O
loci O O
specifically O O
associated O O
in O O
cis O O
with O O
activated O O
gene O O
expression O O
. O O

We O O
further O O
fine O O
- O O
mapped O O
and O O
validated O O
a O O
single O O
- O O
base O O
variant O O
that O O
modulates O O
YY1 O O
binding O O
and O O
the O O
activity O O
of O O
an O O
enhancer O O
element O O
controlling O O
the O O
autoimmune O O
- O O
associated O O
IL2RA O O
gene O O
, O O
affecting O O
its O O
activity O O
in O O
activated O O
but O O
not O O
regulatory O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

Thus O O
, O O
interindividual O O
variability O O
affects O O
the O O
fundamental O O
immunologic O O
process O O
of O O
T B-CellLine B-CellLine
helper I-CellLine I-CellLine
activation O O
, O O
with O O
important O O
connections O O
to O O
autoimmune O O
disease O O
. O O

Enhancer O O
RNA O O
facilitates O O
NELF O O
release O O
from O O
immediate O O
early O O
genes O O
. O O

Enhancer O O
RNAs O O
( O O
eRNAs O O
) O O
are O O
a O O
class O O
of O O
long O O
noncoding O O
RNAs O O
( O O
lncRNA O O
) O O
expressed O O
from O O
active O O
enhancers O O
, O O
whose O O
function O O
and O O
action O O
mechanism O O
are O O
yet O O
to O O
be O O
firmly O O
established O O
. O O

Here O O
we O O
show O O
that O O
eRNAs O O
facilitate O O
the O O
transition O O
of O O
paused O O
RNA O O
polymerase O O
II O O
( O O
RNAPII O O
) O O
into O O
productive O O
elongation O O
by O O
acting O O
as O O
a O O
decoy O O
for O O
the O O
negative O O
elongation O O
factor O O
( O O
NELF O O
) O O
complex O O
upon O O
induction O O
of O O
immediate O O
early O O
genes O O
( O O
IEGs O O
) O O
in O O
neurons B-CellLine B-CellLine
. O O
eRNAs O O
are O O
synthesized O O
prior O O
to O O
the O O
culmination O O
of O O
target O O
gene O O
transcription O O
and O O
interact O O
with O O
the O O
NELF O O
complex O O
. O O

Knockdown O O
of O O
eRNAs O O
expressed O O
at O O
neuronal O O
enhancers O O
impairs O O
transient O O
release O O
of O O
NELF O O
from O O
the O O
specific O O
target O O
promoters O O
during O O
transcriptional O O
activation O O
, O O
coinciding O O
with O O
a O O
decrease O O
in O O
target O O
mRNA O O
induction O O
. O O

The O O
enhancer O O
- O O
promoter O O
interaction O O
was O O
unaffected O O
by O O
eRNA O O
knockdown O O
. O O

Instead O O
, O O
chromatin O O
looping O O
might O O
enable O O
eRNAs O O
to O O
act O O
locally O O
at O O
a O O
specific O O
promoter O O
. O O

Our O O
findings O O
highlight O O
the O O
spatiotemporally O O
regulated O O
action O O
mechanism O O
of O O
eRNAs O O
during O O
early O O
transcriptional O O
elongation O O
. O O

SRY O O
interference O O
of O O
normal O O
regulation O O
of O O
the O O
RET O O
gene O O
suggests O O
a O O
potential O O
role O O
of O O
the O O
Y O O
- O O
chromosome O O
gene O O
in O O
sexual O O
dimorphism O O
in O O
Hirschsprung O O
disease O O
. O O

The O O
Hirschsprung O O
disease O O
( O O
HSCR O O
) O O
is O O
a O O
complex O O
congenital O O
disorder O O
, O O
arising O O
from O O
abnormalities O O
in O O
enteric O B-CellLine
nervous O I-CellLine
system O I-CellLine
( O O
ENS O B-CellLine
) O O
development O O
. O O

There O O
is O O
a O O
gender O O
disparity O O
among O O
the O O
patients O O
, O O
with O O
the O O
male O O
to O O
female O O
ratio O O
as O O
high O O
as O O
5 O O
: O O
1 O O
. O O

Loss O O
- O O
of O O
- O O
function O O
mutations O O
of O O
HSCR O O
genes O O
and O O
haploinsufficiency O O
of O O
their O O
gene O O
products O O
are O O
the O O
primary O O
pathogenic O O
mechanisms O O
for O O
disease O O
development O O
. O O

Recent O O
studies O O
identified O O
over O O
half O O
of O O
the O O
HSCR O O
disease O O
susceptibility O O
genes O O
as O O
targets O O
for O O
the O O
sex O O
- O O
determining O O
factor O O
SRY O O
, O O
suggesting O O
that O O
this O O
Y O O
- O O
encoded O O
transcription O O
factor O O
could O O
be O O
involved O O
in O O
sexual O O
dimorphism O O
in O O
HSCR O O
. O O

Among O O
the O O
SRY O O
targets O O
, O O
the O O
tyrosine O O
kinase O O
receptor O O
RET O O
represents O O
the O O
most O O
important O O
disease O O
gene O O
, O O
whose O O
mutations O O
account O O
for O O
half O O
of O O
the O O
familial O O
and O O
up O O
to O O
one O O
- O O
third O O
of O O
the O O
sporadic O O
forms O O
of O O
HSCR O O
. O O
RET O O
is O O
regulated O O
by O O
a O O
distal O O
and O O
a O O
proximal O O
enhancer O O
at O O
its O O
promoter O O
, O O
in O O
which O O
PAX3 O O
and O O
NKX2 O O
- O O
1 O O
are O O
the O O
resident O O
transcription O O
factors O O
respectively O O
. O O

We O O
show O O
that O O
the O O
SRY O O
- O O
box O O
10 O O
( O O
SOX10 O O
) O O
co O O
- O O
activator O O
interacts O O
and O O
forms O O
transcriptional O O
complexes O O
with O O
PAX3 O O
and O O
NKX2 O O
- O O
1 O O
in O O
a O O
sequence O O
- O O
independent O O
manner O O
and O O
exacerbates O O
their O O
respective O O
transactivation O O
activities O O
on O O
the O O
RET O O
promoter O O
. O O
SRY O O
competitively O O
displaces O O
SOX10 O O
in O O
such O O
transcription O O
complexes O O
and O O
represses O O
their O O
regulatory O O
functions O O
on O O
RET O O
. O O
We O O
show O O
that O O
the O O
SRY O O
- O O
box O O
10 O O
( O O
SOX10 O O
) O O
co O O
- O O
activator O O
interacts O O
and O O
forms O O
transcriptional O O
complexes O O
with O O
PAX3 O O
and O O
NKX2 O O
- O O
1 O O
in O O
a O O
sequence O O
- O O
independent O O
manner O O
and O O
exacerbates O O
their O O
respective O O
transactivation O O
activities O O
on O O
the O O
RET O O
promoter O O
. O O
SRY O O
competitively O O
displaces O O
SOX10 O O
in O O
such O O
transcription O O
complexes O O
and O O
represses O O
their O O
regulatory O O
functions O O
on O O
RET O O
. O O

Hence O O
SRY O O
could O O
be O O
a O O
Y O O
- O O
located O O
negative O O
modifier O O
of O O
RET O O
expression O O
; O O
and O O
if O O
it O O
is O O
ectopically O O
expressed O O
during O O
ENS O B-CellLine
development O O
, O O
such O O
SRY O O
repression O O
could O O
result O O
in O O
RET O O
protein O O
haploinsufficiency O O
and O O
promotion O O
of O O
HSCR O O
development O O
, O O
thereby O O
contributing O O
to O O
sexual O O
dimorphism O O
in O O
HSCR O O
. O O

TGF O O
- O O
beta1 O O
, O O
but O O
not O O
bone B-CellLine O
morphogenetic O O
proteins O O
, O O
activates O O
Smad1 O O
/ O O
5 O O
pathway O O
in O O
primary O O
human O O
macrophages B-CellLine B-CellLine
and O O
induces O O
expression O O
of O O
proatherogenic O O
genes O O
. O O
Macrophages B-CellLine B-CellLine
are O O
responsible O O
for O O
the O O
control O O
of O O
inflammation O O
and O O
healing O O
, O O
and O O
their O O
malfunction O O
results O O
in O O
cardiometabolic O O
disorders O O
. O O
TGF O O
- O O
beta O O
is O O
a O O
pleiotropic O O
growth O O
factor O O
with O O
dual O O
( O O
protective O O
and O O
detrimental O O
) O O
roles O O
in O O
atherogenesis O O
. O O

We O O
have O O
previously O O
shown O O
that O O
in O O
human O O
macrophages B-CellLine B-CellLine
, O O
TGF O O
- O O
beta1 O O
activates O O
Smad2 O O
/ O O
3 O O
signaling O O
and O O
induces O O
a O O
complex O O
gene O O
expression O O
program O O
. O O

However O O
, O O
activated O O
genes O O
were O O
not O O
limited O O
to O O
known O O
Smad2 O O
/ O O
3 O O
- O O
dependent O O
ones O O
, O O
which O O
prompted O O
us O O
to O O
study O O
TGF O O
- O O
beta1 O O
- O O
induced O O
signaling O O
in O O
macrophages B-CellLine B-CellLine
in O O
detail O O
. O O

Analysis O O
of O O
Id3 O O
regulatory O O
sequences O O
revealed O O
a O O
novel O O
enhancer O O
, O O
located O O
between O O
+ O O
4517 O O
and O O
4662 O O
bp O O
, O O
but O O
the O O
luciferase O O
reporter O O
assay O O
demonstrated O O
that O O
this O O
enhancer O O
is O O
not O O
Smad2 O O
/ O O
3 O O
dependent O O
. O O

Because O O
Id3 O O
expression O O
is O O
regulated O O
by O O
Smad1 O O
/ O O
5 O O
in O O
endothelial B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
we O O
analyzed O O
activation O O
of O O
Smad1 O O
/ O O
5 O O
in O O
macrophages B-CellLine B-CellLine
. O O

We O O
demonstrate O O
here O O
for O O
the O O
first O O
time O O
, O O
to O O
our O O
knowledge O O
, O O
that O O
TGF O O
- O O
beta1 O O
, O O
but O O
not O O
BMPs O O
, O O
activates O O
Smad1 O O
/ O O
5 O O
in O O
macrophages B-CellLine B-CellLine
. O O

We O O
show O O
that O O
an O O
ALK5 O O
/ O O
ALK1 O O
heterodimer O O
is O O
responsible O O
for O O
the O O
induction O O
of O O
Smad1 O O
/ O O
5 O O
signaling O O
by O O
TGF O O
- O O
beta1 O O
in O O
mature O O
human O O
macrophages B-CellLine B-CellLine
. O O

Activation O O
of O O
Smad1 O O
/ O O
5 O O
by O O
TGF O O
- O O
beta1 O O
induces O O
not O O
only O O
Id3 O O
, O O
but O O
also O O
HAMP O O
and O O
PLAUR O O
, O O
which O O
contribute O O
to O O
atherosclerotic O O
plaque O O
vulnerability O O
. O O

We O O
suggest O O
that O O
the O O
balance O O
between O O
Smad1 O O
/ O O
5 O O
- O O
and O O
Smad2 O O
/ O O
3 O O
- O O
dependent O O
signaling O O
defines O O
the O O
outcome O O
of O O
the O O
effect O O
of O O
TGF O O
- O O
beta O O
on O O
atherosclerosis O O
where O O
Smad1 O O
/ O O
5 O O
is O O
responsible O O
for O O
proatherogenic O O
effects O O
, O O
whereas O O
Smad2 O O
/ O O
3 O O
regulate O O
atheroprotective O O
effects O O
of O O
TGF O O
- O O
beta O O
. O O

Dynamic O O
switching O O
of O O
active O O
promoter O O
and O O
enhancer O O
domains O O
regulates O O
Tet1 O O
and O O
Tet2 O O
expression O O
during O O
cell O O
state O O
transitions O O
between O O
pluripotency O O
and O O
differentiation O O
. O O

The O O
Tet O O
5 O O
- O O
methylcytosine O O
dioxygenases O O
catalyze O O
DNA O O
demethylation O O
by O O
producing O O
5 O O
- O O
hydroxymethylcytosine O O
and O O
further O O
oxidized O O
products O O
. O O
Tet1 O O
and O O
Tet2 O O
are O O
highly O O
expressed O O
in O O
mouse O O
pluripotent O B-CellLine
cells O I-CellLine
and O O
downregulated O O
to O O
different O O
extents O O
in O O
somatic B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
but O O
the O O
transcriptional O O
mechanisms O O
are O O
unclear O O
. O O

Here O O
we O O
defined O O
the O O
promoter O O
and O O
enhancer O O
domains O O
in O O
Tet1 O O
and O O
Tet2 O O
. O O
Here O O
we O O
defined O O
the O O
promoter O O
and O O
enhancer O O
domains O O
in O O
Tet1 O O
and O O
Tet2 O O
. O O

Within O O
a O O
15 O O
- O O
kb O O
" O O
superenhancer O O
" O O
of O O
Tet1 O O
, O O
there O O
are O O
two O O
transcription O O
start O O
sites O O
( O O
TSSs O O
) O O
with O O
different O O
activation O O
patterns O O
during O O
development O O
. O O
Within O O
a O O
15 O O
- O O
kb O O
" O O
superenhancer O O
" O O
of O O
Tet1 O O
, O O
there O O
are O O
two O O
transcription O O
start O O
sites O O
( O O
TSSs O O
) O O
with O O
different O O
activation O O
patterns O O
during O O
development O O
. O O

A O O
6 O O
- O O
kb O O
promoter O O
region O O
upstream O O
of O O
the O O
distal O O
TSS O O
is O O
highly O O
active O O
in O O
naive O O
pluripotent O B-CellLine
cells O I-CellLine
, O O
autonomously O O
reports O O
Tet1 O O
expression O O
in O O
a O O
transgenic O O
system O O
, O O
and O O
rapidly O O
undergoes O O
DNA O O
methylation O O
and O O
silencing O O
upon O O
differentiation O O
in O O
cultured O O
cells O O
and O O
native O O
epiblast B-CellLine B-CellLine
. O O

A O O
second O O
TSS O O
downstream O O
, O O
associated O O
with O O
a O O
constitutively O O
weak O O
CpG O O
- O O
rich O O
promoter O O
, O O
is O O
activated O O
by O O
a O O
neighboring O O
enhancer O O
in O O
naive O O
embryonic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
ESCs B-CellLine B-CellLine
) O O
and O O
primed O O
epiblast B-CellLine B-CellLine
- I-CellLine I-CellLine
like I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
EpiLCs B-CellLine B-CellLine
) O O
. O O
Tet2 O O
has O O
a O O
CpG O O
island O O
promoter O O
with O O
pluripotency O O
- O O
independent O O
activity O O
and O O
an O O
ESC B-CellLine B-CellLine
- O O
specific O O
distal O O
intragenic O O
enhancer O O
; O O
the O O
latter O O
is O O
rapidly O O
downregulated O O
in O O
EpiLCs B-CellLine B-CellLine
. O O
A O O
second O O
TSS O O
downstream O O
, O O
associated O O
with O O
a O O
constitutively O O
weak O O
CpG O O
- O O
rich O O
promoter O O
, O O
is O O
activated O O
by O O
a O O
neighboring O O
enhancer O O
in O O
naive O O
embryonic B-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
ESCs B-CellLine B-CellLine
) O O
and O O
primed O O
epiblast B-CellLine B-CellLine
- I-CellLine I-CellLine
like I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
EpiLCs B-CellLine B-CellLine
) O O
. O O
Tet2 O O
has O O
a O O
CpG O O
island O O
promoter O O
with O O
pluripotency O O
- O O
independent O O
activity O O
and O O
an O O
ESC B-CellLine B-CellLine
- O O
specific O O
distal O O
intragenic O O
enhancer O O
; O O
the O O
latter O O
is O O
rapidly O O
downregulated O O
in O O
EpiLCs B-CellLine B-CellLine
. O O

Our O O
study O O
reveals O O
distinct O O
modes O O
of O O
transcriptional O O
regulation O O
at O O
Tet1 O O
and O O
Tet2 O O
during O O
cell O O
state O O
transitions O O
of O O
early O O
development O O
. O O

New O O
transgenic O O
reporters O O
using O O
Tet1 O O
and O O
Tet2 O O
cis O O
- O O
regulatory O O
domains O O
may O O
serve O O
to O O
distinguish O O
nuanced O O
changes O O
in O O
pluripotent O O
states O O
and O O
the O O
underlying O O
epigenetic O O
variations O O
. O O

Wnt3a O O
signal O O
pathways O O
activate O O
MyoD O O
expression O O
by O O
targeting O O
cis O O
- O O
elements O O
inside O O
and O O
outside O O
its O O
distal O O
enhancer O O
. O O

Wnt O O
proteins O O
are O O
secreted O O
cytokines O O
and O O
several O O
Wnts O O
are O O
expressed O O
in O O
the O O
developing O O
somites B-CellLine B-CellLine
and O O
surrounding O O
tissues O O
. O O

Without O O
proper O O
Wnt O O
stimulation O O
, O O
the O O
organization O O
of O O
the O O
dermomyotome B-CellLine B-CellLine
and O O
myotome B-CellLine B-CellLine
can O O
become O O
defective O O
. O O

These O O
Wnt O O
signals O O
received O O
by O O
somitic B-CellLine B-CellLine
cells I-CellLine I-CellLine
can O O
lead O O
to O O
activation O O
of O O
Pax3 O O
/ O O
Pax7 O O
and O O
myogenic O O
regulatory O O
factors O O
( O O
MRFs O O
) O O
, O O
especially O O
Myf5 O O
and O O
MyoD O O
. O O

However O O
, O O
it O O
is O O
currently O O
unknown O O
whether O O
Wnts O O
activate O O
Myf5 O O
and O O
MyoD O O
through O O
direct O O
targeting O O
of O O
their O O
cis O O
- O O
regulatory O O
elements O O
or O O
via O O
indirect O O
pathways O O
. O O

To O O
clarify O O
this O O
issue O O
, O O
in O O
the O O
present O O
study O O
, O O
we O O
tested O O
the O O
regulation O O
of O O
MyoD O O
cis O O
- O O
regulatory O O
elements O O
by O O
Wnt3a O O
secreted O O
from O O
human O B-CellLine
embryonic O I-CellLine
kidney B-CellLine I-CellLine
( I-CellLine I-CellLine
HEK I-CellLine I-CellLine
) I-CellLine I-CellLine
- I-CellLine I-CellLine
293T I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

We O O
found O O
that O O
Wnt3a O O
activated O O
the O O
MyoD O O
proximal O O
6 O O
. O O
0k O O
promoter O O
( O O
P6P O O
) O O
only O O
marginally O O
, O O
but O O
highly O O
enhanced O O
the O O
activity O O
of O O
the O O
composite O O
P6P O O
plus O O
distal O O
enhancer O O
( O O
DE O O
) O O
reporter O O
through O O
canonical O O
and O O
non O O
- O O
canonical O O
pathways O O
. O O
We O O
found O O
that O O
Wnt3a O O
activated O O
the O O
MyoD O O
proximal O O
6 O O
. O O
0k O O
promoter O O
( O O
P6P O O
) O O
only O O
marginally O O
, O O
but O O
highly O O
enhanced O O
the O O
activity O O
of O O
the O O
composite O O
P6P O O
plus O O
distal O O
enhancer O O
( O O
DE O O
) O O
reporter O O
through O O
canonical O O
and O O
non O O
- O O
canonical O O
pathways O O
. O O

Further O O
screening O O
of O O
the O O
intervening O O
fragments O O
between O O
the O O
DE O O
and O O
the O O
P6P O O
identified O O
a O O
strong O O
Wnt O O
- O O
response O O
element O O
( O O
WRE O O
) O O
in O O
the O O
upstream O O
- O O
8 O O
to O O
- O O
9k O O
region O O
( O O
L O O
fragment O O
) O O
that O O
acted O O
independently O O
of O O
the O O
DE O O
, O O
but O O
was O O
dependent O O
on O O
the O O
P6P O O
. O O

Deletion O O
of O O
a O O
Pax3 O O
/ O O
Pax7 O O
- O O
targeted O O
site O O
in O O
the O O
L O O
fragment O O
significantly O O
reduced O O
its O O
response O O
to O O
Wnt3a O O
, O O
implying O O
that O O
Wnt3a O O
activates O O
the O O
L O O
fragment O O
partially O O
through O O
Pax3 O O
/ O O
Pax7 O O
action O O
. O O
Deletion O O
of O O
a O O
Pax3 O O
/ O O
Pax7 O O
- O O
targeted O O
site O O
in O O
the O O
L O O
fragment O O
significantly O O
reduced O O
its O O
response O O
to O O
Wnt3a O O
, O O
implying O O
that O O
Wnt3a O O
activates O O
the O O
L O O
fragment O O
partially O O
through O O
Pax3 O O
/ O O
Pax7 O O
action O O
. O O

Binding O O
of O O
beta O O
- O O
catenin O O
and O O
Pax7 O O
to O O
their O O
target O O
sites O O
in O O
the O O
DE O O
and O O
the O O
L O O
fragment O O
respectively O O
was O O
also O O
demonstrated O O
by O O
ChIP O O
. O O

These O O
observations O O
demonstrated O O
the O O
first O O
time O O
that O O
Wnt3a O O
can O O
directly O O
activate O O
MyoD O O
expression O O
through O O
targeting O O
cis O O
- O O
elements O O
in O O
the O O
DE O O
and O O
the O O
L O O
fragment O O
. O O

Enhancer O O
cooperativity O O
as O O
a O O
novel O O
mechanism O O
underlying O O
the O O
transcriptional O O
regulation O O
of O O
E O O
- O O
cadherin O O
during O O
mesenchymal O O
to O O
epithelial O O
transition O O
. O O

Epithelial O O
- O O
mesenchymal O O
transition O O
( O O
EMT O O
) O O
and O O
mesenchymal O O
- O O
epithelial O O
transition O O
( O O
MET O O
) O O
highlight O O
crucial O O
steps O O
during O O
embryogenesis O O
and O O
tumorigenesis O O
. O O

Induction O O
of O O
dramatic O O
changes O O
in O O
gene O O
expression O O
and O O
cell O O
features O O
is O O
reflected O O
by O O
modulation O O
of O O
Cdh1 O O
( O O
E O O
- O O
cadherin O O
) O O
expression O O
. O O

We O O
show O O
that O O
Cdh1 O O
activity O O
during O O
MET O O
is O O
governed O O
by O O
two O O
enhancers O O
at O O
+ O O
7 O O
. O O
8 O O
kb O O
and O O
at O O
+ O O
11 O O
. O O
5 O O
kb O O
within O O
intron O O
2 O O
that O O
are O O
activated O O
by O O
binding O O
of O O
Grhl3 O O
and O O
Hnf4alpha O O
, O O
respectively O O
. O O

Recruitment O O
of O O
Grhl3 O O
and O O
Hnf4alpha O O
to O O
the O O
enhancers O O
is O O
crucial O O
for O O
activating O O
Cdh1 O O
and O O
accomplishing O O
MET O O
in O O
non B-CellLine O
- I-CellLine O
tumorigenic I-CellLine O
mouse I-CellLine O
mammary I-CellLine B-CellLine
gland I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
NMuMG B-CellLine B-CellLine
) O O
. O O

Moreover O O
, O O
the O O
two O O
enhancers O O
cooperate O O
via O O
Grhl3 O O
and O O
Hnf4alpha O O
binding O O
, O O
induction O O
of O O
DNA O O
- O O
looping O O
and O O
clustering O O
at O O
the O O
promoter O O
to O O
orchestrate O O
E O O
- O O
cadherin O O
re O O
- O O
expression O O
. O O

Our O O
results O O
provide O O
novel O O
insights O O
into O O
the O O
cellular O O
mechanisms O O
whereby O O
cells O O
respond O O
to O O
MET O O
signals O O
and O O
re O O
- O O
establish O O
an O O
epithelial O O
phenotype O O
by O O
enhancer O O
cooperativity O O
. O O

A O O
general O O
importance O O
of O O
our O O
findings O O
including O O
MET O O
- O O
mediated O O
colonization O O
of O O
metastasizing O O
tumor B-CellLine B-CellLine
cells I-CellLine I-CellLine
is O O
suggested O O
. O O

p53 O O
- O O
dependent O O
expression O O
of O O
CXCR5 O O
chemokine O O
receptor O O
in O O
MCF B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
breast I-CellLine I-CellLine
cancer I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Elevated O O
expression O O
of O O
chemokine O O
receptors O O
in O O
tumors O O
has O O
been O O
reported O O
in O O
many O O
instances O O
and O O
is O O
related O O
to O O
a O O
number O O
of O O
survival O O
advantages O O
for O O
tumor B-CellLine B-CellLine
cells I-CellLine I-CellLine
including O O
abnormal O O
activation O O
of O O
prosurvival O O
intracellular O O
pathways O O
. O O

In O O
this O O
work O O
we O O
demonstrated O O
an O O
inverse O O
correlation O O
between O O
expression O O
levels O O
of O O
p53 O O
tumor O O
suppressor O O
and O O
CXCR5 O O
chemokine O O
receptor O O
in O O
MCF B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
human I-CellLine I-CellLine
breast I-CellLine I-CellLine
cancer I-CellLine I-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
. O O

Lentiviral O O
transduction O O
of O O
MCF B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
cells I-CellLine I-CellLine
with O O
p53 O O
shRNA O O
led O O
to O O
elevated O O
CXCR5 O O
at O O
both O O
mRNA O O
and O O
protein O O
levels O O
. O O

Functional O O
activity O O
of O O
CXCR5 O O
in O O
p53 O O
- O O
knockdown O O
MCF B-CellLine B-CellLine
- I-CellLine I-CellLine
7 I-CellLine I-CellLine
cells I-CellLine I-CellLine
was O O
also O O
increased O O
as O O
shown O O
by O O
activation O O
of O O
target O O
gene O O
expression O O
and O O
chemotaxis O O
in O O
response O O
to O O
B O O
- O O
lymphocyte O O
chemoattractant O O
CXCL13 O O
. O O

Using O O
deletion O O
analysis O O
and O O
site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
cxcr5 O O
gene O O
promoter O O
and O O
enhancer O O
elements O O
, O O
we O O
demonstrated O O
that O O
p53 O O
appears O O
to O O
act O O
upon O O
cxcr5 O O
promoter O O
indirectly O O
, O O
by O O
repressing O O
the O O
activity O O
of O O
NFkappaB O O
transcription O O
factors O O
. O O
Using O O
deletion O O
analysis O O
and O O
site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
cxcr5 O O
gene O O
promoter O O
and O O
enhancer O O
elements O O
, O O
we O O
demonstrated O O
that O O
p53 O O
appears O O
to O O
act O O
upon O O
cxcr5 O O
promoter O O
indirectly O O
, O O
by O O
repressing O O
the O O
activity O O
of O O
NFkappaB O O
transcription O O
factors O O
. O O

Using O O
chromatin O O
immunoprecipitation O O
and O O
reporter O O
gene O O
analysis O O
, O O
we O O
further O O
demonstrated O O
that O O
p65 O O
/ O O
RelA O O
was O O
able O O
to O O
bind O O
the O O
cxcr5 O O
promoter O O
in O O
p53 O O
- O O
dependent O O
manner O O
and O O
to O O
directly O O
transactivate O O
it O O
when O O
overexpressed O O
. O O
Using O O
chromatin O O
immunoprecipitation O O
and O O
reporter O O
gene O O
analysis O O
, O O
we O O
further O O
demonstrated O O
that O O
p65 O O
/ O O
RelA O O
was O O
able O O
to O O
bind O O
the O O
cxcr5 O O
promoter O O
in O O
p53 O O
- O O
dependent O O
manner O O
and O O
to O O
directly O O
transactivate O O
it O O
when O O
overexpressed O O
. O O

Through O O
the O O
described O O
mechanism O O
, O O
elevated O O
CXCR5 O O
expression O O
may O O
contribute O O
to O O
abnormal O O
cell O O
survival O O
and O O
migration O O
in O O
breast O O
tumors O O
that O O
lack O O
functional O O
p53 O O
. O O

Id2 O O
deletion O O
attenuates O O
Apc O O
- O O
deficient O O
ileal O O
tumor O O
formation O O
. O O

The O O
expression O O
level O O
of O O
inhibitor O O
of O O
DNA O O
binding O O
2 O O
( O O
Id2 O O
) O O
is O O
increased O O
in O O
colorectal O O
carcinomas O O
and O O
is O O
positively O O
correlated O O
with O O
poor O O
prognosis O O
. O O

However O O
, O O
the O O
functional O O
significance O O
of O O
Id2 O O
in O O
intestinal O O
tumorigenesis O O
has O O
not O O
been O O
fully O O
defined O O
using O O
genetic O O
approaches O O
. O O

Here O O
, O O
we O O
show O O
that O O
Id2 O O
promotes O O
ileal O O
tumor O O
initiation O O
in O O
Apc O O
- O O
deficient O O
mice O O
. O O

Expression O O
of O O
Id2 O O
was O O
stimulated O O
by O O
Wnt O O
signaling O O
through O O
the O O
enhancer O O
region O O
of O O
the O O
Id2 O O
promoter O O
at O O
the O O
early O O
stage O O
of O O
tumorigenesis O O
in O O
Apc O O
( O O
+ O O
/ O O
Delta716 O O
) O O
( O O
Apc O O
( O O
Delta716 O O
) O O
) O O
mice O O
. O O
Expression O O
of O O
Id2 O O
was O O
stimulated O O
by O O
Wnt O O
signaling O O
through O O
the O O
enhancer O O
region O O
of O O
the O O
Id2 O O
promoter O O
at O O
the O O
early O O
stage O O
of O O
tumorigenesis O O
in O O
Apc O O
( O O
+ O O
/ O O
Delta716 O O
) O O
( O O
Apc O O
( O O
Delta716 O O
) O O
) O O
mice O O
. O O

Genetic O O
depletion O O
of O O
Id2 O O
in O O
Apc O O
( O O
Delta716 O O
) O O
mice O O
caused O O
~ O O
80 O O
% O O
reduction O O
in O O
the O O
number O O
of O O
ileal O O
polyps O O
, O O
but O O
had O O
little O O
effect O O
on O O
tumor O O
size O O
. O O

Notably O O
, O O
the O O
lack O O
of O O
Id2 O O
increased O O
the O O
number O O
of O O
apoptotic O O
cells O O
in O O
the O O
normal O O
crypt O B-CellLine
epithelium B-CellLine I-CellLine
of O O
the O O
mice O O
. O O

Furthermore O O
, O O
DNA O O
microarray O O
analysis O O
revealed O O
that O O
the O O
expression O O
level O O
of O O
Max O O
dimerization O O
protein O O
1 O O
( O O
Mxd1 O O
) O O
, O O
known O O
as O O
a O O
c O O
- O O
Myc O O
antagonist O O
, O O
was O O
specifically O O
increased O O
by O O
Id2 O O
deletion O O
in O O
the O O
ileal B-CellLine B-CellLine
intestinal I-CellLine I-CellLine
epithelium I-CellLine I-CellLine
of O O
Apc O O
( O O
Delta716 O O
) O O
mice O O
. O O

In O O
contrast O O
, O O
the O O
protein O O
level O O
of O O
c O O
- O O
Myc O O
, O O
but O O
not O O
the O O
mRNA O O
level O O
, O O
was O O
decreased O O
by O O
loss O O
of O O
Id2 O O
in O O
these O O
mice O O
. O O

These O O
results O O
indicate O O
that O O
loss O O
of O O
Id2 O O
inhibits O O
tumor O O
initiation O O
by O O
up O O
- O O
regulation O O
of O O
Mxd1 O O
and O O
down O O
- O O
regulation O O
of O O
c O O
- O O
Myc O O
in O O
Apc O O
( O O
Delta716 O O
) O O
mice O O
. O O

Chimeric O O
EWSR1 O O
- O O
FLI1 O O
regulates O O
the O O
Ewing O O
sarcoma O O
susceptibility O O
gene O O
EGR2 O O
via O O
a O O
GGAA O O
microsatellite O O
. O O

Deciphering O O
the O O
ways O O
in O O
which O O
somatic O O
mutations O O
and O O
germline O O
susceptibility O O
variants O O
cooperate O O
to O O
promote O O
cancer O O
is O O
challenging O O
. O O
Ewing O O
sarcoma O O
is O O
characterized O O
by O O
fusions O O
between O O
EWSR1 O O
and O O
members O O
of O O
the O O
ETS O O
gene O O
family O O
, O O
usually O O
EWSR1 O O
- O O
FLI1 O O
, O O
leading O O
to O O
the O O
generation O O
of O O
oncogenic O O
transcription O O
factors O O
that O O
bind O O
DNA O O
at O O
GGAA O O
motifs O O
. O O

A O O
recent O O
genome O O
- O O
wide O O
association O O
study O O
identified O O
susceptibility O O
variants O O
near O O
EGR2 O O
. O O

Here O O
we O O
found O O
that O O
EGR2 O O
knockdown O O
inhibited O O
proliferation O O
, O O
clonogenicity O O
and O O
spheroidal O O
growth O O
in O O
vitro O O
and O O
induced O O
regression O O
of O O
Ewing O O
sarcoma O O
xenografts O O
. O O

Targeted O O
germline O O
deep O O
sequencing O O
of O O
the O O
EGR2 O O
locus O O
in O O
affected O O
subjects O O
and O O
controls O O
identified O O
291 O O
Ewing O O
- O O
associated O O
SNPs O O
. O O

At O O
rs79965208 O O
, O O
the O O
A O O
risk O O
allele O O
connected O O
adjacent O O
GGAA O O
repeats O O
by O O
converting O O
an O O
interspaced O O
GGAT O O
motif O O
into O O
a O O
GGAA O O
motif O O
, O O
thereby O O
increasing O O
the O O
number O O
of O O
consecutive O O
GGAA O O
motifs O O
and O O
thus O O
the O O
EWSR1 O O
- O O
FLI1 O O
- O O
dependent O O
enhancer O O
activity O O
of O O
this O O
sequence O O
, O O
with O O
epigenetic O O
characteristics O O
of O O
an O O
active O O
regulatory O O
element O O
. O O
EWSR1 O O
- O O
FLI1 O O
preferentially O O
bound O O
to O O
the O O
A O O
risk O O
allele O O
, O O
which O O
increased O O
global O O
and O O
allele O O
- O O
specific O O
EGR2 O O
expression O O
. O O
At O O
rs79965208 O O
, O O
the O O
A O O
risk O O
allele O O
connected O O
adjacent O O
GGAA O O
repeats O O
by O O
converting O O
an O O
interspaced O O
GGAT O O
motif O O
into O O
a O O
GGAA O O
motif O O
, O O
thereby O O
increasing O O
the O O
number O O
of O O
consecutive O O
GGAA O O
motifs O O
and O O
thus O O
the O O
EWSR1 O O
- O O
FLI1 O O
- O O
dependent O O
enhancer O O
activity O O
of O O
this O O
sequence O O
, O O
with O O
epigenetic O O
characteristics O O
of O O
an O O
active O O
regulatory O O
element O O
. O O
EWSR1 O O
- O O
FLI1 O O
preferentially O O
bound O O
to O O
the O O
A O O
risk O O
allele O O
, O O
which O O
increased O O
global O O
and O O
allele O O
- O O
specific O O
EGR2 O O
expression O O
. O O

Collectively O O
, O O
our O O
findings O O
establish O O
cooperation O O
between O O
a O O
dominant O O
oncogene O O
and O O
a O O
susceptibility O O
variant O O
that O O
regulates O O
a O O
major O O
driver O O
of O O
Ewing O O
sarcomagenesis O O
. O O

A O O
chromosomal O O
rearrangement O O
in O O
a O O
child O O
with O O
severe O O
speech O O
and O O
language O O
disorder O O
separates O O
FOXP2 O O
from O O
a O O
functional O O
enhancer O O
. O O

Mutations O O
of O O
FOXP2 O O
in O O
7q31 O O
cause O O
a O O
rare O O
disorder O O
involving O O
speech O O
apraxia O O
, O O
accompanied O O
by O O
expressive O O
and O O
receptive O O
language O O
impairments O O
. O O

A O O
recent O O
report O O
described O O
a O O
child O O
with O O
speech O O
and O O
language O O
deficits O O
, O O
and O O
a O O
genomic O O
rearrangement O O
affecting O O
chromosomes O O
7 O O
and O O
11 O O
. O O

One O O
breakpoint O O
mapped O O
to O O
7q31 O O
and O O
, O O
although O O
outside O O
its O O
coding O O
region O O
, O O
was O O
hypothesised O O
to O O
disrupt O O
FOXP2 O O
expression O O
. O O

We O O
identified O O
an O O
element O O
2 O O
kb O O
downstream O O
of O O
this O O
breakpoint O O
with O O
epigenetic O O
characteristics O O
of O O
an O O
enhancer O O
. O O

We O O
show O O
that O O
this O O
element O O
drives O O
reporter O O
gene O O
expression O O
in O O
human O O
cell O O
- O O
lines O O
. O O

Thus O O
, O O
displacement O O
of O O
this O O
element O O
by O O
translocation O O
may O O
disturb O O
gene O O
expression O O
, O O
contributing O O
to O O
the O O
observed O O
language O O
phenotype O O
. O O

Identification O O
and O O
functional O O
analysis O O
of O O
acute O O
myeloid O O
leukemia O O
susceptibility O O
associated O O
single O O
nucleotide O O
polymorphisms O O
at O O
non O O
- O O
protein O O
coding O O
regions O O
of O O
RUNX1 O O
. O O

Little O O
is O O
known O O
about O O
the O O
susceptibility O O
to O O
acute O O
myeloid O O
leukemia O O
. O O

We O O
aim O O
to O O
search O O
non O O
- O O
protein O O
coding O O
regions O O
of O O
key O O
hematopoiesis O O
transcription O O
factors O O
for O O
genetic O O
variations O O
associated O O
with O O
acute O O
myeloid O O
leukemia O O
susceptibility O O
. O O

We O O
genotyped O O
SNPs O O
of O O
RUNX1 O O
P1 O O
promoter O O
, O O
P2 O O
promoter O O
, O O
+ O O
23 O O
enhancer O O
, O O
intron O O
5 O O
. O O
2 O O
enhancer O O
, O O
PU O O
. O O
1 O O
promoter O O
, O O
CEBPA O O
promoter O O
, O O
and O O
CEBPE O O
promoter O O
from O O
acute O O
myeloid O O
leukemia O O
patients O O
and O O
healthy O O
controls O O
. O O
Rs2249650 O O
and O O
rs2268276 O O
at O O
RUNX1 O O
intron O O
5 O O
. O O
2 O O
enhancer O O
were O O
found O O
to O O
be O O
associated O O
with O O
acute O O
myeloid O O
leukemia O O
susceptibility O O
. O O
We O O
genotyped O O
SNPs O O
of O O
RUNX1 O O
P1 O O
promoter O O
, O O
P2 O O
promoter O O
, O O
+ O O
23 O O
enhancer O O
, O O
intron O O
5 O O
. O O
2 O O
enhancer O O
, O O
PU O O
. O O
1 O O
promoter O O
, O O
CEBPA O O
promoter O O
, O O
and O O
CEBPE O O
promoter O O
from O O
acute O O
myeloid O O
leukemia O O
patients O O
and O O
healthy O O
controls O O
. O O
Rs2249650 O O
and O O
rs2268276 O O
at O O
RUNX1 O O
intron O O
5 O O
. O O
2 O O
enhancer O O
were O O
found O O
to O O
be O O
associated O O
with O O
acute O O
myeloid O O
leukemia O O
susceptibility O O
. O O

Artificial O O
reporters O O
containing O O
different O O
rs2249650 O O
and O O
rs2268276 O O
alleles O O
showed O O
differential O O
activities O O
in O O
the O O
K562 B-CellLine B-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
, O O
a O O
human B-CellLine O
immortalized I-CellLine O
myeloid I-CellLine B-CellLine
leukemia I-CellLine I-CellLine
line I-CellLine I-CellLine
. O O
Rs2249650 O O
contributes O O
to O O
reporter O O
activities O O
more O O
than O O
rs2268276 O O
. O O

Gel O O
shift O O
assay O O
is O O
consistent O O
with O O
the O O
luciferase O O
assay O O
. O O

Supershift O O
assay O O
indicated O O
that O O
one O O
potential O O
binding O O
protein O O
was O O
PU O O
. O O
1 O O
. O O

To O O
sum O O
up O O
, O O
rs2268276 O O
and O O
especially O O
rs2249650 O O
may O O
be O O
qualified O O
as O O
new O O
acute O O
myeloid O O
leukemia O O
susceptibility O O
- O O
associated O O
SNPs O O
. O O

Dynamic O O
enhancer O O
- O O
gene O O
body O O
contacts O O
during O O
transcription O O
elongation O O
. O O

Enhancers O O
govern O O
transcription O O
through O O
multiple O O
mechanisms O O
, O O
including O O
the O O
regulation O O
of O O
elongation O O
by O O
RNA O O
polymerase O O
II O O
( O O
RNAPII O O
) O O
. O O

We O O
characterized O O
the O O
dynamics O O
of O O
looped O O
enhancer O O
contacts O O
during O O
synchronous O O
transcription O O
elongation O O
. O O

We O O
found O O
that O O
many O O
distal O O
enhancers O O
form O O
stable O O
contacts O O
with O O
their O O
target O O
promoters O O
during O O
the O O
entire O O
interval O O
of O O
elongation O O
. O O

Notably O O
, O O
we O O
detected O O
additional O O
dynamic O O
enhancer O O
contacts O O
throughout O O
the O O
gene O O
bodies O O
that O O
track O O
with O O
elongating O O
RNAPII O O
and O O
the O O
leading O O
edge O O
of O O
RNA O O
synthesis O O
. O O

These O O
results O O
support O O
a O O
model O O
in O O
which O O
the O O
gene O O
body O O
changes O O
its O O
position O O
relative O O
to O O
a O O
stable O O
enhancer O O
- O O
promoter O O
complex O O
, O O
which O O
has O O
broad O O
ramifications O O
for O O
enhancer O O
function O O
and O O
architectural O O
models O O
of O O
transcriptional O O
elongation O O
. O O

Potent O O
and O O
Targeted O O
Activation O O
of O O
Latent O O
HIV O O
- O O
1 O O
Using O O
the O O
CRISPR O O
/ O O
dCas9 O O
Activator O O
Complex O O
. O O
HIV O O
- O O
1 O O
provirus O O
integration O O
results O O
in O O
a O O
persistent O O
latently O O
infected O O
reservoir O O
that O O
is O O
recalcitrant O O
to O O
combined O O
antiretroviral O O
therapy O O
( O O
cART O O
) O O
with O O
lifelong O O
treatment O O
being O O
the O O
only O O
option O O
. O O

The O O
" O O
shock O O
and O O
kill O O
" O O
strategy O O
aims O O
to O O
eradicate O O
latent O O
HIV O O
by O O
reactivating O O
proviral O O
gene O O
expression O O
in O O
the O O
context O O
of O O
cART O O
treatment O O
. O O

Gene O O
- O O
specific O O
transcriptional O O
activation O O
can O O
be O O
achieved O O
using O O
the O O
RNA O O
- O O
guided O O
CRISPR O O
- O O
Cas9 O O
system O O
comprising O O
single O O
guide O O
RNAs O O
( O O
sgRNAs O O
) O O
with O O
a O O
nuclease O O
- O O
deficient O O
Cas9 O O
mutant O O
( O O
dCas9 O O
) O O
fused O O
to O O
the O O
VP64 O O
transactivation O O
domain O O
( O O
dCas9 O O
- O O
VP64 O O
) O O
. O O

We O O
engineered O O
this O O
system O O
to O O
target O O
23 O O
sites O O
within O O
the O O
long O O
terminal O O
repeat O O
promoter O O
of O O
HIV O O
- O O
1 O O
and O O
identified O O
a O O
" O O
hotspot O O
" O O
for O O
activation O O
within O O
the O O
viral O O
enhancer O O
sequence O O
. O O

Activating O O
sgRNAs O O
transcriptionally O O
modulated O O
the O O
latent O O
proviral O O
genome O O
across O O
multiple O O
different O O
in O O
vitro O O
latency O O
cell O O
models O O
including O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
comprising O O
a O O
clonally O O
integrated O O
mCherry O O
- O O
IRES O O
- O O
Tat O O
( O O
LChIT O O
) O O
latency O O
system O O
. O O

We O O
detected O O
consistent O O
and O O
effective O O
activation O O
of O O
latent O O
virus O O
mediated O O
by O O
activator O O
sgRNAs O O
, O O
whereas O O
latency O O
reversal O O
agents O O
produced O O
variable O O
activation O O
responses O O
. O O

Transcriptomic O O
analysis O O
revealed O O
dCas9 O O
- O O
VP64 O O
/ O O
sgRNAs O O
to O O
be O O
highly O O
specific O O
, O O
while O O
the O O
well O O
- O O
characterized O O
chemical O O
activator O O
TNFalpha O O
induced O O
widespread O O
gene O O
dysregulation O O
. O O

CRISPR O O
- O O
mediated O O
gene O O
activation O O
represents O O
a O O
novel O O
system O O
which O O
provides O O
enhanced O O
efficiency O O
and O O
specificity O O
in O O
a O O
targeted O O
latency O O
reactivation O O
strategy O O
and O O
represents O O
a O O
promising O O
approach O O
to O O
a O O
" O O
functional O O
cure O O
" O O
of O O
HIV O O
/ O O
AIDS O O
. O O

Functional O O
analysis O O
of O O
the O O
11q23 O O
. O O
3 O O
glioma O O
susceptibility O O
locus O O
implicates O O
PHLDB1 O O
and O O
DDX6 O O
in O O
glioma O O
susceptibility O O
. O O
Glioma O O
is O O
the O O
most O O
common O O
malignant O O
primary O O
brain O O
tumor O O
and O O
is O O
associated O O
with O O
poor O O
prognosis O O
. O O

Genetic O O
factors O O
contributing O O
to O O
glioma O O
risk O O
have O O
recently O O
been O O
investigated O O
through O O
genome O O
- O O
wide O O
association O O
studies O O
( O O
GWAS O O
) O O
, O O
implicating O O
seven O O
independent O O
glioma O O
risk O O
loci O O
in O O
six O O
chromosomal O O
regions O O
. O O

Here O O
, O O
we O O
performed O O
an O O
in O O
- O O
depth O O
functional O O
analysis O O
of O O
the O O
risk O O
locus O O
proximal O O
to O O
the O O
PHLDB1 O O
gene O O
on O O
11q23 O O
. O O
3 O O
. O O

We O O
retrieved O O
all O O
SNPs O O
in O O
linkage O O
disequilibrium O O
( O O
r O O
( O O
2 O O
) O O
> O O
= O O
0 O O
. O O
2 O O
) O O
with O O
the O O
glioma O O
- O O
associated O O
SNP O O
( O O
rs498872 O O
) O O
and O O
performed O O
a O O
comprehensive O O
bioinformatics O O
and O O
experimental O O
functional O O
analysis O O
for O O
the O O
region O O
. O O

After O O
testing O O
candidate O O
SNPs O O
for O O
allele O O
- O O
specific O O
activity O O
in O O
a O O
luciferase O O
- O O
based O O
enhancer O O
scanning O O
assay O O
, O O
we O O
established O O
a O O
subset O O
of O O
10 O O
functional O O
SNPs O O
in O O
the O O
promoters O O
of O O
PHLDB1 O O
and O O
DDX6 O O
, O O
and O O
in O O
a O O
putative O O
enhancer O O
element O O
. O O
After O O
testing O O
candidate O O
SNPs O O
for O O
allele O O
- O O
specific O O
activity O O
in O O
a O O
luciferase O O
- O O
based O O
enhancer O O
scanning O O
assay O O
, O O
we O O
established O O
a O O
subset O O
of O O
10 O O
functional O O
SNPs O O
in O O
the O O
promoters O O
of O O
PHLDB1 O O
and O O
DDX6 O O
, O O
and O O
in O O
a O O
putative O O
enhancer O O
element O O
. O O

Chromatin O O
conformation O O
capture O O
( O O
3C O O
) O O
identified O O
a O O
physical O O
interaction O O
between O O
the O O
enhancer O O
element O O
containing O O
a O O
functional O O
SNP O O
( O O
rs73001406 O O
) O O
and O O
the O O
promoter O O
of O O
the O O
DDX6 O O
gene O O
. O O
Chromatin O O
conformation O O
capture O O
( O O
3C O O
) O O
identified O O
a O O
physical O O
interaction O O
between O O
the O O
enhancer O O
element O O
containing O O
a O O
functional O O
SNP O O
( O O
rs73001406 O O
) O O
and O O
the O O
promoter O O
of O O
the O O
DDX6 O O
gene O O
. O O

Knockdown O O
experiments O O
in O O
cell O O
culture O O
and O O
3D O O
assays O O
to O O
evaluate O O
the O O
role O O
of O O
PHLDB1 O O
and O O
DDX6 O O
suggest O O
that O O
both O O
genes O O
may O O
contribute O O
to O O
the O O
phenotype O O
. O O

These O O
studies O O
reveal O O
the O O
functional O O
landscape O O
of O O
the O O
11q23 O O
. O O
3 O O
glioma O O
susceptibility O O
locus O O
and O O
identify O O
a O O
network O O
of O O
functional O O
SNPs O O
in O O
regulatory O O
elements O O
and O O
two O O
target O O
genes O O
as O O
a O O
possible O O
mechanism O O
driving O O
glioma O O
risk O O
association O O
. O O

Regulation O O
of O O
the O O
imprinted O O
Dlk1 O O
- O O
Dio3 O O
locus O O
by O O
allele O O
- O O
specific O O
enhancer O O
activity O O
. O O

Genomic O O
imprinting O O
is O O
a O O
critical O O
developmental O O
process O O
characteristic O O
of O O
parent O O
of O O
origin O O
- O O
specific O O
gene O O
expression O O
. O O

It O O
is O O
well O O
accepted O O
that O O
differentially O O
DNA O O
- O O
methylated O O
regions O O
( O O
DMRs O O
) O O
and O O
enhancers O O
are O O
two O O
major O O
classes O O
of O O
cis O O
- O O
elements O O
determining O O
parent O O
of O O
origin O O
- O O
specific O O
gene O O
expression O O
, O O
with O O
each O O
recruiting O O
different O O
sets O O
of O O
transcription O O
factors O O
. O O

Previously O O
, O O
we O O
identified O O
the O O
AF4 O O
/ O O
FMR2 O O
( O O
AFF O O
) O O
family O O
protein O O
AFF3 O O
within O O
the O O
transcription O O
elongation O O
complex O O
SEC O O
- O O
L3 O O
. O O

Here O O
, O O
we O O
report O O
that O O
AFF3 O O
can O O
specifically O O
bind O O
both O O
gametic O O
DMRs O O
( O O
gDMRs O O
) O O
and O O
enhancers O O
within O O
imprinted O O
loci O O
in O O
an O O
allele O O
- O O
specific O O
manner O O
. O O

We O O
identify O O
the O O
molecular O O
regulators O O
involved O O
in O O
the O O
recruitment O O
of O O
AFF3 O O
to O O
gDMRs O O
and O O
provide O O
mechanistic O O
insight O O
into O O
the O O
requirement O O
of O O
AFF3 O O
at O O
an O O
enhancer O O
for O O
the O O
expression O O
of O O
an O O
~ O O
200 O O
- O O
kb O O
polycistronic O O
transcript O O
within O O
the O O
imprinted O O
Dlk1 O O
- O O
Dio3 O O
locus O O
. O O

Our O O
data O O
suggest O O
that O O
the O O
heterochromatic O O
environment O O
at O O
the O O
gDMR O O
reinforces O O
silencing O O
of O O
its O O
related O O
enhancer O O
by O O
controlling O O
the O O
binding O O
and O O
activity O O
of O O
AFF3 O O
in O O
an O O
allele O O
- O O
specific O O
manner O O
. O O

In O O
summary O O
, O O
this O O
study O O
provides O O
molecular O O
details O O
about O O
the O O
regulation O O
of O O
dosage O O
- O O
critical O O
imprinted O O
gene O O
expression O O
through O O
the O O
regulated O O
binding O O
of O O
the O O
transcription O O
elongation O O
factor O O
AFF3 O O
between O O
a O O
DMR O O
and O O
an O O
enhancer O O
. O O

Utility O O
of O O
next O O
- O O
generation O O
RNA O O
- O O
sequencing O O
in O O
identifying O O
chimeric O O
transcription O O
involving O O
human O O
endogenous O O
retroviruses O O
. O O

Several O O
studies O O
have O O
shown O O
that O O
human O O
endogenous O O
retroviruses O O
and O O
endogenous O O
retrovirus O O
- O O
like O O
repeats O O
( O O
here O O
collectively O O
HERVs O O
) O O
impose O O
direct O O
regulation O O
on O O
human O O
genes O O
through O O
enhancer O O
and O O
promoter O O
motifs O O
present O O
in O O
their O O
long O O
terminal O O
repeats O O
( O O
LTRs O O
) O O
. O O

Although O O
chimeric O O
transcription O O
in O O
which O O
novel O O
gene O O
isoforms O O
containing O O
retroviral O O
and O O
human O O
sequence O O
are O O
transcribed O O
from O O
viral O O
promoters O O
are O O
commonly O O
associated O O
with O O
disease O O
, O O
regulation O O
by O O
HERVs O O
is O O
beneficial O O
in O O
other O O
settings O O
; O O
for O O
example O O
, O O
in O O
human O O
testis B-CellLine B-CellLine
chimeric O O
isoforms O O
of O O
TP63 O O
induced O O
by O O
an O O
ERV9 O O
LTR O O
protect O O
the O O
male O O
germ O B-CellLine
line O I-CellLine
upon O O
DNA O O
damage O O
by O O
inducing O O
apoptosis O O
, O O
whereas O O
in O O
the O O
human O O
globin O O
locus O O
the O O
gamma O O
- O O
and O O
beta O O
- O O
globin O O
switch O O
during O O
normal O O
hematopoiesis O O
is O O
mediated O O
by O O
complex O O
interactions O O
of O O
an O O
ERV9 O O
LTR O O
and O O
surrounding O O
human O O
sequence O O
. O O

The O O
advent O O
of O O
deep O O
sequencing O O
or O O
next O O
- O O
generation O O
sequencing O O
( O O
NGS O O
) O O
has O O
revolutionized O O
the O O
way O O
researchers O O
solve O O
important O O
scientific O O
questions O O
and O O
develop O O
novel O O
hypotheses O O
in O O
relation O O
to O O
human O O
genome O O
regulation O O
. O O

We O O
recently O O
applied O O
next O O
- O O
generation O O
paired O O
- O O
end O O
RNA O O
- O O
sequencing O O
( O O
RNA O O
- O O
seq O O
) O O
together O O
with O O
chromatin O O
immunoprecipitation O O
with O O
sequencing O O
( O O
ChIP O O
- O O
seq O O
) O O
to O O
examine O O
ERV9 O O
chimeric O O
transcription O O
in O O
human O O
reference O O
cell O O
lines O O
from O O
Encyclopedia O O
of O O
DNA O O
Elements O O
( O O
ENCODE O O
) O O
. O O

This O O
led O O
to O O
the O O
discovery O O
of O O
advanced O O
regulation O O
mechanisms O O
by O O
ERV9s O O
and O O
other O O
HERVs O O
across O O
numerous O O
human O O
loci O O
including O O
transcription O O
of O O
large O O
gene O O
- O O
unannotated O O
genomic O O
regions O O
, O O
as O O
well O O
as O O
cooperative O O
regulation O O
by O O
multiple O O
HERVs O O
and O O
non O O
- O O
LTR O O
repeats O O
such O O
as O O
Alu O O
elements O O
. O O

In O O
this O O
article O O
, O O
well O O
- O O
established O O
examples O O
of O O
human O O
gene O O
regulation O O
by O O
HERVs O O
are O O
reviewed O O
followed O O
by O O
a O O
description O O
of O O
paired O O
- O O
end O O
RNA O O
- O O
seq O O
, O O
and O O
its O O
application O O
in O O
identifying O O
chimeric O O
transcription O O
genome O O
- O O
widely O O
. O O

Based O O
on O O
integrative O O
analyses O O
of O O
RNA O O
- O O
seq O O
and O O
ChIP O O
- O O
seq O O
, O O
data O O
we O O
then O O
present O O
novel O O
examples O O
of O O
regulation O O
by O O
ERV9s O O
of O O
tumor O O
suppressor O O
genes O O
CADM2 O O
and O O
SEMA3A O O
, O O
as O O
well O O
as O O
transcription O O
of O O
an O O
unannotated O O
region O O
. O O

Taken O O
together O O
, O O
this O O
article O O
highlights O O
the O O
high O O
suitability O O
of O O
contemporary O O
sequencing O O
methods O O
in O O
future O O
analyses O O
of O O
human O O
biology O O
in O O
relation O O
to O O
evolutionary O O
acquired O O
retroviruses O O
in O O
the O O
human O O
genome O O
. O O

Differential O O
Roles O O
for O O
DUSP O O
Family O O
Members O O
in O O
Epithelial O O
- O O
to O O
- O O
Mesenchymal O O
Transition O O
and O O
Cancer B-CellLine B-CellLine
Stem I-CellLine I-CellLine
Cell I-CellLine I-CellLine
Regulation O O
in O O
Breast O O
Cancer O O
. O O

Dual O O
- O O
specificity O O
phosphatases O O
( O O
DUSPs O O
) O O
dephosphorylate O O
threonine O O
/ O O
serine O O
and O O
tyrosine O O
residues O O
on O O
their O O
substrates O O
. O O

Here O O
we O O
show O O
that O O
DUSP1 O O
, O O
DUSP4 O O
, O O
and O O
DUSP6 O O
are O O
involved O O
in O O
epithelial O O
- O O
to O O
- O O
mesenchymal O O
transition O O
( O O
EMT O O
) O O
and O O
breast B-CellLine B-CellLine
cancer I-CellLine I-CellLine
stem I-CellLine I-CellLine
cell I-CellLine I-CellLine
( O O
CSC B-CellLine B-CellLine
) O O
regulation O O
. O O
DUSP1 O O
, O O
DUSP4 O O
, O O
and O O
DUSP6 O O
are O O
induced O O
during O O
EMT O O
in O O
a O O
PKC O O
pathway O O
signal O O
- O O
mediated O O
EMT O O
model O O
. O O

We O O
show O O
for O O
the O O
first O O
time O O
that O O
the O O
key O O
chromatin O O
- O O
associated O O
kinase O O
PKC O O
- O O
theta O O
directly O O
regulates O O
a O O
subset O O
of O O
DUSP O O
family O O
members O O
. O O
DUSP1 O O
, O O
DUSP4 O O
, O O
and O O
DUSP6 O O
globally O O
but O O
differentially O O
co O O
- O O
exist O O
with O O
enhancer O O
and O O
permissive O O
active O O
histone O O
post O O
- O O
translational O O
modifications O O
, O O
suggesting O O
that O O
they O O
play O O
distinct O O
roles O O
in O O
gene O O
regulation O O
in O O
EMT O O
/ O O
CSCs O B-CellLine
. O O

We O O
show O O
that O O
nuclear O O
DUSP4 O O
associates O O
with O O
the O O
key O O
acetyltransferase O O
p300 O O
in O O
the O O
context O O
of O O
the O O
chromatin O O
template O O
and O O
dynamically O O
regulates O O
the O O
interplay O O
between O O
two O O
key O O
phosphorylation O O
marks O O
: O O
the O O
1834 O O
( O O
active O O
) O O
and O O
89 O O
( O O
inhibitory O O
) O O
residues O O
central O O
to O O
p300 O O
' O O
s O O
acetyltransferase O O
activity O O
. O O

Furthermore O O
, O O
knockdown O O
with O O
small O O
- O O
interfering O O
RNAs O O
( O O
siRNAs O O
) O O
shows O O
that O O
DUSP4 O O
is O O
required O O
for O O
maintaining O O
H3K27ac O O
, O O
a O O
mark O O
mediated O O
by O O
p300 O O
. O O
DUSP1 O O
, O O
DUSP4 O O
, O O
and O O
DUSP6 O O
knockdown O O
with O O
siRNAs O O
shows O O
that O O
they O O
participate O O
in O O
the O O
formation O O
of O O
CD44hi O B-CellLine
/ O I-CellLine
CD24lo O I-CellLine
/ O I-CellLine
EpCAM O I-CellLine
+ O I-CellLine
breast B-CellLine I-CellLine
CSCs I-CellLine I-CellLine
: O O
DUSP1 O O
knockdown O O
reduces O O
CSC B-CellLine B-CellLine
formation O O
, O O
while O O
DUSP4 O O
and O O
DUSP6 O O
knockdown O O
enhance O O
CSC B-CellLine B-CellLine
formation O O
. O O

Moreover O O
, O O
DUSP6 O O
is O O
overexpressed O O
in O O
patient O O
- O O
derived O O
HER2 O O
+ O O
breast O O
carcinomas O O
compared O O
to O O
benign O O
mammary O O
tissue O O
. O O

Taken O O
together O O
, O O
these O O
findings O O
illustrate O O
novel O O
pleiotropic O O
roles O O
for O O
DUSP O O
family O O
members O O
in O O
EMT O O
and O O
CSC B-CellLine B-CellLine
regulation O O
in O O
breast O O
cancer O O
. O O

Differential O O
regulation O O
of O O
mouse O O
and O O
human O O
nephron B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
by O O
the O O
Six O O
family O O
of O O
transcriptional O O
regulators O O
. O O
Nephron B-CellLine B-CellLine
endowment O O
is O O
determined O O
by O O
the O O
self O O
- O O
renewal O O
and O O
induction O O
of O O
a O O
nephron B-CellLine B-CellLine
progenitor I-CellLine I-CellLine
pool O O
established O O
at O O
the O O
onset O O
of O O
kidney B-CellLine B-CellLine
development O O
. O O

In O O
the O O
mouse O O
, O O
the O O
related O O
transcriptional O O
regulators O O
Six1 O O
and O O
Six2 O O
play O O
non O O
- O O
overlapping O O
roles O O
in O O
nephron B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
. O O

Transient O O
Six1 O O
activity O O
prefigures O O
, O O
and O O
is O O
essential O O
for O O
, O O
active O O
nephrogenesis O O
. O O

By O O
contrast O O
, O O
Six2 O O
maintains O O
later O O
progenitor O O
self O O
- O O
renewal O O
from O O
the O O
onset O O
of O O
nephrogenesis O O
. O O

We O O
compared O O
the O O
regulatory O O
actions O O
of O O
Six2 O O
in O O
mouse O O
and O O
human O O
nephron B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
by O O
chromatin O O
immunoprecipitation O O
followed O O
by O O
DNA O O
sequencing O O
( O O
ChIP O O
- O O
seq O O
) O O
. O O

Surprisingly O O
, O O
SIX1 O O
was O O
identified O O
as O O
a O O
SIX2 O O
target O O
unique O O
to O O
the O O
human O O
nephron B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
. O O

Furthermore O O
, O O
RNA O O
- O O
seq O O
and O O
immunostaining O O
revealed O O
overlapping O O
SIX1 O O
and O O
SIX2 O O
activity O O
in O O
16 O O
week O O
human O O
fetal O O
nephron B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
. O O

Comparative O O
bioinformatic O O
analysis O O
of O O
human O O
SIX1 O O
and O O
SIX2 O O
ChIP O O
- O O
seq O O
showed O O
each O O
factor O O
targeted O O
a O O
similar O O
set O O
of O O
cis O O
- O O
regulatory O O
modules O O
binding O O
an O O
identical O O
target O O
recognition O O
motif O O
. O O

In O O
contrast O O
to O O
the O O
mouse O O
where O O
Six2 O O
binds O O
its O O
own O O
enhancers O O
but O O
does O O
not O O
interact O O
with O O
DNA O O
around O O
Six1 O O
, O O
both O O
human O O
SIX1 O O
and O O
SIX2 O O
bind O O
homologous O O
SIX2 O O
enhancers O O
and O O
putative O O
enhancers O O
positioned O O
around O O
SIX1 O O
. O O
In O O
contrast O O
to O O
the O O
mouse O O
where O O
Six2 O O
binds O O
its O O
own O O
enhancers O O
but O O
does O O
not O O
interact O O
with O O
DNA O O
around O O
Six1 O O
, O O
both O O
human O O
SIX1 O O
and O O
SIX2 O O
bind O O
homologous O O
SIX2 O O
enhancers O O
and O O
putative O O
enhancers O O
positioned O O
around O O
SIX1 O O
. O O

Transgenic O O
analysis O O
of O O
a O O
putative O O
human O O
SIX1 O O
enhancer O O
in O O
the O O
mouse O O
revealed O O
a O O
transient O O
, O O
mouse O O
- O O
like O O
, O O
pre O O
- O O
nephrogenic O O
, O O
Six1 O O
regulatory O O
pattern O O
. O O
Transgenic O O
analysis O O
of O O
a O O
putative O O
human O O
SIX1 O O
enhancer O O
in O O
the O O
mouse O O
revealed O O
a O O
transient O O
, O O
mouse O O
- O O
like O O
, O O
pre O O
- O O
nephrogenic O O
, O O
Six1 O O
regulatory O O
pattern O O
. O O

Together O O
, O O
these O O
data O O
demonstrate O O
a O O
divergence O O
in O O
SIX O O
- O O
factor O O
regulation O O
between O O
mouse O O
and O O
human O O
nephron B-CellLine B-CellLine
progenitors I-CellLine I-CellLine
. O O

In O O
the O O
human O O
, O O
an O O
auto O O
/ O O
cross O O
- O O
regulatory O O
loop O O
drives O O
continued O O
SIX1 O O
and O O
SIX2 O O
expression O O
during O O
active O O
nephrogenesis O O
. O O

By O O
contrast O O
, O O
the O O
mouse O O
establishes O O
only O O
an O O
auto O O
- O O
regulatory O O
Six2 O O
loop O O
. O O

These O O
data O O
suggest O O
differential O O
SIX O O
- O O
factor O O
regulation O O
might O O
have O O
contributed O O
to O O
species O O
differences O O
in O O
nephron B-CellLine B-CellLine
progenitor I-CellLine I-CellLine
programs O O
such O O
as O O
the O O
duration O O
of O O
nephrogenesis O O
and O O
the O O
final O O
nephron B-CellLine B-CellLine
count O O
. O O

Putting O O
cryptogenic O O
stroke O O
into O O
perspective O O
. O O

In O O
patients O O
who O O
have O O
a O O
cryptogenic O O
stroke O O
and O O
have O O
their O O
PFO O O
closed O O
, O O
the O O
recurrence O O
rate O O
of O O
" O O
cerebral O O
ischemia O O
" O O
is O O
much O O
greater O O
in O O
patients O O
who O O
are O O
older O O
than O O
55 O O
years O O
. O O

Most O O
of O O
these O O
recurrent O O
events O O
( O O
2 O O
strokes O O
and O O
4TIAs O O
) O O
in O O
the O O
older O O
age O O
group O O
were O O
due O O
to O O
identifiable O O
causes O O
. O O

These O O
findings O O
corroborate O O
the O O
long O O
- O O
term O O
results O O
from O O
the O O
RESPECT O O
randomized O O
clinical O O
trial O O
of O O
PFO O O
closure O O
versus O O
medical O O
therapy O O
. O O

4C O O
- O O
seq O O
revealed O O
long O O
- O O
range O O
interactions O O
of O O
a O O
functional O O
enhancer O O
at O O
the O O
8q24 O O
prostate O O
cancer O O
risk O O
locus O O
. O O

Genome O O
- O O
wide O O
association O O
studies O O
( O O
GWAS O O
) O O
have O O
identified O O
> O O
100 O O
independent O O
susceptibility O O
loci O O
for O O
prostate O O
cancer O O
, O O
including O O
the O O
hot O O
spot O O
at O O
8q24 O O
. O O

However O O
, O O
how O O
genetic O O
variants O O
at O O
this O O
locus O O
confer O O
disease O O
risk O O
hasn O O
' O O
t O O
been O O
fully O O
characterized O O
. O O

Using O O
circularized O O
chromosome O O
conformation O O
capture O O
( O O
4C O O
) O O
coupled O O
with O O
next O O
- O O
generation O O
sequencing O O
and O O
an O O
enhancer O O
at O O
8q24 O O
as O O
" O O
bait O O
" O O
, O O
we O O
identified O O
genome O O
- O O
wide O O
partners O O
interacting O O
with O O
this O O
enhancer O O
in O O
cell O O
lines O O
LNCaP B-CellLine B-CellLine
and O O
C4 B-CellLine B-CellLine
- I-CellLine I-CellLine
2B I-CellLine I-CellLine
. O O

These O O
4C O O
- O O
identified O O
regions O O
are O O
distributed O O
in O O
open O O
nuclear O O
compartments O O
, O O
featuring O O
active O O
histone O O
marks O O
( O O
H3K4me1 O O
, O O
H3K4me2 O O
and O O
H3K27Ac O O
) O O
. O O

Transcription O O
factors O O
NKX3 O O
- O O
1 O O
, O O
FOXA1 O O
and O O
AR O O
( O O
androgen O O
receptor O O
) O O
tend O O
to O O
occupy O O
these O O
4C O O
regions O O
. O O

We O O
identified O O
genes O O
located O O
at O O
the O O
interacting O O
regions O O
, O O
and O O
found O O
them O O
linked O O
to O O
positive O O
regulation O O
of O O
mesenchymal B-CellLine B-CellLine
cell I-CellLine I-CellLine
proliferation O O
in O O
LNCaP B-CellLine B-CellLine
and O O
C4 B-CellLine O
- I-CellLine O
2B I-CellLine O
, O O
and O O
several O O
pathways O O
( O O
TGF O O
beta O O
signaling O O
pathway O O
in O O
LNCaP B-CellLine B-CellLine
and O O
p53 O O
pathway O O
in O O
C4 O O
- O O
2B O O
) O O
. O O

Common O O
genes O O
( O O
e O O
. O O
g O O
. O O
MYC O O
and O O
POU5F1B O O
) O O
were O O
identified O O
in O O
both O O
prostate B-CellLine B-CellLine
cancer I-CellLine I-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
. O O

However O O
, O O
each O O
cell O O
line O O
also O O
had O O
exclusive O O
genes O O
( O O
e O O
. O O
g O O
. O O
ELAC2 O O
and O O
PTEN O O
in O O
LNCaP B-CellLine B-CellLine
and O O
BRCA2 O O
and O O
ZFHX3 O O
in O O
C4 B-CellLine O
- I-CellLine O
2B I-CellLine O
) O O
. O O

In O O
addition O O
, O O
BCL O O
- O O
2 O O
identified O O
in O O
C4 B-CellLine O
- I-CellLine O
2B I-CellLine O
might O O
contribute O O
to O O
the O O
progression O O
of O O
androgen O O
- O O
refractory O O
prostate O O
cancer O O
. O O

Overall O O
, O O
our O O
work O O
reveals O O
key O O
genes O O
and O O
pathways O O
involved O O
in O O
prostate O O
cancer O O
onset O O
and O O
progression O O
. O O

Comprehensive O O
benchmarking O O
reveals O O
H2BK20 O O
acetylation O O
as O O
a O O
distinctive O O
signature O O
of O O
cell O O
- O O
state O O
- O O
specific O O
enhancers O O
and O O
promoters O O
. O O

Although O O
over O O
35 O O
different O O
histone O O
acetylation O O
marks O O
have O O
been O O
described O O
, O O
the O O
overwhelming O O
majority O O
of O O
regulatory O O
genomics O O
studies O O
focus O O
exclusively O O
on O O
H3K27ac O O
and O O
H3K9ac O O
. O O

In O O
order O O
to O O
identify O O
novel O O
epigenomic O O
traits O O
of O O
regulatory O O
elements O O
, O O
we O O
constructed O O
a O O
benchmark O O
set O O
of O O
validated O O
enhancers O O
by O O
performing O O
140 O O
enhancer O O
assays O O
in O O
human O O
T B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

We O O
tested O O
40 O O
chromatin O O
signatures O O
on O O
this O O
unbiased O O
enhancer O O
set O O
and O O
identified O O
H2BK20ac O O
, O O
a O O
little O O
- O O
studied O O
histone O O
modification O O
, O O
as O O
the O O
most O O
predictive O O
mark O O
of O O
active O O
enhancers O O
. O O

Notably O O
, O O
we O O
detected O O
a O O
novel O O
class O O
of O O
functionally O O
distinct O O
enhancers O O
enriched O O
in O O
H2BK20ac O O
but O O
lacking O O
H3K27ac O O
, O O
which O O
was O O
present O O
in O O
all O O
examined O O
cell O O
lines O O
and O O
also O O
in O O
embryonic O O
forebrain O B-CellLine
tissue O O
. O O

H2BK20ac O O
was O O
also O O
unique O O
in O O
highlighting O O
cell O O
- O O
type O O
- O O
specific O O
promoters O O
. O O

In O O
contrast O O
, O O
other O O
acetylation O O
marks O O
were O O
present O O
in O O
all O O
active O O
promoters O O
, O O
regardless O O
of O O
cell O O
- O O
type O O
specificity O O
. O O

In O O
stimulated O O
microglial B-CellLine B-CellLine
cells I-CellLine I-CellLine
, O O
H2BK20ac O O
was O O
more O O
correlated O O
with O O
cell O O
- O O
state O O
- O O
specific O O
expression O O
changes O O
than O O
H3K27ac O O
, O O
with O O
TGF O O
- O O
beta O O
signaling O O
decoupling O O
the O O
two O O
acetylation O O
marks O O
at O O
a O O
subset O O
of O O
regulatory O O
elements O O
. O O

In O O
summary O O
, O O
our O O
study O O
reveals O O
a O O
previously O O
unknown O O
connection O O
between O O
histone O O
acetylation O O
and O O
cell O O
- O O
type O O
- O O
specific O O
gene O O
regulation O O
and O O
indicates O O
that O O
H2BK20ac O O
profiling O O
can O O
be O O
used O O
to O O
uncover O O
new O O
dimensions O O
of O O
gene O O
regulation O O
. O O

Identification O O
of O O
a O O
novel O O
putative O O
mitochondrial O O
protein O O
FAM210B O O
associated O O
with O O
erythroid B-CellLine B-CellLine
differentiation O O
. O O

The O O
transcription O O
factor O O
GATA O O
- O O
1 O O
plays O O
an O O
essential O O
role O O
in O O
erythroid B-CellLine B-CellLine
differentiation O O
. O O

To O O
identify O O
novel O O
GATA O O
- O O
1 O O
target O O
genes O O
, O O
we O O
analyzed O O
a O O
merged O O
ChIP O O
- O O
seq O O
and O O
expression O O
profiling O O
dataset O O
. O O

We O O
identified O O
FAM210B O O
as O O
a O O
putative O O
novel O O
GATA O O
- O O
1 O O
target O O
gene O O
. O O

Study O O
results O O
demonstrated O O
that O O
GATA O O
- O O
1 O O
directly O O
regulates O O
FAM210B O O
expression O O
, O O
presumably O O
by O O
binding O O
to O O
an O O
intronic O O
enhancer O O
region O O
. O O

Both O O
human O O
and O O
murine O O
FAM210B O O
are O O
abundantly O O
expressed O O
in O O
the O O
later O O
stages O O
of O O
erythroblast B-CellLine B-CellLine
development O O
. O O

Moreover O O
, O O
the O O
deduced O O
amino O O
acid O O
sequence O O
predicted O O
that O O
FAM210B O O
is O O
a O O
membrane O O
protein O O
, O O
and O O
Western O O
blot O O
analysis O O
demonstrated O O
its O O
mitochondrial O O
localization O O
. O O

Loss O O
- O O
of O O
- O O
function O O
analysis O O
in O O
erythroid B-CellLine B-CellLine
cells I-CellLine I-CellLine
suggested O O
that O O
FAM210B O O
may O O
be O O
involved O O
in O O
erythroid B-CellLine B-CellLine
differentiation O O
. O O

The O O
identification O O
and O O
characterization O O
of O O
FAM210B O O
provides O O
new O O
insights O O
in O O
the O O
study O O
of O O
erythropoiesis O O
and O O
hereditary O O
anemias O O
. O O

Regulation O O
of O O
Laminin O O
gamma2 O O
Expression O O
by O O
CDX2 O O
in O O
Colonic B-CellLine B-CellLine
Epithelial I-CellLine I-CellLine
Cells I-CellLine I-CellLine
Is O O
Impaired O O
During O O
Active O O
Inflammation O O
. O O

The O O
expression O O
of O O
Caudal O O
- O O
related O O
homeobox O O
transcription O O
factor O O
2 O O
( O O
CDX2 O O
) O O
is O O
impaired O O
by O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNF O O
- O O
alpha O O
) O O
- O O
mediated O O
activation O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
( O O
NF O O
- O O
kappaB O O
) O O
in O O
ulcerative O O
colitis O O
( O O
UC O O
) O O
. O O
Laminin O O
subunit O O
gamma2 O O
( O O
LAMC2 O O
) O O
is O O
an O O
epithelial O O
basement O O
membrane O O
protein O O
implicated O O
in O O
cell O O
migration O O
, O O
proliferation O O
, O O
differentiation O O
, O O
as O O
well O O
as O O
tumor O O
invasion O O
and O O
intestinal O O
inflammation O O
, O O
and O O
its O O
expression O O
is O O
enhanced O O
by O O
TNF O O
- O O
alpha O O
in O O
a O O
NF O O
- O O
kappaB O O
- O O
dependent O O
regulation O O
of O O
the O O
recently O O
identified O O
LAMC2 O O
enhancer O O
. O O
The O O
expression O O
of O O
Caudal O O
- O O
related O O
homeobox O O
transcription O O
factor O O
2 O O
( O O
CDX2 O O
) O O
is O O
impaired O O
by O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNF O O
- O O
alpha O O
) O O
- O O
mediated O O
activation O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
( O O
NF O O
- O O
kappaB O O
) O O
in O O
ulcerative O O
colitis O O
( O O
UC O O
) O O
. O O
Laminin O O
subunit O O
gamma2 O O
( O O
LAMC2 O O
) O O
is O O
an O O
epithelial O O
basement O O
membrane O O
protein O O
implicated O O
in O O
cell O O
migration O O
, O O
proliferation O O
, O O
differentiation O O
, O O
as O O
well O O
as O O
tumor O O
invasion O O
and O O
intestinal O O
inflammation O O
, O O
and O O
its O O
expression O O
is O O
enhanced O O
by O O
TNF O O
- O O
alpha O O
in O O
a O O
NF O O
- O O
kappaB O O
- O O
dependent O O
regulation O O
of O O
the O O
recently O O
identified O O
LAMC2 O O
enhancer O O
. O O

The O O
aim O O
was O O
to O O
determine O O
whether O O
CDX2 O O
is O O
involved O O
in O O
the O O
basal O O
regulation O O
of O O
LAMC2 O O
in O O
epithelial B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
to O O
assess O O
the O O
influence O O
of O O
inflammation O O
. O O

Transcriptional O O
regulation O O
of O O
LAMC2 O O
was O O
examined O O
by O O
reporter O O
gene O O
assays O O
, O O
overexpression O O
, O O
and O O
shRNA O O
- O O
mediated O O
knock O O
- O O
down O O
of O O
CDX2 O O
. O O
CDX2 O O
- O O
DNA O O
interactions O O
were O O
assessed O O
by O O
chromatin O O
immunoprecipitation O O
on O O
Caco B-CellLine B-CellLine
- I-CellLine I-CellLine
2 I-CellLine I-CellLine
cells I-CellLine I-CellLine
without O O
or O O
with O O
TNF O O
- O O
alpha O O
, O O
as O O
well O O
as O O
in O O
purified O O
colonic B-CellLine B-CellLine
human I-CellLine I-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Immunohistochemical O O
staining O O
and O O
quantitative O O
reverse O O
- O O
transcription O O
polymerase O O
chain O O
reaction O O
analyses O O
were O O
used O O
to O O
measure O O
the O O
expression O O
of O O
CDX2 O O
and O O
LAMC2 O O
in O O
colonic B-CellLine O
biopsies I-CellLine O
from O O
healthy O O
controls O O
and O O
patients O O
with O O
UC O O
. O O

These O O
data O O
indicate O O
that O O
CDX2 O O
directly O O
regulates O O
LAMC2 O O
gene O O
expression O O
through O O
interaction O O
with O O
elements O O
in O O
the O O
LAMC2 O O
promoter O O
region O O
. O O
These O O
data O O
indicate O O
that O O
CDX2 O O
directly O O
regulates O O
LAMC2 O O
gene O O
expression O O
through O O
interaction O O
with O O
elements O O
in O O
the O O
LAMC2 O O
promoter O O
region O O
. O O

We O O
further O O
revealed O O
an O O
inverse O O
effect O O
of O O
inflammation O O
on O O
CDX2 O O
and O O
LAMC2 O O
. O O

The O O
data O O
presented O O
provide O O
a O O
novel O O
insight O O
into O O
how O O
CDX2 O O
is O O
implicated O O
in O O
the O O
transcriptional O O
regulation O O
of O O
LAMC2 O O
in O O
intestinal B-CellLine B-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
, O O
a O O
function O O
that O O
is O O
impaired O O
during O O
mucosal O O
inflammation O O
where O O
a O O
high O O
level O O
of O O
TNF O O
- O O
alpha O O
is O O
present O O
. O O

J O O
. O O
Cell O O
. O O

Biochem O O
. O O

118 O O
: O O
298 O O
- O O
307 O O
, O O
2017 O O
. O O

2016 O O
Wiley O O
Periodicals O O
, O O
Inc O O
. O O

BRD4 O O
promotes O O
p63 O O
and O O
GRHL3 O O
expression O O
downstream O O
of O O
FOXO O O
in O O
mammary B-CellLine B-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O
Bromodomain O O
- O O
containing O O
protein O O
4 O O
( O O
BRD4 O O
) O O
is O O
a O O
member O O
of O O
the O O
bromo O O
- O O
and O O
extraterminal O O
( O O
BET O O
) O O
domain O O
- O O
containing O O
family O O
of O O
epigenetic O O
readers O O
which O O
is O O
under O O
intensive O O
investigation O O
as O O
a O O
target O O
for O O
anti O O
- O O
tumor O O
therapy O O
. O O
BRD4 O O
plays O O
a O O
central O O
role O O
in O O
promoting O O
the O O
expression O O
of O O
select O O
subsets O O
of O O
genes O O
including O O
many O O
driven O O
by O O
oncogenic O O
transcription O O
factors O O
and O O
signaling O O
pathways O O
. O O

However O O
, O O
the O O
role O O
of O O
BRD4 O O
and O O
the O O
effects O O
of O O
BET O O
inhibitors O O
in O O
non O O
- O O
transformed O O
cells O O
remain O O
mostly O O
unclear O O
. O O

We O O
demonstrate O O
that O O
BRD4 O O
is O O
required O O
for O O
the O O
maintenance O O
of O O
a O O
basal O O
epithelial O O
phenotype O O
by O O
regulating O O
the O O
expression O O
of O O
epithelial O O
- O O
specific O O
genes O O
including O O
TP63 O O
and O O
Grainy O O
Head O O
- O O
like O O
transcription O O
factor O O
- O O
3 O O
( O O
GRHL3 O O
) O O
in O O
non O O
- O O
transformed O O
basal O O
- O O
like O O
mammary B-CellLine B-CellLine
epithelial I-CellLine I-CellLine
cells I-CellLine I-CellLine
. O O

Moreover O O
, O O
BRD4 O O
occupancy O O
correlates O O
with O O
enhancer O O
activity O O
and O O
enhancer O O
RNA O O
( O O
eRNA O O
) O O
transcription O O
. O O

Motif O O
analyses O O
of O O
cell O O
context O O
- O O
specific O O
BRD4 O O
- O O
enriched O O
regions O O
predicted O O
the O O
involvement O O
of O O
FOXO O O
transcription O O
factors O O
. O O

Consistently O O
, O O
activation O O
of O O
FOXO1 O O
function O O
via O O
inhibition O O
of O O
EGFR O O
- O O
AKT O O
signaling O O
promoted O O
the O O
expression O O
of O O
TP63 O O
and O O
GRHL3 O O
. O O

Moreover O O
, O O
activation O O
of O O
Src O O
kinase O O
signaling O O
and O O
FOXO1 O O
inhibition O O
decreased O O
the O O
expression O O
of O O
FOXO O O
/ O O
BRD4 O O
target O O
genes O O
. O O

Together O O
, O O
our O O
findings O O
support O O
a O O
function O O
for O O
BRD4 O O
in O O
promoting O O
basal O O
mammary B-CellLine B-CellLine
cell I-CellLine I-CellLine
epithelial O O
differentiation O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
regulating O O
FOXO O O
factor O O
function O O
on O O
enhancers O O
to O O
activate O O
TP63 O O
and O O
GRHL3 O O
expression O O
. O O

Isoform O O
- O O
Specific O O
Expression O O
and O O
Feedback O O
Regulation O O
of O O
E O O
Protein O O
TCF4 O O
Control O O
Dendritic B-CellLine B-CellLine
Cell I-CellLine I-CellLine
Lineage O O
Specification O O
. O O

The O O
cell O O
fate O O
decision O O
between O O
interferon O O
- O O
producing O O
plasmacytoid B-CellLine B-CellLine
DC I-CellLine I-CellLine
( O O
pDC B-CellLine B-CellLine
) O O
and O O
antigen O O
- O O
presenting O O
classical B-CellLine O
DC I-CellLine B-CellLine
( O O
cDC B-CellLine B-CellLine
) O O
is O O
controlled O O
by O O
the O O
E O O
protein O O
transcription O O
factor O O
TCF4 O O
( O O
E2 O O
- O O
2 O O
) O O
. O O

We O O
report O O
that O O
TCF4 O O
comprises O O
two O O
transcriptional O O
isoforms O O
, O O
both O O
of O O
which O O
are O O
required O O
for O O
optimal O O
pDC B-CellLine B-CellLine
development O O
in O O
vitro O O
. O O

The O O
long O O
Tcf4 O O
isoform O O
is O O
expressed O O
specifically O O
in O O
pDCs B-CellLine B-CellLine
, O O
and O O
its O O
deletion O O
in O O
mice O O
impaired O O
pDCs B-CellLine B-CellLine
development O O
and O O
led O O
to O O
the O O
expansion O O
of O O
non O O
- O O
canonical O O
CD8 B-CellLine B-CellLine
+ I-CellLine I-CellLine
cDCs I-CellLine I-CellLine
. O O

The O O
expression O O
of O O
Tcf4 O O
commenced O O
in O O
progenitors O O
and O O
was O O
further O O
upregulated O O
in O O
pDCs B-CellLine B-CellLine
, O O
correlating O O
with O O
stage O O
- O O
specific O O
activity O O
of O O
multiple O O
enhancer O O
elements O O
. O O

A O O
conserved O O
enhancer O O
downstream O O
of O O
Tcf4 O O
was O O
required O O
for O O
its O O
upregulation O O
during O O
pDC B-CellLine B-CellLine
differentiation O O
, O O
revealing O O
a O O
positive O O
feedback O O
loop O O
. O O
A O O
conserved O O
enhancer O O
downstream O O
of O O
Tcf4 O O
was O O
required O O
for O O
its O O
upregulation O O
during O O
pDC B-CellLine B-CellLine
differentiation O O
, O O
revealing O O
a O O
positive O O
feedback O O
loop O O
. O O

The O O
expression O O
of O O
Tcf4 O O
and O O
the O O
resulting O O
pDC B-CellLine B-CellLine
differentiation O O
were O O
selectively O O
sensitive O O
to O O
the O O
inhibition O O
of O O
enhancer O O
- O O
binding O O
BET O O
protein O O
activity O O
. O O

Thus O O
, O O
lineage O O
- O O
specifying O O
function O O
of O O
E O O
proteins O O
is O O
facilitated O O
by O O
lineage O O
- O O
specific O O
isoform O O
expression O O
and O O
by O O
BET O O
- O O
dependent O O
feedback O O
regulation O O
through O O
distal O O
regulatory O O
elements O O
. O O

RNA O O
Binding O O
to O O
CBP O O
Stimulates O O
Histone O O
Acetylation O O
and O O
Transcription O O
. O O
CBP O O
/ O O
p300 O O
are O O
transcription O O
co O O
- O O
activators O O
whose O O
binding O O
is O O
a O O
signature O O
of O O
enhancers O O
, O O
cis O O
- O O
regulatory O O
elements O O
that O O
control O O
patterns O O
of O O
gene O O
expression O O
in O O
multicellular O O
organisms O O
. O O

Active O O
enhancers O O
produce O O
bi O O
- O O
directional O O
enhancer O O
RNAs O O
( O O
eRNAs O O
) O O
and O O
display O O
CBP O O
/ O O
p300 O O
- O O
dependent O O
histone O O
acetylation O O
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
CBP O O
binds O O
directly O O
to O O
RNAs O O
in O O
vivo O O
and O O
in O O
vitro O O
. O O

RNAs O O
bound O O
to O O
CBP O O
in O O
vivo O O
include O O
a O O
large O O
number O O
of O O
eRNAs O O
. O O

Using O O
steady O O
- O O
state O O
histone O O
acetyltransferase O O
( O O
HAT O O
) O O
assays O O
, O O
we O O
show O O
that O O
an O O
RNA O O
binding O O
region O O
in O O
the O O
HAT O O
domain O O
of O O
CBP O O
- O O
a O O
regulatory O O
motif O O
unique O O
to O O
CBP O O
/ O O
p300 O O
- O O
allows O O
RNA O O
to O O
stimulate O O
CBP O O
' O O
s O O
HAT O O
activity O O
. O O

At O O
enhancers O O
where O O
CBP O O
interacts O O
with O O
eRNAs O O
, O O
stimulation O O
manifests O O
in O O
RNA O O
- O O
dependent O O
changes O O
in O O
the O O
histone O O
acetylation O O
mediated O O
by O O
CBP O O
, O O
such O O
as O O
H3K27ac O O
, O O
and O O
by O O
corresponding O O
changes O O
in O O
gene O O
expression O O
. O O

By O O
interacting O O
directly O O
with O O
CBP O O
, O O
eRNAs O O
contribute O O
to O O
the O O
unique O O
chromatin O O
structure O O
at O O
active O O
enhancers O O
, O O
which O O
, O O
in O O
turn O O
, O O
is O O
required O O
for O O
regulation O O
of O O
target O O
genes O O
. O O

PAX3 O O
- O O
FOXO1 O O
Establishes O O
Myogenic O O
Super O O
Enhancers O O
and O O
Confers O O
BET O O
Bromodomain O O
Vulnerability O O
. O O
Alveolar O O
rhabdomyosarcoma O O
is O O
a O O
life O O
- O O
threatening O O
myogenic O O
cancer O O
of O O
children O O
and O O
adolescent O O
young O O
adults O O
, O O
driven O O
primarily O O
by O O
the O O
chimeric O O
transcription O O
factor O O
PAX3 O O
- O O
FOXO1 O O
. O O

The O O
mechanisms O O
by O O
which O O
PAX3 O O
- O O
FOXO1 O O
dysregulates O O
chromatin O O
are O O
unknown O O
. O O

We O O
find O O
PAX3 O O
- O O
FOXO1 O O
reprograms O O
the O O
cis O O
- O O
regulatory O O
landscape O O
by O O
inducing O O
de O O
novo O O
super O O
enhancers O O
. O O
PAX3 O O
- O O
FOXO1 O O
uses O O
super O O
enhancers O O
to O O
set O O
up O O
autoregulatory O O
loops O O
in O O
collaboration O O
with O O
the O O
master O O
transcription O O
factors O O
MYOG O O
, O O
MYOD O O
, O O
and O O
MYCN O O
. O O

This O O
myogenic O O
super O O
enhancer O O
circuitry O O
is O O
consistent O O
across O O
cell O O
lines O O
and O O
primary O O
tumors O O
. O O

Cells O O
harboring O O
the O O
fusion O O
gene O O
are O O
selectively O O
sensitive O O
to O O
small O O
- O O
molecule O O
inhibition O O
of O O
protein O O
targets O O
induced O O
by O O
, O O
or O O
bound O O
to O O
, O O
PAX3 O O
- O O
FOXO1 O O
- O O
occupied O O
super O O
enhancers O O
. O O
Cells O O
harboring O O
the O O
fusion O O
gene O O
are O O
selectively O O
sensitive O O
to O O
small O O
- O O
molecule O O
inhibition O O
of O O
protein O O
targets O O
induced O O
by O O
, O O
or O O
bound O O
to O O
, O O
PAX3 O O
- O O
FOXO1 O O
- O O
occupied O O
super O O
enhancers O O
. O O

Furthermore O O
, O O
PAX3 O O
- O O
FOXO1 O O
recruits O O
and O O
requires O O
the O O
BET O O
bromodomain O O
protein O O
BRD4 O O
to O O
function O O
at O O
super O O
enhancers O O
, O O
resulting O O
in O O
a O O
complete O O
dependence O O
on O O
BRD4 O O
and O O
a O O
significant O O
susceptibility O O
to O O
BRD O O
inhibition O O
. O O

These O O
results O O
yield O O
insights O O
into O O
the O O
epigenetic O O
functions O O
of O O
PAX3 O O
- O O
FOXO1 O O
and O O
reveal O O
a O O
specific O O
vulnerability O O
that O O
can O O
be O O
exploited O O
for O O
precision O O
therapy O O
. O O
Significance O O
: O O
PAX3 O O
- O O
FOXO1 O O
drives O O
pediatric O O
fusion O O
- O O
positive O O
rhabdomyosarcoma O O
, O O
and O O
its O O
chromatin O O
- O O
level O O
functions O O
are O O
critical O O
to O O
understanding O O
its O O
oncogenic O O
activity O O
. O O

We O O
find O O
that O O
PAX3 O O
- O O
FOXO1 O O
establishes O O
a O O
myoblastic O O
super O O
enhancer O O
landscape O O
and O O
creates O O
a O O
profound O O
subtype O O
- O O
unique O O
dependence O O
on O O
BET O O
bromodomains O O
, O O
the O O
inhibition O O
of O O
which O O
ablates O O
PAX3 O O
- O O
FOXO1 O O
function O O
, O O
providing O O
a O O
mechanistic O O
rationale O O
for O O
exploring O O
BET O O
inhibitors O O
for O O
patients O O
bearing O O
PAX O O
- O O
fusion O O
rhabdomyosarcoma O O
. O O
Cancer O O
Discov O O
; O O
7 O O
( O O
8 O O
) O O
; O O
884 O O
- O O
99 O O
. O O

2017 O O
AACR O O
. O O
This O O
article O O
is O O
highlighted O O
in O O
the O O
In O O
This O O
Issue O O
feature O O
, O O
p O O
. O O

783 O O
. O O

Potential O O
contribution O O
of O O
tandem O O
circadian O O
enhancers O O
to O O
nonlinear O O
oscillations O O
in O O
clock O O
gene O O
expression O O
. O O

Limit O O
- O O
cycle O O
oscillations O O
require O O
the O O
presence O O
of O O
nonlinear O O
processes O O
. O O

Although O O
mathematical O O
studies O O
have O O
long O O
suggested O O
that O O
multiple O O
nonlinear O O
processes O O
are O O
required O O
for O O
autonomous O O
circadian O O
oscillation O O
in O O
clock O O
gene O O
expression O O
, O O
the O O
underlying O O
mechanism O O
remains O O
controversial O O
. O O

Here O O
we O O
show O O
experimentally O O
that O O
cell O O
- O O
autonomous O O
circadian O O
transcription O O
of O O
a O O
mammalian O O
clock O O
gene O O
requires O O
a O O
functionally O O
interdependent O O
tandem O O
E O O
- O O
box O O
motif O O
; O O
the O O
lack O O
of O O
either O O
of O O
the O O
two O O
E O O
- O O
boxes O O
results O O
in O O
arrhythmic O O
transcription O O
. O O

Although O O
previous O O
studies O O
indicated O O
the O O
role O O
of O O
the O O
tandem O O
motifs O O
in O O
increasing O O
circadian O O
amplitude O O
, O O
enhancing O O
amplitude O O
does O O
not O O
explain O O
the O O
mechanism O O
for O O
limit O O
- O O
cycle O O
oscillations O O
in O O
transcription O O
. O O

In O O
this O O
study O O
, O O
mathematical O O
analysis O O
suggests O O
that O O
the O O
interdependent O O
behavior O O
of O O
enhancer O O
elements O O
including O O
not O O
only O O
E O O
- O O
boxes O O
but O O
also O O
ROR O O
response O O
elements O O
might O O
contribute O O
to O O
limit O O
- O O
cycle O O
oscillations O O
by O O
increasing O O
transcriptional O O
nonlinearity O O
. O O

As O O
expected O O
, O O
introduction O O
of O O
the O O
interdependence O O
of O O
circadian O O
enhancer O O
elements O O
into O O
mathematical O O
models O O
resulted O O
in O O
autonomous O O
transcriptional O O
oscillation O O
with O O
low O O
Hill O O
coefficients O O
. O O

Together O O
these O O
findings O O
suggest O O
that O O
interdependent O O
tandem O O
enhancer O O
motifs O O
on O O
multiple O O
clock O O
genes O O
might O O
cooperatively O O
enhance O O
nonlinearity O O
in O O
the O O
whole O O
circadian O O
feedback O O
system O O
, O O
which O O
would O O
lead O O
to O O
limit O O
- O O
cycle O O
oscillations O O
in O O
clock O O
gene O O
expression O O
. O O

Arid1a O O
regulates O O
response O O
to O O
anti O O
- O O
angiogenic O O
therapy O O
in O O
advanced O O
hepatocellular O O
carcinoma O O
. O O

BACKGROUND O O
& O O
AIMS O O
: O O
AT O O
- O O
rich O O
interaction O O
domain O O
1a O O
( O O
Arid1a O O
) O O
, O O
a O O
component O O
of O O
the O O
chromatin O O
remodeling O O
complex O O
, O O
has O O
emerged O O
as O O
a O O
tumor O O
suppressor O O
gene O O
. O O

It O O
is O O
frequently O O
mutated O O
in O O
hepatocellular O O
carcinoma O O
( O O
HCC O O
) O O
. O O

However O O
, O O
it O O
remains O O
unknown O O
how O O
Arid1a O O
suppresses O O
HCC O O
development O O
and O O
whether O O
Arid1a O O
deficiency O O
could O O
be O O
exploited O O
for O O
therapy O O
, O O
we O O
aimed O O
to O O
explore O O
these O O
questions O O
. O O

METHODS O O
: O O
The O O
expression O O
of O O
Arid1a O O
in O O
human O O
and O O
mouse O O
HCCs O B-CellLine
was O O
determined O O
by O O
immunohistochemical O O
( O O
IHC O O
) O O
staining O O
. O O

Gene O O
expression O O
was O O
determined O O
by O O
quantitative O O
PCR O O
, O O
ELISA O O
or O O
western O O
blotting O O
. O O
Arid1a O O
knockdown O O
HCC B-CellLine B-CellLine
cell I-CellLine I-CellLine
lines I-CellLine I-CellLine
were O O
established O O
by O O
lentiviral O O
- O O
based O O
shRNA O O
. O O
Tumor O O
angiogenesis O O
was O O
quantified O O
based O O
on O O
vessel O O
density O O
. O O

The O O
regulation O O
of O O
angiopoietin O O
( O O
Ang2 O O
) O O
expression O O
by O O
Arid1a O O
was O O
identified O O
by O O
chromatin O O
immunoprecipitation O O
( O O
ChIP O O
) O O
assay O O
. O O

The O O
tumor O O
promoting O O
function O O
of O O
Arid1a O O
loss O O
was O O
studied O O
with O O
a O O
xenograft O O
model O O
in O O
nude O O
mice O O
and O O
diethylnitrosamine O O
( O O
DEN O O
) O O
- O O
induced O O
HCC O O
in O O
Arid1a O O
conditional O O
knockout O O
mice O O
. O O

The O O
therapeutic O O
values O O
of O O
Ang2 O O
antibody O O
and O O
sorafenib O O
treatment O O
were O O
evaluated O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

RESULTS O O
: O O
We O O
demonstrate O O
that O O
Arid1a O O
deficiency O O
, O O
occurring O O
in O O
advanced O O
human O O
HCCs O O
, O O
is O O
associated O O
with O O
increased O O
vessel O O
density O O
. O O

Mechanistically O O
, O O
loss O O
of O O
Arid1a O O
causes O O
aberrant O O
histone O O
H3K27ac O O
deposition O O
at O O
the O O
angiopoietin O O
- O O
2 O O
( O O
Ang2 O O
) O O
enhancer O O
and O O
promoter O O
, O O
which O O
eventually O O
leads O O
to O O
ectopic O O
expression O O
of O O
Ang2 O O
and O O
promotes O O
HCC O O
development O O
. O O
Ang2 O O
blockade O O
in O O
Arid1a O O
- O O
deficient O O
HCCs O O
significantly O O
reduces O O
vessel O O
density O O
and O O
tumor O O
progression O O
. O O
Mechanistically O O
, O O
loss O O
of O O
Arid1a O O
causes O O
aberrant O O
histone O O
H3K27ac O O
deposition O O
at O O
the O O
angiopoietin O O
- O O
2 O O
( O O
Ang2 O O
) O O
enhancer O O
and O O
promoter O O
, O O
which O O
eventually O O
leads O O
to O O
ectopic O O
expression O O
of O O
Ang2 O O
and O O
promotes O O
HCC O O
development O O
. O O
Ang2 O O
blockade O O
in O O
Arid1a O O
- O O
deficient O O
HCCs O O
significantly O O
reduces O O
vessel O O
density O O
and O O
tumor O O
progression O O
. O O

Importantly O O
, O O
sorafenib O O
treatment O O
, O O
which O O
suppresses O O
H3K27 O O
acetylation O O
and O O
Ang2 O O
expression O O
, O O
profoundly O O
halts O O
the O O
progression O O
of O O
Arid1a O O
- O O
deficient O O
HCCs O O
. O O

CONCLUSIONS O O
: O O
Arid1a O O
- O O
deficiency O O
activates O O
Ang2 O O
- O O
dependent O O
angiogenesis O O
and O O
promotes O O
HCC O O
progression O O
. O O

Loss O O
of O O
Arid1a O O
in O O
HCCs O O
confers O O
sensitivity O O
to O O
Ang2 O O
blockade O O
and O O
sorafenib O O
treatment O O
. O O

LAY O O
SUMMARY O O
: O O
AT O O
- O O
rich O O
interaction O O
domain O O
1a O O
( O O
Arid1a O O
) O O
, O O
is O O
a O O
tumor O O
suppressor O O
gene O O
. O O

Arid1a O O
- O O
deficiency O O
promotes O O
Ang2 O O
- O O
dependent O O
angiogenesis O O
leading O O
to O O
hepatocellular O O
carcinoma O O
progression O O
. O O

Arid1a O O
- O O
deficiency O O
also O O
sensitizes O O
tumors O O
to O O
Ang2 O O
blockade O O
by O O
sorafenib O O
treatment O O
. O O

Transcription O O
factor O O
activity O O
rhythms O O
and O O
tissue O O
- O O
specific O O
chromatin O O
interactions O O
explain O O
circadian O O
gene O O
expression O O
across O O
organs O O
. O O

Temporal O O
control O O
of O O
physiology O O
requires O O
the O O
interplay O O
between O O
gene O O
networks O O
involved O O
in O O
daily O O
timekeeping O O
and O O
tissue O O
function O O
across O O
different O O
organs O O
. O O

How O O
the O O
circadian O O
clock O O
interweaves O O
with O O
tissue O O
- O O
specific O O
transcriptional O O
programs O O
is O O
poorly O O
understood O O
. O O

Here O O
, O O
we O O
dissected O O
temporal O O
and O O
tissue O O
- O O
specific O O
regulation O O
at O O
multiple O O
gene O O
regulatory O O
layers O O
by O O
examining O O
mouse O O
tissues O O
with O O
an O O
intact O O
or O O
disrupted O O
clock O O
over O O
time O O
. O O

Integrated O O
analysis O O
uncovered O O
two O O
distinct O O
regulatory O O
modes O O
underlying O O
tissue O O
- O O
specific O O
rhythms O O
: O O
tissue O O
- O O
specific O O
oscillations O O
in O O
transcription O O
factor O O
( O O
TF O O
) O O
activity O O
, O O
which O O
were O O
linked O O
to O O
feeding O O
- O O
fasting O O
cycles O O
in O O
liver B-CellLine B-CellLine
and O O
sodium O O
homeostasis O O
in O O
kidney B-CellLine B-CellLine
; O O
and O O
colocalized O O
binding O O
of O O
clock O O
and O O
tissue O O
- O O
specific O O
transcription O O
factors O O
at O O
distal O O
enhancers O O
. O O

Chromosome O O
conformation O O
capture O O
( O O
4C O O
- O O
seq O O
) O O
in O O
liver B-CellLine B-CellLine
and O O
kidney B-CellLine B-CellLine
identified O O
liver B-CellLine B-CellLine
- O O
specific O O
chromatin O O
loops O O
that O O
recruited O O
clock O O
- O O
bound O O
enhancers O O
to O O
promoters O O
to O O
regulate O O
liver B-CellLine B-CellLine
- O O
specific O O
transcriptional O O
rhythms O O
. O O

Furthermore O O
, O O
this O O
looping O O
was O O
remarkably O O
promoter O O
- O O
specific O O
on O O
the O O
scale O O
of O O
less O O
than O O
10 O O
kilobases O O
( O O
kb O O
) O O
. O O

Enhancers O O
can O O
contact O O
a O O
rhythmic O O
promoter O O
while O O
looping O O
out O O
nearby O O
nonrhythmic O O
alternative O O
promoters O O
, O O
confining O O
rhythmic O O
enhancer O O
activity O O
to O O
specific O O
promoters O O
. O O

These O O
findings O O
suggest O O
that O O
chromatin O O
folding O O
enables O O
the O O
clock O O
to O O
regulate O O
rhythmic O O
transcription O O
of O O
specific O O
promoters O O
to O O
output O O
temporal O O
transcriptional O O
programs O O
tailored O O
to O O
different O O
tissues O O
. O O

The O O
transcription O O
factors O O
GATA2 O O
and O O
microphthalmia O O
- O O
associated O O
transcription O O
factor O O
regulate O O
Hdc O O
gene O O
expression O O
in O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
are O O
required O O
for O O
IgE O O
/ O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
mediated O O
anaphylaxis O O
. O O

BACKGROUND O O
: O O
Histamine O O
is O O
a O O
critical O O
mediator O O
of O O
IgE O O
/ O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
mediated O O
anaphylaxis O O
. O O

Histamine O O
is O O
synthesized O O
by O O
decarboxylating O O
the O O
amino O O
acid O O
histidine O O
, O O
a O O
reaction O O
catalyzed O O
by O O
the O O
histidine O O
decarboxylase O O
( O O
Hdc O O
) O O
gene O O
- O O
encoded O O
enzyme O O
HDC O O
. O O

However O O
, O O
regulation O O
of O O
the O O
Hdc O O
gene O O
in O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
is O O
poorly O O
understood O O
. O O

OBJECTIVE O O
: O O
We O O
sought O O
to O O
investigate O O
the O O
in O O
vivo O O
regulation O O
of O O
IgE O O
/ O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
mediated O O
anaphylaxis O O
by O O
the O O
transcription O O
factors O O
GATA2 O O
and O O
microphthalmia O O
- O O
associated O O
transcription O O
factor O O
( O O
MITF O O
) O O
and O O
the O O
mechanisms O O
by O O
which O O
GATA2 O O
and O O
MITF O O
regulate O O
Hdc O O
gene O O
expression O O
in O O
mouse O O
and O O
human O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

METHODS O O
: O O
Mice O O
deficient O O
in O O
the O O
transcription O O
factors O O
Gata2 O O
, O O
aryl O O
hydrocarbon O O
receptor O O
( O O
Ahr O O
) O O
, O O
aryl O O
hydrocarbon O O
receptor O O
repressor O O
( O O
Ahrr O O
) O O
, O O
or O O
basic O O
helix O O
- O O
loop O O
- O O
helix O O
family O O
member O O
E40 O O
( O O
Bhlhe40 O O
) O O
were O O
assessed O O
for O O
anaphylactic O O
reactions O O
. O O

Chromatin O O
immunoprecipitation O O
sequencing O O
analysis O O
identified O O
putative O O
Hdc O O
enhancers O O
. O O
Chromatin O O
immunoprecipitation O O
sequencing O O
analysis O O
identified O O
putative O O
Hdc O O
enhancers O O
. O O

Luciferase O O
reporter O O
transcription O O
assay O O
confirmed O O
enhancer O O
activities O O
of O O
putative O O
enhancers O O
in O O
the O O
Hdc O O
gene O O
. O O
Luciferase O O
reporter O O
transcription O O
assay O O
confirmed O O
enhancer O O
activities O O
of O O
putative O O
enhancers O O
in O O
the O O
Hdc O O
gene O O
. O O

The O O
short O O
hairpin O O
RNA O O
knockdown O O
approach O O
was O O
used O O
to O O
determine O O
the O O
role O O
of O O
MITF O O
in O O
regulating O O
mouse O O
and O O
human O O
HDC O O
gene O O
expression O O
. O O

RESULTS O O
: O O
Connective O O
tissue O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
Gata2 O O
- O O
deficient O O
mice O O
did O O
not O O
have O O
IgE O O
/ O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
mediated O O
anaphylaxis O O
. O O
GATA2 O O
induced O O
the O O
expression O O
of O O
Mitf O O
, O O
Ahr O O
, O O
Ahrr O O
, O O
and O O
Bhlhe40 O O
in O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
MITF O O
, O O
but O O
not O O
AHR O O
, O O
AHRR O O
, O O
or O O
BHLHE40 O O
, O O
was O O
required O O
for O O
anaphylaxis O O
. O O
MITF O O
bound O O
to O O
an O O
enhancer O O
located O O
8 O O
. O O
8 O O
kb O O
upstream O O
of O O
the O O
transcription O O
start O O
site O O
of O O
the O O
Hdc O O
gene O O
and O O
directed O O
enhancer O O
activity O O
. O O
MITF O O
overexpression O O
largely O O
restored O O
Hdc O O
gene O O
expression O O
in O O
the O O
Gata2 B-CellLine O
- I-CellLine O
deficient I-CellLine O
mast I-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
RESULTS O O
: O O
Connective O O
tissue O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
specific O O
Gata2 O O
- O O
deficient O O
mice O O
did O O
not O O
have O O
IgE O O
/ O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
mediated O O
anaphylaxis O O
. O O
GATA2 O O
induced O O
the O O
expression O O
of O O
Mitf O O
, O O
Ahr O O
, O O
Ahrr O O
, O O
and O O
Bhlhe40 O O
in O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O
MITF O O
, O O
but O O
not O O
AHR O O
, O O
AHRR O O
, O O
or O O
BHLHE40 O O
, O O
was O O
required O O
for O O
anaphylaxis O O
. O O
MITF O O
bound O O
to O O
an O O
enhancer O O
located O O
8 O O
. O O
8 O O
kb O O
upstream O O
of O O
the O O
transcription O O
start O O
site O O
of O O
the O O
Hdc O O
gene O O
and O O
directed O O
enhancer O O
activity O O
. O O
MITF O O
overexpression O O
largely O O
restored O O
Hdc O O
gene O O
expression O O
in O O
the O O
Gata2 B-CellLine O
- I-CellLine O
deficient I-CellLine O
mast I-CellLine B-CellLine
cells I-CellLine I-CellLine
. O O

In O O
the O O
human O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
line I-CellLine I-CellLine
LAD2 I-CellLine I-CellLine
, O O
MITF O O
was O O
required O O
for O O
the O O
HDC O O
gene O O
expression O O
and O O
histamine O O
synthesis O O
. O O

CONCLUSION O O
: O O
The O O
transcription O O
factors O O
GATA2 O O
and O O
MITF O O
regulate O O
Hdc O O
gene O O
expression O O
in O O
mast B-CellLine B-CellLine
cells I-CellLine I-CellLine
and O O
are O O
required O O
for O O
IgE O O
/ O O
mast B-CellLine B-CellLine
cell I-CellLine I-CellLine
- O O
mediated O O
anaphylaxis O O
. O O

Sex O O
reversal O O
following O O
deletion O O
of O O
a O O
single O O
distal O O
enhancer O O
of O O
Sox9 O O
. O O
Sex O O
reversal O O
following O O
deletion O O
of O O
a O O
single O O
distal O O
enhancer O O
of O O
Sox9 O O
. O O

Cell O O
fate O O
decisions O O
require O O
appropriate O O
regulation O O
of O O
key O O
genes O O
. O O
Sox9 O O
, O O
a O O
direct O O
target O O
of O O
SRY O O
, O O
is O O
pivotal O O
in O O
mammalian O O
sex O O
determination O O
. O O

In O O
vivo O O
high O O
- O O
throughput O O
chromatin O O
accessibility O O
techniques O O
, O O
transgenic O O
assays O O
, O O
and O O
genome O O
editing O O
revealed O O
several O O
novel O O
gonadal O O
regulatory O O
elements O O
in O O
the O O
2 O O
- O O
megabase O O
gene O O
desert O O
upstream O O
of O O
Sox9 O O
Although O O
others O O
are O O
redundant O O
, O O
enhancer O O
13 O O
( O O
Enh13 O O
) O O
, O O
a O O
557 O O
- O O
base O O
pair O O
element O O
located O O
565 O O
kilobases O O
5 O O
' O O
from O O
the O O
transcriptional O O
start O O
site O O
, O O
is O O
essential O O
to O O
initiate O O
mouse O O
testis B-CellLine B-CellLine
development O O
; O O
its O O
deletion O O
results O O
in O O
XY O O
females O O
with O O
Sox9 O O
transcript O O
levels O O
equivalent O O
to O O
those O O
in O O
XX O O
gonads B-CellLine B-CellLine
. O O

Our O O
data O O
are O O
consistent O O
with O O
the O O
time O O
- O O
sensitive O O
activity O O
of O O
SRY O O
and O O
indicate O O
a O O
strict O O
order O O
of O O
enhancer O O
usage O O
. O O
Enh13 O O
is O O
conserved O O
and O O
embedded O O
within O O
a O O
32 O O
. O O
5 O O
- O O
kilobase O O
region O O
whose O O
deletion O O
in O O
humans O O
is O O
associated O O
with O O
XY O O
sex O O
reversal O O
, O O
suggesting O O
that O O
it O O
is O O
also O O
critical O O
in O O
humans O O
. O O

Combinatorial O O
CRISPR O O
/ O O
Cas9 O O
Approach O O
to O O
Elucidate O O
a O O
Far O O
- O O
Upstream O O
Enhancer O O
Complex O O
for O O
Tissue O O
- O O
Specific O O
Sox9 O O
Expression O O
. O O
SRY O O
- O O
box O O
9 O O
( O O
SOX9 O O
) O O
is O O
a O O
master O O
transcription O O
factor O O
that O O
regulates O O
cartilage O B-CellLine
development O O
. O O
SOX9 O O
haploinsufficiency O O
resulting O O
from O O
breakpoints O O
in O O
a O O
~ O O
1 O O
- O O
Mb O O
region O O
upstream O O
of O O
SOX9 O O
was O O
reported O O
in O O
acampomelic O O
campomelic O O
dysplasia O O
( O O
ACD O O
) O O
patients O O
, O O
suggesting O O
that O O
essential O O
enhancer O O
regions O O
of O O
SOX9 O O
for O O
cartilage O B-CellLine
development O O
are O O
located O O
in O O
this O O
long O O
non O O
- O O
coding O O
sequence O O
. O O
Combinatorial O O
CRISPR O O
/ O O
Cas9 O O
Approach O O
to O O
Elucidate O O
a O O
Far O O
- O O
Upstream O O
Enhancer O O
Complex O O
for O O
Tissue O O
- O O
Specific O O
Sox9 O O
Expression O O
. O O
SRY O O
- O O
box O O
9 O O
( O O
SOX9 O O
) O O
is O O
a O O
master O O
transcription O O
factor O O
that O O
regulates O O
cartilage O B-CellLine
development O O
. O O
SOX9 O O
haploinsufficiency O O
resulting O O
from O O
breakpoints O O
in O O
a O O
~ O O
1 O O
- O O
Mb O O
region O O
upstream O O
of O O
SOX9 O O
was O O
reported O O
in O O
acampomelic O O
campomelic O O
dysplasia O O
( O O
ACD O O
) O O
patients O O
, O O
suggesting O O
that O O
essential O O
enhancer O O
regions O O
of O O
SOX9 O O
for O O
cartilage O B-CellLine
development O O
are O O
located O O
in O O
this O O
long O O
non O O
- O O
coding O O
sequence O O
. O O

However O O
, O O
the O O
cis O O
- O O
acting O O
enhancer O O
region O O
regulating O O
cartilage O B-CellLine
- O O
specific O O
SOX9 O O
expression O O
remains O O
to O O
be O O
identified O O
. O O
However O O
, O O
the O O
cis O O
- O O
acting O O
enhancer O O
region O O
regulating O O
cartilage O B-CellLine
- O O
specific O O
SOX9 O O
expression O O
remains O O
to O O
be O O
identified O O
. O O

To O O
identify O O
distant O O
cartilage O O
Sox9 O O
enhancers O O
, O O
we O O
utilized O O
the O O
combination O O
of O O
multiple O O
CRISPR O O
/ O O
Cas9 O O
technologies O O
including O O
enrichment O O
of O O
the O O
promoter O O
- O O
enhancer O O
complex O O
followed O O
by O O
next O O
- O O
generation O O
sequencing O O
and O O
mass O O
spectrometry O O
( O O
MS O O
) O O
, O O
SIN3A O O
- O O
dCas9 O O
- O O
mediated O O
epigenetic O O
silencing O O
, O O
and O O
generation O O
of O O
enhancer O O
deletion O O
mice O O
. O O
To O O
identify O O
distant O O
cartilage O O
Sox9 O O
enhancers O O
, O O
we O O
utilized O O
the O O
combination O O
of O O
multiple O O
CRISPR O O
/ O O
Cas9 O O
technologies O O
including O O
enrichment O O
of O O
the O O
promoter O O
- O O
enhancer O O
complex O O
followed O O
by O O
next O O
- O O
generation O O
sequencing O O
and O O
mass O O
spectrometry O O
( O O
MS O O
) O O
, O O
SIN3A O O
- O O
dCas9 O O
- O O
mediated O O
epigenetic O O
silencing O O
, O O
and O O
generation O O
of O O
enhancer O O
deletion O O
mice O O
. O O

As O O
a O O
result O O
, O O
we O O
could O O
identify O O
a O O
critical O O
far O O
- O O
upstream O O
cis O O
- O O
element O O
and O O
Stat3 O O
as O O
a O O
trans O O
- O O
acting O O
factor O O
, O O
regulating O O
cartilage O B-CellLine
- O O
specific O O
Sox9 O O
expression O O
and O O
subsequent O O
skeletal O O
development O O
. O O

Our O O
strategy O O
could O O
facilitate O O
definitive O O
ACD O O
diagnosis O O
and O O
should O O
be O O
useful O O
to O O
reveal O O
the O O
detailed O O
chromatin O O
conformation O O
and O O
regulation O O
. O O

Promoter O O
- O O
Enhancer O O
Communication O O
Occurs O O
Primarily O O
within O O
Insulated O O
Neighborhoods O O
. O O
Metazoan O O
chromosomes O O
are O O
sequentially O O
partitioned O O
into O O
topologically O O
associating O O
domains O O
( O O
TADs O O
) O O
and O O
then O O
into O O
smaller O O
sub O O
- O O
domains O O
. O O

One O O
class O O
of O O
sub O O
- O O
domains O O
, O O
insulated O O
neighborhoods O O
, O O
are O O
proposed O O
to O O
spatially O O
sequester O O
and O O
insulate O O
the O O
enclosed O O
genes O O
through O O
self O O
- O O
association O O
and O O
chromatin O O
looping O O
. O O

However O O
, O O
it O O
has O O
not O O
been O O
determined O O
functionally O O
whether O O
promoter O O
- O O
enhancer O O
interactions O O
and O O
gene O O
regulation O O
are O O
broadly O O
restricted O O
to O O
within O O
these O O
loops O O
. O O

Here O O
, O O
we O O
employed O O
published O O
datasets O O
from O O
murine B-CellLine O
embryonic I-CellLine B-CellLine
stem I-CellLine I-CellLine
cells I-CellLine I-CellLine
( O O
mESCs B-CellLine B-CellLine
) O O
to O O
identify O O
insulated O O
neighborhoods O O
that O O
confine O O
promoter O O
- O O
enhancer O O
interactions O O
and O O
demarcate O O
gene O O
regulatory O O
regions O O
. O O

To O O
directly O O
address O O
the O O
functionality O O
of O O
these O O
regions O O
, O O
we O O
depleted O O
estrogen O O
- O O
related O O
receptor O O
beta O O
( O O
Esrrb O O
) O O
, O O
which O O
binds O O
the O O
Mediator O O
co O O
- O O
activator O O
complex O O
, O O
to O O
impair O O
enhancers O O
of O O
genes O O
within O O
222 O O
insulated O O
neighborhoods O O
without O O
causing O O
mESC B-CellLine B-CellLine
differentiation O O
. O O
Esrrb O O
depletion O O
reduces O O
Mediator O O
binding O O
, O O
promoter O O
- O O
enhancer O O
looping O O
, O O
and O O
expression O O
of O O
both O O
nascent O O
RNA O O
and O O
mRNA O O
within O O
the O O
insulated O O
neighborhoods O O
without O O
significantly O O
affecting O O
the O O
flanking O O
genes O O
. O O

Our O O
data O O
indicate O O
that O O
insulated O O
neighborhoods O O
represent O O
functional O O
regulons O O
in O O
mammalian O O
genomes O O
. O O

